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Abstract 
Since their discovery in 1930, -lactam antibiotics have become the standard treatment for bacterial 
infections. However, many bacteria have now developed resistance to these drugs. Of particular 
concern is the metallo--lactamases (MBLs), which are a family of di-zinc containing 
metalloenzymes capable of hydrolyzing a very broad range of common -lactam antibiotics. MBLs 
are not inhibited by clavulanic acid, a drug commonly co-administered with β-lactam antibiotics as 
an inhibitor of other serine -lactamases. The aim of the research is to design, dock (computer 
calculation of an optimum fit of a molecule into an enzyme active site to find a possible docking 
geometry and energy), synthesize and assay of potent and selective inhibitors of MBLs (IMP-1). 
Thiol carboxylic acid derivatives are reported as the most common category of MBL (IMP-1) 
inhibitors. The thiol derivatives below were designed and their predicted interactions within the 
active site of IMP-1 were investigated with the aid of MolDock modeling software. Consequently, 
compounds below were synthesized and assayed against IMP-1. These compounds were 
synthesized in good yields. Their inhibition potencies (Kic values) were determined for MBL (IMP-
1) and L-benzyl tyrosine thiol derivative with n=1 was very potent inhibitor with Kic=0.086±0.024 
µM. Additionally, L-phenylalanine and tryptophan derivatives with n=1 showed good inhibition as 
well with the Kic values of 0.25 µM and 0.47 µM respectively. The rest of inhibitors have shown a 
range of Kic between 1.45 µM to 9.39 µM. 
 
In the second project eleven thiol carboxylic acid compounds were designed, docked and 
synthesized and assayed against IMP-1. These compounds also were synthesized in good yields and 
showed Kic values between 1.04 µM to 4.77 µM. 
 
 II 
 
In the third project, the ZINC Database Library was used for screening virtual compounds against 
IMP-1. Amongst 10000 compounds, four below compounds were obtained as the highest ranked 
docking energy of binding to the active site of IMP-1. From the 10,000 compounds used for virtual 
screening, the four compounds below were ranked by the MolDock modeling software as the best 
binders within the active site of IMP-1. 
 
Due to the commercial availability of cyclohexanoyl chloride, benzoyl chloride and its nitro 
derivatives, the cyclopropyl, cyclobutyl, cyclopentylcarboxamide substituents of these compounds 
were replaced with the corresponding benzamide and cyclohexanecarboxamide side groups. 
Consequently, compounds below were designed and their inhibition activities were measured 
against IMP-1. None of the compounds show inhibition activity of IMP-1. 
 
In the last project, two lead compounds were used for designing of a new project. Twenty-four 
imidazole compounds were designed, docked, synthesized and assayed against IMP-1. The new 
compounds showed better inhibition activity than the lead compounds. However, their Kic were not 
measured as they were not potent inhibitors. 
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1.1 Introduction 
Before the early 20th century, treatments for infections were based primarily on folk 
medicines.[1] Many ancient cultures used specially selected mold and plant material extracts 
against infectious diseases.[2] Synthetic antibiotics and development of antibacterial agents began 
in Germany with Paul Ehrlich in the late 1880s.[3] The observations by many researchers in the 
early 20
th
 century about the inhibition of microbial growth by the extracts of other microorganisms 
led to the discovery of natural antibiotics.[4] The term 'antibiosis', meaning "against life," was first 
coined by the French bacteriologist Jean Paul Vuillemin for this phenomenon exhibited by these 
early antibacterial drugs. Paul Ehrlich screened hundreds of dyes against various organisms and 
finally discovered a medicinally useful drug, the synthetic antibiotic Salvarsan (Figure ‎1-1) which is 
now called arsphenamine.[5] 
 
Figure ‎1-1: The chemical structure of Salvarsan. 
In 1928, Alexander Fleming noticed that a mold growth (Penicillium notatum) over the culture of 
many petri plates with infectious microbes killed those cultures completely. Fleming postulated that 
the effect was due to an antibacterial compound named as penicillin, which could be further 
exploited for chemotherapy.[6] 
The first commercially available antibiotic, Prontosil (Figure ‎1-2) was developed by a research team 
led by Gerhard Domagk in 1932.[6] This initiated a new era of antibacterial agents. Later, Penicillin 
G (Figure ‎1-2) was purified in 1942 by Florey and Chain showed a potent antibacterial activity 
against a wide range of bacteria. This discovery led to a renewed interest in the search of antibiotic 
compounds with similar efficacy and safety.[7] 
 
Figure ‎1-2: The chemical structures of Prontosil and Penicillin G. 
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Since their discovery, antibiotics have become the first line treatment for bacterial infections.[8] 
The use of antibiotics is not monitored strictly in many parts of the world and more than 50% of 
antibiotics are used without prescription worldwide.[9] Due to the clinical overuse of antibiotics, 
many bacteria have developed resistance against several antibiotics. This poses a significant threat 
to public health, and hence necessitates the discovery of new classes/generations of antibiotics.[10] 
There are commonly two kinds of bacteria which are known as Gram-positive and Gram-negative 
bacteria.[11] The difference between the two classes of bacteria is the structures of their cell 
walls.[11] The Gram-positive bacteria membrane has three layers whereas the Gram-negative 
bacteria have more complex cell wall structure with five layers.[11] Gram-negative bacteria are 
usually more resistant against antibiotics because they have additional membrane 
(lipopolysaccharide) which poses a major barrier for some antibiotics to penetrate (Figure ‎1-3).[11] 
 
Figure ‎1-3: The membrane structures of Gram-positive and Gram-negative bacteria.[11] 
1.2 Classification of Antibiotics 
The different antibiotics available can be classified as depicted in Figure ‎1-4.[12] These agents are 
classified based on their structure and mechanism of action which generally include: inhibition of 
cell wall synthesis, destroying the plasma membrane integrity, inhibiting nucleic acid synthesis, 
inhibiting protein synthesis by modifying ribosomal subunit functions and by inhibiting folate 
synthesis which is necessary for bacterial growth.[11] The brief description of each class of 
antibiotics is as follows. 
Aminoglycoside antibiotics include simple naturally occurring glycosides with amino groups 
(Figure ‎1-5). The major drugs in this class are gentamicin, netilmicin, tobramycin, amikacin and 
neomycin. They act by inhibiting the bacterial protein synthesis at 30S ribosomal subunit level.[11, 
13] 
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Figure ‎1-4: Classification of antibiotics. 
 
Figure ‎1-5: Chemical structure of the aminoglycoside antibiotics.[11, 13] 
The aminoglycosides primarily act by binding to the aminoacyl site of 16S ribosomal RNA within 
the 30S ribosomal subunit, leading to misreading of the genetic code and inhibition of translocation 
(Figure ‎1-6). The initial steps required for peptide synthesis, such as binding of mRNA and the 
association of the 50S ribosomal subunit, are uninterrupted, but elongation fails to occur due to 
disruption of the mechanisms for ensuring translational accuracy. The ensuing antimicrobial activity 
is usually bactericidal against susceptible aerobic gram-negative bacilli. Aminoglycosides initially 
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penetrate the organism by disrupting the magnesium and calcium bridges between 
lipopolysaccharide moieties. They are transported across the cytoplasmic membrane in an energy-
dependent manner. This step can be inhibited in vitro by divalent cations, increased osmolality, 
acidic pH, and an anaerobic environment.[11, 13] 
 
Figure ‎1-6: Aminoglycosides Interfering with the translocation of tRNA from the A-site to the P-site.[11, 13] 
Glycopeptides are another class of antibiotics which includes teicoplanin, vancomycin and 
telavancin. Among this class, teicoplanin has long lasting effects (Figure ‎1-7). They have complex 
structures with several aromatic rings. Their mechanism of action is inhibiting peptidoglycan 
synthesis.[11, 14] 
 
Figure ‎1-7: Chemical structure of teicoplanin derivatives.[11, 14] 
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Fluoroquinolone antibiotics were discovered in the early 1960s. This class includes agents such as 
ciprofloxacin, norfloxacin, ofloxacin, moxifloxacin, levofloxacin and nalidixic acid (Figure ‎1-8). 
The mechanism of these drugs is inhibiting the bacterial topoisomerase II (a bacterial DNA gyrase) 
which is essential for DNA spindle formation.[11, 15] 
 
Figure ‎1-8: Chemical structure of the fluoroquinolone antibiotics.[11, 15] 
Tetracycline is a class of widely used antibiotics which also contain broad-spectrum agents which 
include demeclocycline, doxycycline, minocycline, oxytetracycline, tetracycline and lymexycline 
(Figure ‎1-9). The mechanism of this class of antibiotics is based on inhibiting protein synthesis at 
30S ribosomal subunit. Tetracyclines are usually effective against both Gram-positive and Gram-
negative bacteria.[11, 16] 
 
Figure ‎1-9: Chemical structure of the tetracycline antibiotics.[11, 16] 
Linezolid, posizolid, radezolid and torezolid are in the class of oxazolidinones (Figure ‎1-10). 
Linezolid is the first reported antibiotic in this group. This class of antibiotics inhibits binding of N-
formylmethionyl-tRNA to the 70s ribosome. Although this class of antibiotics is widely effective 
against Gram-positive bacteria, they are not effective in the treatment of Gram-negative 
bacteria.[11, 17] 
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Figure ‎1-10: Chemical structure of the oxazolidinone antibiotics.[11, 17] 
Macrolides are prescribed especially for patients who are sensitive to penicillin. This group includes 
azithromycin, clarithromycin, spiramycin, telithromycin, erythromycin and roxithromycin 
(Figure ‎1-11). Their mechanism is inhibition of bacterial protein synthesis by binding to 50S 
subunit of bacterial ribosome.[11, 18] 
 
Figure ‎1-11: Chemical structure of the macrolide antibiotics.[11, 18] 
Lincosamide class of antibiotics contains clindamycin and lincomycin (Figure ‎1-12). These drugs 
are also used for patients who are sensitive to penicillin. Their mechanism of action is based on 
inhibition of protein synthesis by binding to the 23S portion of 50S subunit of bacterial ribosomal 
RNA.[11, 19] 
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Figure ‎1-12: Chemical structure of the lincosamide antibiotcs.[11, 19] 
β-Lactam antibiotics make up more than 50% of all commercially prescribed antibiotics for 
treatment of bacterial infections. The β-lactam ring is part of the structure of several antibiotic 
families; the principal β-lactam antibiotics are carbapenems,[20] cephalosporins,[21] 
penicillins,[21, 22] and monobactams.[23] The general structures of these antibiotics are shown in 
Figure ‎1-13. Monobactams have a four-membered isolated ring system which is not fused with 
another ring.[23] The general mechanism of action of β-lactam antibiotics is inhibition of 
peptidoglycan synthesis which constitutes a major portion of bacterial cell wall synthesis.[11] The 
attachment of β-lactam antibiotics to penicillin-binding protein leads to the inhibition of 
transpeptidase (a bacterial enzyme that cross-links the peptidoglycan chains to form rigid cell walls) 
which eventually leads to the death of bacteria. 
 
Figure ‎1-13: General structures of β-lactam antibiotics.[20-23] 
Carbapenems are effective for both Gram-negative and Gram-positive bacteria. This subclass 
includes ertapenem, doripenem, imipenem, cilastatin and meropenem (Figure ‎1-14). They also act 
by the same mechanism as that of penicillins.[11, 20] 
 9 
 
 
Figure ‎1-14: Chemical structure of carbapenem antibiotics.[11, 20] 
Cephalosporins contain a wide range of β-lactam antibiotics.[22, 24] Like carbapenems they are 
effective against both Gram-negative and Gram-positive bacteria. A few of cephalosporins such as 
cefepime, cefaclor, cefixime and ceftobiprole are shown in Figure ‎1-15.[11, 22, 24]  
 
Figure ‎1-15: Chemical structure of cephalosporin antibiotics. [11, 22, 24] 
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Aztreonam is the first monobactam antibiotic which was approved by the U.S. Food and Drug 
Administration (FDA) in 1986 (Figure ‎1-16). The mechanism of this drug is inhibition of 
mucopeptide synthesis in the bacterial cell wall.[11, 23] 
 
Figure ‎1-16: Chemical structure of aztreonam (monobactam antibiotic).[23] 
Penicillins have been one of the most preferred antibiotics for the treatment of bacterial infections. 
The chemical structures of some examples of penicillin antibiotics like amoxicillin, carbenicillin, 
penicillin V and flucloxacillin are shown in Figure ‎1-17. 
 
Figure ‎1-17: Chemical structure of penicillin antibiotics. 
1.3 β-Lactam Antibiotics Resistance 
As all projects in the following Chapters deal with the hydrolysis of β-lactam antibiotics by 
bacteria, the discussion has only been limited to β-lactam antibiotics resistance. Bacteria have 
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several mechanisms to attain resistance against β-lactam antibiotics.[25] These include a) mutations 
to the active site of penicillin-binding-protein to prevent drug binding,[25] b) modification of the 
cell wall to prevent drug entry and assist active removal of antibiotic compounds,[25] and c) 
producing the class of enzyme known as β-lactamase, which includes serine β-lactamases and 
metallo-β-lactamase (MBLs) which hydrolyze the β-lactam ring of drug compound, thereby 
inactivating them.[25] One solution for the last mechanism is co-administration of antibiotics with 
β-lactamase inhibitors. These inhibitors prevent the metabolism of penicillins and spare their 
antibacterial action by inhibiting β-lactamase.  
For many years, antibiotics have been used extensively by physicians throughout the world and 
hence many bacteria have developed resistance against several agents of this class of drugs. Due to 
this, many infections which were treated effectively in the past have become life-threatening. This 
problem of resistance was overcome by including some new agents along with penicillin (sulbactam 
with ampicillin) which were able to inhibit the β-lactamase enzymes. Later, these agents were also 
found ineffective and there was a need to discover new classes of β-lactamase inhibitors.[11, 26, 27] 
The aim of this research is to investigate, design, dock (using computer modeling software to 
calculate optimized geometries and binding energies of molecules within the enzyme‟s active site), 
synthesize and screen new compounds against metallo-β-lactamase (MBLs). 
1.4 Classification of β-Lactamases 
β-Lactamases are enzymes produced by bacteria which are responsible for bacterial resistance to β-
lactam antibiotics. The β-lactamases act by cleaving the lactam ring and deactivating the molecule's 
antibacterial properties (Figure ‎1-18).[28] 
 
Figure ‎1-18: Hydrolysis of antibiotics by β-lactamase enzyme. 
The β-lactamase enzyme was first identified in Escherichia coli by Abraham and Chain in 
1941[29]. However, the group was not successful in isolating the enzyme until four years later 
when a β-lactamase enzyme was successfully isolated by Kirby from Staphylococcus aureus.[30] 
There are different classification schemes for β-lactamase enzymes which are based on amino acid 
sequence homology, substrate and inhibitor profiles or functional characteristics.[31] 
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The classification proposed by Ambler divides β-lactamases into zinc-containing enzymes (class B) 
and serine β-lactamases (classes A, C, D) based on amino acid sequence homology 
(Figure ‎1-19).[32] The crystal structures of some enzymes are available in Protein Data Bank 
(PDB).[33] 
 
Figure ‎1-19: Ambler‟s classification of β-lactamases.[32] 
1.4.1 Serine β-Lactamases 
1.4.1.1 Serine β-Lactamase Classes 
Table ‎1-1 summarizes all three classes of serine β-lactamases (A, C and D) enzymes and their 
substrates published by Bush et al. and was current as of 2010.[34] 
Table ‎1-1: Classification schemes for serine β-lactamases, expanded from Bush et al.[34] 
Bush-Jacoby 
Group (2010) 
Class Enzyme Substrate(s) 
1 C 
E. coli AmpC, P99, ACT-1, CMY-2, 
FOX-1, MIR-1 
Cephalosporins 
1e C GC1, CMY-37 Cephalosporins 
2a A PC1 Penicillins 
2b A TEM-1, TEM-2, SHV-1 
Penicillins, first and second generation of 
cephalosporins 
2be A 
TEM-3, SHV-2, CTX-M-15, PER-1, 
VEB-1 
Extended-spectrum cephalosporins, monobactams 
2br A TEM-30, SHV-10 Penicillins 
2ber A TEM-50 Extended-spectrum cephalosporins, monobactams 
2c A PSE-1, CARB-3 Carbenicillin 
2ce A RTG-4 Carbenicillin, cefepime 
2d D OXA-1, OXA-10 Cloxacillin 
2de D OXA-11, OXA-15 Extended-spectrum cephalosporins 
2df D OXA-23, OXA-48 Carbapenems 
2e A CepA Extended-spectrum cephalosporins 
2f A KPC-2, IMI-1, SME-1 Carbapenems 
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1.4.1.2 Mechanism of Serine β-Lactamases 
Serine β-lactamases inactivate β-lactam antibiotics by the formation of an acyl enzyme 
intermediate, which is produced by nucleophilic attack on the β-lactam by the hydroxyl group of a 
serine residue. In this proposed mechanism, Glu166 participates in activating a water molecule for 
both acylation (a) and deacylation (c) steps (Figure ‎1-20).[31] 
 
Figure ‎1-20: Proposed mechanism for inactivation of typical penicillin by a class A serine β-lactamase enzyme. Hydrogen bonds are 
shown by dashed lines. (The picture was adapted from Drawz et al.).[31] 
1.4.1.3 Inhibitors of Serine β-Lactamases 
Approximately 50% of available antibiotics in the market are β-lactams.[35] Effective inhibitors 
have been discovered for a number of serine β-lactamases such as clavulanic acid, sulbactam and 
tazobactam (Figure ‎1-21).[32, 36-38] Clavulanic acid is a commercially and clinically available 
inhibitor for serine β-lactamases which is co-administrated with antibiotics such as amoxicillin 
(typically sold as Co-amoxiclav).[39] 
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Figure ‎1-21: Structure of sulbactam, tazobactam and clavulanic acid.[39] 
Figure ‎1-22 shows that how serine β-lactamase is inhibited by clavulanic acid which is the inhibitor 
of this class. The author has reported different mechanism for inhibition of serine β-lactamase by its 
inhibitor; clavulanic acid. For facilitation of the study, only one step of the mechanism has been 
shown in Figure ‎1-22.[40] The reaction between serine β-lactamase and clavulanic acid is 
irreversible, therefore, serine β-lactamase is inhibited by clavulanic acid.  
 
Figure ‎1-22: Proposed mechanism of inactivation of serine β-lactamase by clavulanic acid.[40] 
1.4.2 Metallo-β-Lactamases 
In contrast to serine β-lactamases, MBLs use at least one but more commonly two Zn2+ ions in their 
active site to catalyze the hydrolysis of β-lactam rings. In 2009, a new carbapenem-resistant 
Klebsiella pneumoniae strain was found in New Delhi (India) by a group of researchers led by 
Yong. It was later named as NDM-1.[41] This posed a new challenge to develop new MBL 
inhibitors as none of the antibiotics were effective against NDM-1.  
1.4.2.1 Metallo-β-Lactamase Subclasses 
MBLs are classified into three subclasses (B1, B2 and B3).[42] This division is based on substrate 
selectivity and amino acid sequence, particularly the amino acid ligands that chelate the Zn
2+
 
ions.[43, 44] Table ‎1-2 summarizes various MBLs according to their subclasses.[45, 46] 
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Table ‎1-2: Classification of Metallo-β-lactamases.[45, 46] 
Subclass Enzyme
a 
Organism
b Genbank accession 
number 
PDB code
c 
B1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B2 
 
 
 
B3 
BcII 
CcrA 
IMP-1 
 
IMP-4 
VIM-2 
 
VIM-4 
 
VIM-7 
 
BlaB 
SPM-1 
NDM-1 
 
VIM-1 
 
GIM-1 
SIM-1 
DIM-1 
TMB-1 
Bla2 
KHM-1 
 
CphA 
Sfh-1 
ImiS 
 
L1 
FEZ-1 
BJP-1 
AIM-1 
THIN-B 
GOB-1 
CAU-1 
CAR-1 
SMB-1 
POM-1 
CRB11 
Bacillus cereus 
Bacteroides fragilis 
Pseudomonas aeruginosa 
Serratia marcescens, 
Enterobacter cloacae 
Pseudomonas aeruginosa, 
Acinetobacter baumanii 
Pseudomonas aeruginosa, 
Acinetobacter baumanii 
Pseudomonas aeruginosa, 
Acinetobacter baumanii 
Chryseobacterium meningoseptica 
Pseudomonas aeruginosa 
Klebsiella pneumonia, 
Escherichia coli 
Pseudomonas aeruginosa, 
Acinetobacter baumanii 
Pseudomonas aeruginosa 
Acinetobacter baumanii 
Pseudomonas stutzeri 
Achromobacter xylobacter 
Bacillus anthracis 
Citrobacter freundii 
 
Aeromonas hydrophila 
Serratia fonticola 
Aeromonas veronii 
 
Stenotrophomonas maltophilia 
Legionella gormannii 
Bradyrhizobium japonicum 
Pseudomonas aeruginosa 
Janthinobacterium lividum 
Chryseobacterium meningoseptica 
Caulobacter crescentus 
Erwinia caratovora 
Serratia marcescens 
Pseudomonas otitidis 
Uncultured bacterium 
M11189  
M63556  
M4PZF0 
S71932  
YP_006965428 
AF191564  
 
AY135661  
 
AM778842  
 
AF189298  
AY341249  
JN420336  
 
T18050 
 
AJ620678 
AY887066 
GU323019 
FR771847 
CP001598 
AB364006 
 
X57102  
AF197943  
Y01415 
 
AB294542  
Y17896  
NP772870  
AM998375  
CAC33832 
ABO21417 
CAC87665 
Q6D395 
AB636283 
ADC79555 
ACS83724 
1BMC 
1ZNB 
1JJT 
1DD6 
 
2YZ3, 1K02 
 
2WHG 
 
2Y87 
 
1M2X 
2FHX 
3Q6X, 
3SPU,3RKJ 
 
 
 
 
 
 
 
 
 
1X8G, 3F9O 
3SD9 
 
 
1SML 
1K07 
3LVZ45 
4AWY 
 
 
 
 
 
 
 
a Enzyme variants are not included in this table unless an X-ray structure of the variant is available. For example, there are many variants of IMP-1 
that are not listed in the table. 
b The strains listed represent the original strain(s) for which the enzyme was identified and does not include the bacteria to which the gene has spread. 
c Protein Data Bank codes are listed for all enzymes for which X-ray structures have been determined. 
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1.4.2.2 Metallo-β-Lactamase Structures 
A typical metallo β-lactamase has been shown in Figure ‎1-23. The picture below illustrates a 
surface picture of IMP-1. The active site is in the region which is shown by the yellow dotted line. 
For creation of this picture, IMP-1 (PDB Code: 1JJT) was downloaded and chain B was deleted as 
the topologies of the active sites of both chain A and chain B are identical then the surface was 
created with Maestro software. The active site of this enzyme contains two zinc atoms which are 
responsible for hydrolysis of β-lactam rings. However, they are not shown in this picture as single 
atoms are too small to be visible at this scale. In all chapters for showing the better results of 
docking, the size of both zinc atoms has been increased in the region of the active site of IMP-1. 
 
Figure ‎1-23: Representative typical active-site pocket of MBL (IMP-1). Figure was created with Maestro software 
(www.schrodinger.com/Maestro).[47] 
MBLs are classified into three groups on the basis of amino acid homology and conservation of 
active site residues as B1, B2 and B3.[42, 48-50] The availability of X-ray crystal structures has 
greatly facilitated the classification of MBLs.[50] In all three types of MBL (B1, B2 and B3), the 
active site possesses at least one but more often two zinc atoms, commonly labeled as Zn1 and Zn2. 
Both zinc atoms are chelated by three different amino acids. The numbering of amino acids that 
coordinate with two zinc ions is summarized in Table ‎1-3.[48-51] 
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Table ‎1-3: Subclasses of MBLs and their respective amino acid that coordinate the metal ions in active site.[48-51] 
Subclass Examples 
Substrate 
profile 
Amino acid ligands Involvement of Zn2+ ions for 
catalytic activity Zn1 ligands Zn2 ligands 
B1 
BcII, IMP-1, CcrA, 
VIM, NDM-1 
Broad Spectrum 
His 116 
His 118 
His 196 
Asp 120 
Cys 221 
His 263 
Mainly di-zinc but BcII is active 
with either one or two Zn2+ ions 
B2 CphA, Imis 
Only 
Carbapenems 
Asn 116 
His 118 
His 196 
Asp 120 
Cys 221 
His 263 
Mono-zinc (Zn2 site) but binding 
of Zn1 inhibits the MBL 
B3 L1 (tetramer), FEZ-1 Broad Spectrum 
His/Gln 116 
His 118 
His 196 
Asp 120 
His 121 
His 263 
Di-zinc 
The members of subclass B1 show more than 23% identity. In the active site of subclass B1 
(Figure ‎1-24a), one of the zinc ions is coordinated by three histidines (His116, His118 and His196) 
and a water molecule with the arrangement of the zinc ion being tetrahedral. The second zinc ion is 
coordinated by the carboxylate group of Asp120, the methylthiolate group of Cys221, the nitrogen 
atom in the imidazole group of His263 and two molecules of water. The geometry of this complex 
is distorted trigonal bipyramidal.[48-50] 
 
Figure ‎1-24: Representative structure of active site in MBLs. (a) Subclass B1, IMP-1 (PDB code: 1JJT). (b) Subclass B2, CphA 
(PDB code: 3F9O). (c) Subclass B3, L1 (PDB code: 1SML).[48-50]  
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The members of subclass B2 share only 11% of identity with subclass B1. In this subclass (B2), 
Zn1 is coordinated by Asn116, His118, His196 and Zn2 is bonded to Asp120, Cys221, His263 
(Figure ‎1-24b).[48-50] In addition, some members of the B2 subclass have only one zinc atom in 
the active site such as 18XG and 3SD9 enzymes.[45, 52] 
The coordination of Zn1 in subclass B3 is the same as in B1 (Figure ‎1-24c). Coordination around 
the Zn2 site, however, is different. In this case one of the coordinating residues for Zn2 has changed 
from Cys221 to His121. An associated change is that the Cys221 has been substituted for Ser221 
which now engages in a hydrogen bond interaction with the zinc bound water.[48-50] 
1.4.2.3 Crystal Structures of Metallo-β-Lactamases 
Despite their aforementioned differences, all MBLs are collectively characterized by αββα 
quaternary structural fold.[48, 50] The Zn
2+
 ion(s) containing active site is located at the edge of the 
ββ sheets.[48, 50] The distance between two zinc ions is roughly 3.4-4.4 Å for most of the 
MBLs.[43] There is a bridging water molecule between two zinc ions and it plays an important role 
in the hydrolysis of antibiotics (Figure ‎1-25). [48, 50, 53] 
 
Figure ‎1-25: 3D structures representing MBLs. The α-helices are shown in purple and yellow, β-sheets in green and red and Zn2+ 
ions as red spheres. (a) Subclass B1, IMP-1 (PDB code: 1JJT). (b) Subclass B2, CphA (PDB code: 1X8G). (c) Subclass B3, L1 
(PDB code: 1SML). Figure was created with Maestro software (www.schrodinger.com/Maestro). 
1.4.2.4 Substrates of MBLs 
As mentioned earlier, MBLs have the ability to hydrolytically degrade almost all of the β-lactam 
antibiotics including newer generation β-lactam antibiotics like cephalosporins and 
carbapenems.[43, 48] Clinical inhibitors of serine β-lactamase such as clavulanic acid, sulbactam 
and tazobactam are also substrates of MBLs.[31, 54] Additionally, none of the serine β-lactamase 
inhibitors are effective against MBLs. MBL substrates are collectively depicted in Figure ‎1-26.  
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Figure ‎1-26: Substrates of MBLs. 
1.4.2.5 Mechanism of Metallo-β-Lactamases 
As mentioned above, MBLs use at least one but more commonly two Zn
2+
 ions in their active site to 
catalyze the hydrolysis of β-lactam rings.[28] Two mechanisms are proposed for MBLs based on 
mono-zinc and di-zinc ions.[43, 48] In the mono-zinc mechanism, the formation of hydroxide 
nucleophile is facilitated with interaction of both the Asp120 residue and Zn
2+
 ion.[43, 48] The 
hydroxide group attacks the electrophilic carbonyl carbon to form the tetrahedral intermediate.[43, 
48] Finally, protonation of the tetrahedral intermediate nitrogen by the Asp120 residue results in C-
N bond cleavage and deactivation of penicillin (Figure ‎1-27).[43, 48] 
 
Figure ‎1-27: The proposed catalytic mono-zinc mechanism for MBLs with penicillin.[43, 48] 
The catalytic mechanism of di-zinc MBLs is slightly different. In this mechanism, the bridging 
hydroxide ion that is bound between the two Zn
2+
 ions is the attacking nucleophile.[43, 48] As 
usual, formation of the tetrahedral intermediate is necessary from the hydroxyl attack on the 
carbonyl group.[43, 48] In contrast to mono-zinc mechanism, instead of Asp120 residue, the 
perfectly positioned apical water molecule which is bound to Zn2 donates a proton to the leaving 
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nitrogen.[43, 48] The deprotonated apical water then migrates to Zn1 to regenerate the bridging 
hydroxide group (Figure ‎1-28).[43, 48] 
 
Figure ‎1-28: The proposed catalytic di-zinc mechanism for MBLs with penicillin.[43, 48] 
1.4.2.6 Assay of MBLs 
CENTA [49] (a type of cephalosporin) and Penicillin G (benzyl penicillin) [55] are good substrates 
for assays because of their commercial availability and ease of synthesis. As mentioned above, 
MBLs catalyze the hydrolysis of β-lactam antibiotics. The assay procedures for the measurement of 
MBL activity are based on the consequences of the hydrolysis of the lactam bond of the substrate. 
The MBL-catalyzed reaction is usually monitored by following the changing absorbance at the 
wavelength where the difference in the molar absorptivity, ΔɛM, is maximal or near the maximum 
value. For example, after hydrolysis of CENTA by MBL, a chromophore compound (3-carboxy-4-
nitrobenzenethiolate) is produced. This compound gives a yellow color to the solution and can be 
measured at 405 nm (Figure ‎1-29).[49] On the other hand, the concentration of benzyl penicillin 
(which absorbs at 235 nm) is reduced upon hydrolysis by MBL causing a decrease in absorption at 
235 nm over time thereby allowing a means to monitor the reaction (Figure ‎1-30).[56] Inhibitors of 
metallo-β-lactamase will decrease the rate of the hydrolysis of substrates (CENTA and Penicillin 
G), thereby providing a measure of the inhibitor‟s effectiveness. 
 
Figure ‎1-29: Hydrolysis of CENTA by MBL enzyme.[49] 
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The potency of an inhibitor is represented by its IC50, Ki, Kic, Kiuc and Kd. The IC50 is the inhibitor 
concentration required to reduce the enzyme activity by 50%. The Ki is the inhibition constant for 
the equilibrium between the bound and unbound forms of the inhibitor to the enzyme.[22] The Kic 
is defined as competitive inhibitor dissociation constant. Competitive inhibition is a form of enzyme 
inhibition where binding of the inhibitor to the active site on the enzyme prevents binding of the 
substrate and vice versa. The Kiuc is defined as uncompetitive inhibitor dissociation constant. 
Uncompetitive inhibition, also known as anti-competitive inhibition, takes place when an enzyme 
inhibitor binds only to the complex formed between the enzyme and the substrate. The Kd is defined 
as dissociation constant and it is the inverse of the association constant. Compounds which have 
lower values of IC50, Ki, Kic, Kiuc and Kd are identified as more potent inhibitors. 
 
Figure ‎1-30: Hydrolysis of benzyl penicillin by MBL enzyme.[55] 
1.4.2.7 Inhibitors of Metallo-β-Lactamases 
One potential strategy for overcoming the effects of MBLs is to co-administer MBL inhibitors with 
β-lactam antibiotics. Inhibitors prevent binding of the MBL enzyme to β-lactam antibiotics and 
prevent degradation and deactivation of antibiotics.  
Although there are clinically available inhibitors for serine β-lactamase, there are no clinically 
available inhibitors for MBLs. Additionally, none of the inhibitors for serine β-lactamases are 
effective against MBL enzymes.[31] The aim of this research is to design and synthesize inhibitors 
against MBL enzyme class B1 (IMP-1) which is one of the major enzymes for the degradation of β-
lactam antibiotics. Additionally, the crystal structure of IMP-1 is available in the PDB which 
facilitates the study of this enzyme. Furthermore, the IMP-1 enzyme has been expressed and 
purified in the McGeary group by Peter Vella (former PhD student).  
So far, various inhibitors for MBL have been reported in different categories such as thiols,[57-60] 
sulfates, dicarboxylic acids,[56, 61-63] trifluoromethylketones and alcohols,[64, 65] 
hydroxamates,[66] tetrazoles,[67] sulfonamides [68] and sulfonyl hydrazones.[68] They are briefly 
discussed below. 
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1.4.2.7.1 Thiol Inhibitors 
Compounds containing a zinc-binding sulfur atom comprise the first category of MBL 
inhibitors.[47] A number of low molecular weight thiol derivatives which can inhibit IMP-1 have 
been reported with a range of IC50 values from 0.19 to 12 µM (Figure ‎1-31).[57, 59] While Goto et 
al. reported that mercaptoacetic acid is a reversible inhibitor of IMP-1, a number of simple thiol 
ester derivatives of this compound are irreversible inhibitors of BcII, CphA and CcrA. Mass 
spectrometric studies indicated that this was due to the formation of a disulfide bond between the 
mercaptoacetic acid moiety and an active-site cysteine.[69, 70]  
 
Figure ‎1-31: Thiol inhibitors against IMP-1.[57, 59] 
Since that report, a large number of thiol and thiol-carboxylic acids have been reported as strong 
inhibitors against MBLs. Thiomandelic acid (racemic) was reported by Mollard et al. as a potent 
inhibitor of two classes of MBLs (B1 and B3) in 2001.[58] This inhibitor showed IC50=0.029 µM 
against IMP-1.[58] The activity of rac-thiomandelic acid inhibitor against classes B1, B2 and B3 
MBLs are shown in Table ‎1-4. 
Table ‎1-4: Activity of rac-thiomandelic acid inhibitor against classes B1, B2 and B3 MBLs.[58] 
Inhibitor 
B1 B2 B3 
IMP-1
a
 (µM) BcII
a
 (µM) 
CphA
a
 
(µM) 
L1
a
 (µM) 
FEZ-1
a
 
(µM) 
 
0.029
b 
0.34
b
 144
b 
0.081
b 
0.27
b 
a 
Kic values. 
b 
Standard deviation less than 20%.  
L-Captopril is a commercially available antihypertensive drug which functions by inhibiting the 
mono-zinc angiotensin converting enzyme (ACE).[62] Its diastereomer D-captopril is only 
accessible by synthesis from D-proline.[60] Both D- and L-captopril have been studied as broad 
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spectrum inhibitors of MBLs with the D-isomer exhibiting more potent inhibitory activity than the 
L-isomer against the MBLs tested.[60, 62, 71] Activity of D- and L-captopril inhibitors against 
classes B1, B2 and B3 MBLs are shown in Table ‎1-5. 
Table ‎1-5: Activity of D- and L-captopril inhibitors against classes B1, B2 and B3 MBLs.[60, 62, 71] 
Inhibitor 
B1 B2 B3 
IMP-1
a
 (µM) BcII
a 
(µM) NDM-1
b 
(µM) 
CphA
a
 
(µM) 
L1
a
 
(µM) 
FEZ-1
a
 
(µM) 
 
- 45 ± 5 7.9
b 
72 ± 6 20
c 
- 
 
12.5 ± 2.4 63 ± 5 202
b 
950 ± 80 - - 
a 
Kic values. 
b 
IC50 values. 
c Standard deviation less than 20%. „‟-„‟ denotes not determined. 
Figure ‎1-32 depicts the crystal structure of D-captopril in the active site of BlaB (PDB code 
1M2X).[44] Figure ‎1-33 shows a 2D interaction diagram representing bound D-captopril 11 at the 
active site of BlaB. Figure ‎1-32 and Figure ‎1-33 show the most important interactions of D-captopril 
in the active site of BlaB. Figure ‎1-32 shows D-captopril is coordinated to both Zn1 (2.30 Å) and 
Zn2 (2.32 Å). Figure ‎1-33 shows the carboxylate group of D-captopril forms hydrogen bonds with 
Lys167 and Asp119.[44] 
 
Figure ‎1-32: 3D Crystal structure of BlaB with D-captopril 11 (PDB code 1M2X).[44] 
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Figure ‎1-33: 2D interaction diagram representing bound D-captopril 11 at the active site of BlaB (PDB = 1M2X).[44] Figure was 
created with Maestro software (www.schrodinger.com/Maestro). 
Hammond et al.[59] synthesized and reported a few thiol-carboxylic acid derivatives as potent 
inhibitors against IMP-1 with IC50 value as low as 0.023 µM (Figure ‎1-34). No crystal structure and 
representative docking were reported for these inhibitors. 
 
Figure ‎1-34: Thiol-carboxylic acid inhibitors against IMP-1.[59] 
Kurosaki et al.[72] reported two potent irreversible inhibitors of IMP-1 which are shown in 
Figure ‎1-35. The crystal structures of IMP-1 co-crystallized with these two inhibitors show the 
thiolate group binds to the two zinc ions, as is the case with D-captopril. The mechanism of 
irreversible inhibition is also shown in Figure ‎1-36.[72] 
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Figure ‎1-35: Irreversible inhibitors of IMP-1.[72] 
 
Figure ‎1-36: Mechanism for irreversible inhibition of IMP-1 (PDB code 1DD6) with compound 18.[72] 
The same authors later reported the dansyl-modified thiols as inhibitors of IMP-1 and fluorescent 
probes for the detection of MBLs.[73] These inhibitors are not irreversible and the most potent of 
this series (n=4) had a Kic value of 0.14 µM (Figure ‎1-37 and Table ‎1-6).[73] 
 
Figure ‎1-37: Structures of DansylCnSHs (n=2–6).[73] 
Table ‎1-6: Kic and IC50 values for DansylCnSHs (n=2–6) toward IMP-1.[73] 
Number Compound Kd[µM]
 [a] 
Kic [µM]
 [b] 
IC50 [µM]
[b] 
19 
20 
21 
22 
23 
DansylC2SH 
DansylC3SH 
DansylC4SH 
DansylC5SH 
DansylC6SH 
0.36 ± 0.07 
0.98 ± 0.11 
0.07 ± 0.01 
0.15 ± 0.04 
0.11 ± 0.04 
1.10 ±0.06 
1.30 ± 0.10 
0.14 ± 0.01 
0.28 ± 0.01 
0.16 ± 0.01 
5.2 ± 0.4 
6.3 ± 0.7 
0.7 ± 0.1 
1.6 ± 0.1 
1.0 ± 0.1 
[a] Determined at 25 °C. [b] Determined at 30 °C. 
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Thus far, in this category, Lienard et al.[44] reported the most potent thiol-carboxylic acid 
inhibitors against different subclasses B1, B2 and B3. The structures and their kinetic data are 
shown in Table ‎1-7.[44] Entry 27 (2-(3-mercaptopropanamido)-2-phenylacetic acid) shows the 
lowest Ki value as 0.019 µM against IMP-1.[44] 
Table ‎1-7 : Competitive inhibition constants Ki (µM) of potent thiol-carboxylic acid inhibitors against MBLs.[44] 
 
1.4.2.7.2 Dicarboxylate inhibitors 
The dicarboxylate compounds are the second most common inhibitors of MBL enzymes.[47] Some 
carboxylate inhibitors are reported with IC50 values as low as 0.003 µM.[47] 
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Hiraiwa et al.[56] synthesized some phthalic acid derivatives and assayed them against IMP-1.[56] 
These compounds showed good inhibitory effect against IMP-1 and the benzyl phthalic acid 
derivative (32) showed the lowest IC50 value amongst inhibitors with 0.968 µM (Figure ‎1-38).[56]
 
 
Figure ‎1-38: Phthalic acid inhibitors against IMP-1.[56] 
The same authors also reported some more 4-substituted phthalic acid derivatives, but the IC50 
values were not as good as previous inhibitors, ranging from 16 to 300 µM (Figure ‎1-39).[56] 
 
Figure ‎1-39: IMP-1 inhibitory activity of 4-substituted phthalic acid derivatives.[56] 
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In 2004, Moloughney et al.[74] reported some dicarboxylate inhibitors against IMP-1. The most 
potent one has Ki value of 3.3 µM. Figure ‎1-40 shows three most potent of these inhibitors.[74] 
 
Figure ‎1-40: Three potent dicarboxylate inhibitors against IMP-1 enzyme.[74] 
The most potent inhibitors against IMP-1 were reported by Toney et al.[61] in 2001. This group 
identified a number of dicarboxylate compounds and assayed them against IMP-1 enzyme.[61] 
They identified succinic acid (48) with IC50=6.3 mM is not a good inhibitor against IMP-1 whereas 
the (2S,3S)-disubstituted succinic acids were very potent inhibitors. Four compounds (51-54) 
showed IC50 between 2.7 nM and 13 nM (Figure ‎1-41).[61] The 2,2-disubstituted succinic acids 
(49-50) were not potent IMP-1 inhibitors. Among all different categories of IMP-1 inhibitors, 
compound 51 was identified as the most potent inhibitor with lowest IC50=2.7 nM 
(Figure ‎1-41).[61] 
 
Figure ‎1-41: Dicarboxylate inhibitors against IMP-1.[61] 
The crystal structure of compound 53 co-crystalized with IMP-1 (PDB=1JJT) was also reported by 
Toney et al. (Figure ‎1-42).[61] Figure ‎1-42 shows one of the carboxylates is coordinated to both 
Zn1(2.13 Å) and Zn2 (2.05 Å) whereas the other carboxylate is coordinated to only Zn2 (2.49 Å). 
In addition, both carboxylates form hydrogen bonds with amino acid residues Gly232 and 
Asn233.[61] 
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Figure ‎1-42: Crystal structure of IMP-1 co-crystalized with potent inhibitor 53 (PDB = 1JJT).[61] 
1.4.2.7.3 Trifluoromethyl Ketone and Alcohol Inhibitors 
In 1996, Walter et al.[64] reported trifluromethyl ketone and alcohol derivatives as inhibitors 
against MBLs (Figure ‎1-43). These compounds were assayed against different subclasses of MBL 
and Ki values measured against BcII (subclass B1), VIM-2 (subclass B1), CphA (subclass B2) and 
L1 (subclass B3) were as low as 1.5 µM.[64] The oxygen atom of the trifluromethyl ketone group 
of these inhibitors was presumed to bind to the active site zinc ion in its hydrate form (non-
fluorinated analogues were inactive).[64] In addition, binding of these compounds to CphA was 
shown to be irreversible, indicating a different mechanism of inhibition of these compounds for 
different MBLs.[64] Table ‎1-8 shows Ki values of these inhibitors against three MBLs. 
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Figure ‎1-43: Trifluoromethyl ketones and alcohols inhibitors against metallo-β-lactamases.[64] 
Table ‎1-8: Ki values (in µM) against three MBLs (Subclasses B1 and B3).[64] 
Compound 
B1
* 
B3 
BcII IMP-1 L1 
55a (2R, 3S); (2S, 3S) 300 400 >5000 
55b (2R, 3R); (2S, 3R) 700 400 35 ± 2 
57a (3S) 300 300 1.5±0.01 
57b (3R) 700 500 3.0 ± 0.4 
56a (2R, 3S); (2S, 3S) 1000 900 >5000 
56b (2R, 3R); (2S, 3R) 30 60 >5000 
58a (3S) 500 530 15±1 
58b (3R) 1000 Not tested Not tested 
* The author has not reported any errors for theses kinetic assay. 
1.4.2.7.4 Sulfonamide Inhibitors 
Sulfonamides are another common class of MBL inhibitors. A number of sulfonyl hydrazones were 
examined against IMP-1 by Siemann et al.[68] For some of these compounds IC50 values ranged 
from 2 to 150 µM (Table ‎1-9). The compounds having anthracenyl group showed the lowest IC50. 
Among all compounds, compound 59c showed the maximum inhibition with IC50 value of 2.2 µM.  
The docking study of compound 59c with IC50 value 2.2 µM predicted that one of the oxygen atoms 
of this inhibitor bonded to the zinc in the active site while the other oxygen made a hydrogen bond 
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with Asp167. No crystal structure has been reported for the enzyme with these molecules bonded 
into the active site. 
Table ‎1-9: Inhibitory activity of various 2-hydroxynaphthyl, 2-methoxynaphthyl and anthracenyl derivatives against IMP-1.[68] 
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1.5 Docking 
In the field of molecular modeling, docking is a method which predicts the preferred orientation of 
one molecule to a second when bound to each other to form a stable complex. Knowledge of the 
preferred orientation in turn may be used to predict the strength of association or binding affinity 
between two molecules using, for example, scoring functions (Escore). 
Docking is frequently used to predict the binding orientation of small molecule drug candidates to 
their protein targets in order to in turn predict the affinity and activity of the small molecule. Hence 
docking plays an important role in the rational design of drugs.[2] Given the biological and 
pharmaceutical significance of molecular docking, considerable efforts have been directed towards 
improving the methods used to predict docking. 
The crystal structures of appropriate proteins are available in Protein Data Bank. Therefore, it is 
possible to download the enzymes and use them for docking study. There are different software for 
docking purposes such as MolDock, Gold, Maestro, Pymol and SYBYL. Each program has its own 
system for calculation of scoring functions. In the following Chapters, MolDock has been used for 
docking study. Some pictures are created with Maestro as its outcome results have very good 
quality. 
Escore values are not same in different docking software and it is not also expected to see the same 
results of docking. Using different software can also help to have better judgment about the binding 
and orientation of the molecule into the active site of the enzyme. In MolDock program, in order to 
compare different inhibitors, the effectiveness of the binding interaction is represented as a relative 
value (MolDock score), which is calculated by the addition of calculated intra- (internal energy of 
the inhibitor) and inter-molecular (inhibitor-protein interaction) energies (Equation 1.1). Higher 
calculated energy (Escore) indicates a prediction of stronger binding of the inhibitor to the enzyme. 
 
1.6 Aims of This Work 
As discussed in this chapter, IMP-1 is an enzyme which is produced by bacteria to inactivate the 
action of antibiotics by hydrolyzing their β-lactam ring. Co-administration of IMP-1 inhibitors with 
antibiotics may show significant antibacterial activity. Thus, the aims of the research are: 
a) To design new IMP-1 Inhibitors. 
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b) To use the MolDock software to predict and visualize the optimum binding of the potential 
inhibitors in the active site of the IMP-1. 
c) To synthesize new IMP-1 inhibitors. 
d) To express and purify IMP-1. 
e) To investigate the inhibition properties of the new IMP-1 inhibitors. 
Chapter 2: 
As already discussed, thiol carboxylic acid compounds were reported as the most common category 
of MBL (IMP-1). In this category, thiol carboxylic acid compound 29 was reported as potent 
inhibitor with Kic value 0.088 µM.[44] Compound 29 is shown below. 
 
Therefore, this compound was used as a lead for future investigation and future work. 
Consequently, compounds below were designed, docked (computational modeling of their 
interactions with the active site of the IMP-1), synthesized and assayed against IMP-1. 
 
Chapter 3: 
Compound 75a was obtained as a potent inhibitor of IMP-1 with Kic value of 0.086±0.024 µM. This 
compound was used as a lead for new project. There were two options for designing new 
compounds: manipulation of the benzyl group or the central phenyl ring of compound 75a. The 
design of new compounds was carried out based on the docking study and the cost of commercial 
compounds. Accordingly, eleven derivatives of compound 75a were designed and docked 
(computational modeling of their interactions with the active site of the enzyme). The docking 
energy calculations predicted that these compounds would be better inhibitors than 75a. Therefore, 
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they were expected to show lower Kic values. Compounds below were synthesized and assayed 
against IMP-1. 
 
Chapter 4: 
The next approach in IMP-1 inhibitor design was to screen virtual compounds from the ZINC 
Database Library (www.zinc.docking.org) for their affinity towards the enzyme. Accordingly, four 
compounds were found to have the highest binding energies. However, they were modified with 
changing substituents to simplify synthesis and reduce costs, the side chains were modified. Due to 
commercial availability of cyclohexanoyl chloride, benzoyl chloride and its nitro derivatives, the 
substituents were replaced with these moieties. The docking results were investigated and suggested 
that the syntheses would be worthwhile. Consequently, compounds 113-116 were synthesized and 
assayed against IMP-1. 
 
Chapter 5: 
Two lead imidazole derivatives (compounds 152 and 154) were introduced by Vella et al. against 
IMP-1.[75] These two compounds showed 53% and 50% inhibition at the concentration of 1 mM. 
Accordingly, twenty-four derivatives of these compounds were designed, docked, synthesized and 
assayed against IMP-1. 
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2 Chapter 2 
Synthesis of Thiol Carboxylic Acid Inhibitors Against IMP-1
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2.1 Introduction 
As discussed in Chapter 1, β-lactam antibiotics are the most widely prescribed drugs for the 
treatment of bacterial infections. However, in recent years the emergence of pathogenic bacteria 
that can secrete β-lactamases (enzymes that deactivate these antibiotics by hydrolysis of their β-
lactam ring) has led to great concern regarding the abilities of current drugs to adequately treat 
disease.[1] β-Lactamases may be classified into serine-β-lactamases (Classes A, C and D) and 
metallo-β-lactamases (MBLs, Class B), according to their mechanisms of action. MBLs are further 
divided into three subclasses, B1, B2 and B3, depending on their amino acid sequences and metal 
occupancies.[2] There can be one or two zinc (II) ions in their active sites.[3-7] There are currently 
no clinically available inhibitors of metallo-β-lactamases (MBLs). These enzymes confer resistance 
against a broad range of commonly used antibiotics and are produced by many pathogenic bacteria. 
Compounds containing a thiol functionality are the most commonly reported category of MBLs 
inhibitors.[8] In this Chapter, the design, docking, syntheses, and inhibitory effects of several thiol 
derivatives of L-amino acids against the metallo-β-lactamase IMP-1 (subclass B1) are described. 
The most potent compound, derived from L-tyrosine, exhibited competitive inhibition, with a Kic of 
0.086±0.024 µM. The ability of this compound to render MBL-expressing bacteria susceptible to 
imipenem was examined. Reductions in MIC (minimum inhibitory concentration: the lowest 
concentration of antimicrobial that inhibits the growth of a microorganism) values up to 5.2-fold 
were observed. Minimum inhibitory concentrations are important in diagnostic laboratories to 
confirm resistance of microorganisms to an antimicrobial agent and also to monitor the activity of 
new antimicrobial agents. 
2.2 Result and Discussion 
The design of the first project was based on the work of Liénard et al. on thiol carboxylic acid 
derivatives.[9] The authors reported that the N-(3-mercapto)propanoyl derivative of unnatural D-
phenylalanine (68b) was a competitive inhibitor of IMP-1, with a Kic of 0.088 µM (Figure ‎2-1). 
Because of the low Kic value for this inhibitor, investigation and design of a new series of thiol 
carboxylic acid inhibitors were very promising. Accordingly, the compounds which are shown in 
Figure ‎2-2 were designed and the result of computational modeling was acquired and compared to 
the reference compound 68b (2.2.1). The docking results of computational modeling were 
investigated and suggested that the syntheses would be worthwhile. Consequently, compounds 72a-
c, 73a-c, 74 a-c and 75a-c were synthesized and their inhibitory activities were measured against 
IMP-1.  
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Figure ‎2-1: IMP-1 inhibitor reported by Liénard et al.[9] 
 
Figure ‎2-2: Designed thiol carboxylic acid inhibitors of IMP-1. 
2.2.1 Docking Studies 
Computational modeling can assist in identifying the mode of binding of an inhibitor when 
compared with the known reference compound (an inhibitor which is reported and known such as 
compound 68b), it also gives possible binding interactions (hydrogen bonding, ionic interactions, 
etc). Thomsen et al. have shown that among different docking software packages, MolDock (within 
the Molegro program) [10] is the most accurate software for computational modeling of the binding 
of small molecules to proteins.[11] The docking accuracy of MolDock has been evaluated by 
docking flexible ligands to 77 protein targets. MolDock was able to identify the correct binding 
mode of 87% of the complexes. In comparison, the accuracy of Glide and Surflex is 82% and 75%, 
respectively. FlexX obtained 58% and GOLD 78% on subsets containing 76 and 55 cases, 
respectively.[11] 
As already discussed in Chapter 1, In order to compare different inhibitors, the effectiveness of the 
binding interaction is represented as a relative value (MolDock score), which is calculated by the 
addition of calculated intra- (internal energy of the inhibitor) and inter-molecular (inhibitor-protein 
interaction) energies (Equation 1.1). Higher calculated energies (Escore) indicate a prediction of 
stronger binding of the inhibitor into the active site of the enzyme. 
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For computational modeling, the crystal structure of IMP-1 enzyme (PDB code 1JJT) [12] was 
downloaded from the Protein Data Bank (PDB) and used in all subsequent docking studies.[13] 
1JJT is a functionally monomer protein but crystallized as a dimer with 221 amino acids in each 
chain A and B. Both chain A and chain B have identical amino acid residues and two zinc atoms at 
the active site. The topologies of the active sites of both chain A and chain B are identical and hence 
chain B was deleted and chain A was used for the docking study. As mentioned in Chapter 1, the 
active site (which contains the di-zinc centre) is situated in a pocket. The cavity of the active site 
with two zinc atoms was determined by MolDock and it was used for the docking study. This cavity 
was determined with Detect Cavity Option in MolDock software. The assay of inhibitors against 
IMP-1 was modeled in the well at pH=7. Since the pKa of carboxylic acids are typically ~4.2 it 
would be expected that they would predominantly exist in the ionized state (carboxylate). On the 
other hand, despite the fact thiols have a pKa of ~8 (and therefore would be anticipated to exist in 
the unionized form), coordination to the Lewis acidic zinc atoms would increase the ionizability of 
the sulfur centre, thereby allowing deprotonation. The software is incapable of predicting these 
chemical changes. Therefore, for the purposes of modeling, thiols and carboxylic acids were 
converted to thiolate and carboxylate groups before starting docking. All of the compounds and the 
reference compound 68b were docked in silico to IMP-1. 
The reference compound 68b showed Escore = -176.9 kcal/mol whereas most D- and L- amino acid 
thiol carboxylic acid compounds showed higher calculated energies (Escore) than compound 68b 
(Table ‎2-1). Therefore, it was predicted that the compounds with higher calculated energy (Escore) 
than the reference compound 68b show better inhibitory activity. 
Table ‎2-1: Molegro Virtual Docker Escore results for D- and L- amino acid derivatives (Escore for carboxylate and thiolate). 
Compound 
MolDock Score (kcal/mol) for 
D-derivatives (COO
-
 and S
-
) 
 Compound 
MolDock Score (kcal/mol) for 
L-derivatives (COO
-
 and S
-
) 
68a -159.9  72a -161.1 
68b -176.9
* 
 72b -174.0 
68c -182.4  72c -180.1 
69a -183.5  73a -178.1 
69b -195.6  73b -194.0 
69c -202.3  73c -198.7 
70a -164.8  74a -166.5 
70b -180.6  74b -179.2 
70c -189.2  74c -187.2 
71a -190.0  75a -190.8 
71b -191.6  75b -188.2 
71c -190.4  75c -192.2 
* Liénard‟s compound as Reference    
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The results of computational modeling predicted that all inhibitors coordinate directly to the Zn1 
and Zn2 of the active site of IMP-1 via their thiolate group. Additionally, it was also predicted that 
all inhibitors interact with other regions of the enzyme (the hydrophobic loop, hydrophilic residues 
near the active site) in order to increase the strength of the overall binding. The study of 
computational modeling also showed that the predicted distance between either Zn(II) ion in the 
enzyme and the thiolate in the inhibitors would be in the range of 1.90 to 2.0 Å. As no crystal 
structure has been reported for the reference compound 68b, this compound was also docked into 
the active site of IMP-1 and its calculated energy value (Escore) as well as the orientation of binding 
were used as the reference. The prediction of the result of computational modeling showed that 
compound 68b was coordinated to the Zn1 (1.86 Å) and Zn2 (1.94 Å) of the active site of IMP-1 
via their thiolate group (Figure ‎2-3 and Figure ‎2-4). 
Therefore compound 68b was used for the prediction of the strength of binding of designed thiol 
carboxylic acid inhibitors 72a-c, 73a-c, 74 a-c and 75a-c in the active site of IMP-1. Analogously to 
compound 68b, all designed compounds were predicted to coordinate to either or both zinc atoms 
with the predicted distances in the range of 1.80 to 2.0 Å. Additionally, the predictions of modeling 
also showed that the orientation of the aromatic rings of inhibitors 72a-c, 73a-c, 74 a-c and 75a-c to 
the aromatic rings of Trp64 and His263 may provide π-π stacking interaction as well.  
Although all D- and L- amino acid derivatives showed higher calculated energies (Escore) than the 
reference compound 68b, only the natural L-amino acid derivatives were synthesized. This was due 
to the ready availability and lower cost when compared to the D-amino acid starting materials. 
Because of this, the work presented here focuses on discussion and synthesis of thiol derivatives of 
three natural aromatic amino acids (L-phenylalanine, L-tyrosine and L-tryptophan) and their 
subsequent activity against IMP-1. The results of kinetic activities of compounds 72a-c, 73a-c, 74 
a-c and 75a-c are reported in section 2.2.3.1. 
Figure ‎2-3 and Figure ‎2-4 show the reference compound 68b from the D- series docked into the 
active site of IMP-1. The result of computational modeling predicted that the reference compound 
68b is coordinated to both zinc atoms (Zn1=1.86 Å and Zn2=1.94 Å) via its thiolate. The modeling 
also predicted that the reference compound 68b could form two hydrogen bonds with Lys224. The 
other prediction is making π-π stacking interaction between the phenyl ring of this inhibitor and the 
aromatic ring of Trp64. 
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Figure ‎2-3: Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 68b (electrostatic surface view). Atom colors on inhibitor are 
as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. The yellow spheres are zinc atoms. 
 
Figure ‎2-4: Interaction of docked ligand 68b at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–sulfur (on 
inhibitor). 
Figure ‎2-5 and Figure ‎2-6 show the most potent inhibitor 75a (section 2.2.3.1) from the L- series, 
docked into the active site of IMP-1. Docking result for compound 75a predicted that the thiolate is 
coordinated to both zinc atoms (Zn1=1.95 Å and Zn2=1.98 Å). It was also predicted that the oxygen 
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of amide group of ligand forms a hydrogen bond (3.19 Å) with the side chain amide group of 
Asn233. As the predicted distances of the central phenyl ring of the ligand 75a with the aromatic 
rings of Trp64 and His263 are around 4 Å, the other prediction was making π-π stacking interaction 
between the central phenyl ring of this ligand with the aromatic rings of either Trp64 and His263. 
 
Figure ‎2-5: Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 75a (electrostatic surface view). Atom colors on inhibitor are 
as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. The yellow spheres are zinc atoms. 
 
Figure ‎2-6: Interaction of docked ligand 75a at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–sulfur (on 
inhibitor). 
Another compound 72a (section 2.2.3.1) showed Kic value of 0.25±0.20 µM. The study of 
computational modeling showed that binding orientation was predicted to be similar to the other 
compounds including the most potent compound 75a showing thiolate coordination interaction with 
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both zinc atoms (3.18 Å to Zn1 and 1.99 Å to Zn2). The modeling also predicted that the 
carboxylate group of the ligand showed ionic interaction with side chain amine Lys224 (an ionic 
interaction between the negative carboxylate and the positive protonated amine of the Lys224). 
Trp64 is part of the flexible loop that covers the active site of IMP-1. It is known to move when 
substrates or inhibitors bind. As the predicted distance between the aromatic ring of Trp64 and the 
phenyl ring of the ligand 75a is around 4 Å, therefore, it was predicted that the phenyl ring of the 
ligand may make a π-π stacking interaction with Trp64 (Figure ‎2-7 and Figure ‎2-8). 
 
Figure ‎2-7: Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 72a (electrostatic surface view). Atom colors on inhibitor are 
as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. The yellow spheres are zinc atoms. 
 
Figure ‎2-8: Interaction of docked ligand 72a at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–sulfur (on 
inhibitor). 
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The pictures of docking of the other molecules have shown in Appendix C. 
Although the study of Escore and Kic values showed that the calculated energy values (Escore) 
increases from shorter-chain thioacetic acid-derived to the longer-chain but the enzyme kinetic 
studies showed that the activity decreased from shorter-chain thioacetic acid-derived to the longer-
chain. This was contrary to the expectation of the trend. The only expectation was compound 75a 
which showed the expected trend of activity and Escore. Figure ‎2-9 shows the trend of Escore and Kic 
values of compounds 72a-c, 73a-c, 74a-c and 75a-c. The study of the computational modeling of 
compound 75a shows that the distances of thiolate to zinc atoms are 1.95 Å and 1.98 Å whereas 
they are 1.75 Å and 2.04 Å for compound 75b and 1.79 Å and 3.14 Å for compound 75c. It seems 
maybe one of the important predicted reasons for higher activity of compound 75a than 75b and 
75c is the same distances of coordination of thiolate to zinc atoms. The other predicted factor for 
higher activity of 75a than 75b and 75c is the orientation of central phenyl ring of this compound 
with Trp64 and His263 which causes making two π-π stacking interactions with the appropriate 
amino acids. According to the predicted docking, the central phenyl ring of the other two molecules 
(75b-c) could make weaker π-π stacking interactions with Trp64 and His263 as the central phenyl 
rings of compound 75b-c are faced to the half of the aromatic rings of Trp64 and His263. For all 
compounds 72a-c, 73a-c and 74a-c, from shorter-chain thioacetic acid-derived to the longer-chain, 
the quality of making π-π stacking interactions decreases which is predicted to be one of the 
important reason of decreasing inhibitory activities. 
 
Figure ‎2-9: The trend of Escore and Kic values of compounds 72a-c, 73a-c, 74a-c and 75a-c. 
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2.2.2 Synthesis 
When the docking studies were completed, twelve inhibitors were synthesized. Scheme ‎2-1 shows 
the retrosynthesis of these compounds (72a-c, 73a-c, 74a-c and 75a-c).  
 
Scheme ‎2-1: The retrosynthsis of compounds 78a-c, 87a-c, 89a-c, 91a-c, 93a-c, 72a-c, 73a-c, 74a-c and 75a-c. 
Compounds 72a-c, 73a-c, 74a-c and 75a-c are new compounds and could be synthesized with the 
hydrolysis of intermediates 87a-c, 89a-c, 91a-c and 93a-c. All compounds 87a-c, 89a-c, 91a-c and 
93a-c are also new and have not been previously reported except the other enantiomer of compound 
72b. These compounds could be synthesized with L-methyl ester of compounds 86, 88, 90, 85 and 
compounds 78a-c as well as using HBTU as coupling reagent and DIPEA as a base. The L-methyl 
ester of compounds 94, 95, 82 and 84 should be used for coupling with HBTU, otherwise, the 
coupling could happen with both carboxylic acid and amine groups. For the preparation of 
compound 85, it is necessary to protect the amine group of compound L-tyrosine and then reacting 
with benzyl bromide for synthesis of compound 84, otherwise, benzyl bromide could react with 
both hydroxyl and amine groups. 
The synthetic routes to compounds 78a-c are shown in Scheme ‎2-3. Compounds 78a [14] and 78b 
[15] were synthesized by the reaction of thioacetic acid with bromoacetic acid and acrylic acid 
respectively. Compound 78c [16] was prepared by the reaction of potassium thioacetate and 4-
chlorobutanoic acid. In all cases, yields were around 60%. NMR analysis confirmed the structures 
of the synthesized compounds 78a-c and was consistent with previously reported data.[14-16] 
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Scheme ‎2-2: Reagents and conditions: (a) NaHCO3, H2O, r.t., overnight, 65%; (b) neat, 100 °C, 90 min, 62%; (c) DMF, r.t., 2h, 59%. 
Boc-Protected L-tyrosine 83 was synthesized from L-tyrosine 82 by the method reported by 
McIntosh et al.[17] The method reported by Hamada et al. was used for the synthesis of compound 
84.[18] Benzylation of the phenolic group of 83 using benzyl bromide and sodium methoxide in 
methanol produced benzyl ether 84 in 64% yield (Scheme 2).[18] Heating benzyl ether 84 in 
refluxing methanol containing thionyl chloride produced the methyl ester hydrochloride salt 85 in 
quantitative yield.[19] 
 
Scheme ‎2-3: Reagents and conditions: (a) Boc2O, NaOH, THF/H2O, r.t., overnight, 100%; (b) BnBr, NaOMe, MeOH, 40 °C, 3h, 
64%; (c) SOCl2, MeOH, Δ, 3h, 100%. 
L-Amino acid methyl esters 86, 88 and 90 were synthesized by refluxing the appropriate L-amino 
acids in methanol containing thionyl chloride by standard methods.[20] Compounds 87a-c, 89a-c, 
91a-c and 93a-c were synthesized by amidation of the L-amino acid methyl esters and thioester-acid 
intermediates 78a-c using HBTU/DIPEA as the coupling reagent (Scheme 3).[21] Products were 
confirmed mainly by 
1
H NMR spectroscopy (as observed by the appearance of the characteristic 
thioacetyl methyl group) and HRMS. Hydrolyzed compounds 72a-c, 73a-c, 74a-c and 75a-c were 
prepared by treatment of intermediates 87a-c, 89a-c, 91a-c and 93a-c with degassed sodium 
hydroxide solution under argon. Thiols 72a-c, 73a-c, 74a-c and 75a-c are sensitive to aerial 
oxidation and therefore it is necessary to store them in a sealed flask under argon otherwise they 
will convert to disulfide. The 
1
H NMR spectra of these compounds confirmed the hydrolysis of both 
ester groups (as evidenced by the loss of the thioacetyl methyl and methyl ester signals). Negative 
mode HRMS also supported the successful formation of the compounds. 
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Scheme ‎2-4: Reagents and conditions: (a) 78a, HBTU, DIPEA, THF, r.t, overnight; (b) 78b, HBTU, DIPEA, THF, r.t, overnight; (c) 
78c, HBTU, DIPEA, THF, r.t, overnight; (d) NaOH, H2O/MeOH, r.t, 1 h. 
2.2.3 Enzyme Kinetic Studies 
2.2.3.1 Inhibition Studies 
The potency of an inhibitor is represented by its IC50, Ki, Kic and Kiuc. The IC50 is the inhibitor 
concentration required to reduce the enzyme activity by 50%. The Ki is the inhibition constant for 
the equilibrium between the bound and unbound forms of the inhibitor to the enzyme.[22] The Kic 
is defined as competitive inhibitor dissociation constant. Competitive inhibition is a form of enzyme 
inhibition where binding of the inhibitor to the active site on the enzyme prevents binding of the 
substrate and vice versa. [22] The Kiuc is defined as uncompetitive inhibitor dissociation constant. 
Uncompetitive inhibition, also known as anti-competitive inhibition, takes place when an enzyme 
inhibitor binds only to the complex formed between the enzyme and the substrate. [22] The smaller 
the value of IC50, Ki, Kic and Kiuc, the more potent the inhibitor.  
Thiol carboxylic acid compounds 72a-c, 73a-c, 74a-c and 75a-c were first assayed with CENTA as 
a substrate. However, the compounds reacted with the substrate without the presence of enzyme 
which was shown by the release of nitro thiolate chromophore which was monitored at 405 nm 
(Figure ‎2-10). Therefore, benzyl penicillin was used as the substrate for further assays.  
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Figure ‎2-10: Reaction of thiol inhibitors with CENTA. 
The inhibitory activities (IC50 values) of the compounds against IMP-1 were first evaluated by a 
screening assay which measured the residual activity of the enzyme. The screening results showed 
that all thiol compounds exhibited good inhibitory activities. Further kinetic analyses then allowed 
the determination of Kic values of these compounds (Table ‎2-2). The table below only shows the Kic 
Values. The complete calculations of the Kic values are shown in Appendix B. 
Table ‎2-2: Inhibitory activities of the target compounds 72a-c, 73a-c, 74a-c, 75a-c and 78a-c against IMP-1. 
Compound Kic (µM)
a
 
72a 0.25 ± 0.20 
72b 1.45 ± 0.67 
72c 2.82 ± 1.98 
73a 0.47 ± 0.09 
73b 5.02 ± 1.64 
73c 8.62 ± 3.30 
74a 4.55 ± 1.96 
74b 5.18 ± 1.55 
74c 5.63 ± 4.50 
75a 0.086 ± 0.024 
75b 9.39 ± 4.60 
75c 5.85 ± 1.30 
a
 Kic: Inhibition constant for competitive inhibition mode. 
All compounds demonstrated Kic values lower than 9.39 ± 4.60 µM against IMP-1. It was observed 
that the shorter-chain thioacetic acid-derived inhibitors of 72a, 73a and 75a have higher inhibitory 
activity when compared to their longer chain counterparts (Table ‎2-2). The table also shows that the 
inhibitory activity of inhibitors 74a-c is approximately similar. Compound 75a exhibited the most 
potent inhibitory activity with the Kic value of 0.086 ± 0.024 µM. Compounds 72a and 73a are the 
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next potent inhibitors with Kic values 0.25 ± 0.20 µM and 0.47 ± 0.09 µM respectively. Since 
several low-molecular weight thiols have been reported to exhibit inhibitory activities against 
MBLs (Table ‎2-2).[23-25] The calculations of the Kic values of the most potent compounds 72a and 
75a are shown in Figure ‎2-11. 
 
Figure ‎2-11: The calculation of the Kic values of compounds 72a and 75a. 
Table ‎2-3 compares the Kic values and Escore of compounds 72a-c, 73a-c, 74a-c and 75a-c. The table 
shows that compounds with longer-chain thioacyl-groups have higher calculated energies (Escore), 
and so these are predicted to be more potent inhibitors than shorter-chain thioacyl-derived 
compounds. However, the results of assay showed that the compounds with the shorter-chain 
thioacyl chains are in fact more potent. It means the trend of Kic values and the predicted energy 
(Escore) values are in contrary trend. In conclusion, although the results of docking could be used for 
the design of thiol carboxylic acid project but the outputs of computational modeling and Kic values 
are not expected to be in the same trend. The only compound which Kic and Escore values are 
roughly in the expected trend was compound 75a. 
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Table ‎2-3: The comparison of Kic and Escore of compounds 72a, 73a, 74a and 75a. 
Compound Kic (µM)
a
 MolDock Score (kcal/mol) for L-
derivatives (COO
-
 and S
-
) 
72a 0.25 ± 0.20 -161.1 
72b 1.45 ± 0.67 -174.0 
72c 2.82 ± 1.98 -180.1 
73a 0.47 ± 0.09 -178.1 
73b 5.02 ± 1.64 -194.0 
73c 8.62 ± 3.30 -198.7 
74a 4.55 ± 1.96 -166.5 
74b 5.18 ± 1.55 -179.2 
74c 5.63 ± 4.50 -187.2 
75a 0.086 ± 0.024 -190.8 
75b 9.39 ± 4.60 -188.2 
75c 5.85 ± 1.30 -192.2 
2.2.3.2 Determination of imipenem MICs with the supplementation of MBL-inhibitor 
Imipenem MICs by Etest (bioMerieux, VIC) with the inhibitor 75a were tested by Dr 
Hanna Sidjabat at the University of Queensland Centre for Clinical Research. A preliminary testing 
of potency of 75a MBL-inhibitor was performed to IMP-1 and IMP-4 producing bacteria 
(Table ‎2-4). The imipenem MIC in combination with 75a compound was tested by incorporating 20 
μL of the 75a compound at concentration of 50 mM into Muller-Hinton (MH) agar. Two E. cloacae 
clinical isolates with IMP-4 genes and blaIMP-1 construct in BL21 E. coli were included. Bacterial 
suspension at 0.5 McFarland was spread onto the media supplemented with compound 75a. The 
imipenem E-test strip was placed on the media. The imipenem MICs of the three tested strains were 
also determined on plain MH agar (Figure ‎2-12). The MICs to imipenem are listed below: 
Table ‎2-4: The MICs to imipenem for inhibitor 75a. 
Strains β-lactamases 
Imipenem MICs (μg/ml) 
Folds of 
decrease 
Without 
inhibitor 
With inhibitor 
(75a) 
IMP-1 plasmid construct in 
BL21 Escherichia coli 
IMP-1 2.00 0.38 5.2 
Enterobacter cloacae ECL1 IMP-4 1.50 0.38 3.9 
Enterobacter cloacae ECL2 IMP-4 0.50 0.50 None 
Table ‎2-4 shows the minimum concentration of imipenem needed for prevention of growing up 
bacteria which contain IMP-1 is 2 μg/ml whereas this concentration was decreased to 0.38 μg/ml 
when imipenem was used with inhibitor 75a. 
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Figure ‎2-12: Determination of imipenem MIC with the supplementation of MBL inhibitor (75a). 
2.3 Conclusions 
A straightforward and efficient synthesis of novel thiol carboxylic acid compounds based on 
naturally occurring aromatic amino acids as IMP-1 inhibitors has been described. Firstly, a new 
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series of thiol carboxylic acid inhibitors 72a-c, 73a-c, 74a-c and 75a-c has been designed. 
Secondly, the results of computational modeling were investigated and compared with the reference 
compounds 68b which was reported by Liénard et al. as potent inhibitor with Kic value of 0.088 
µM. The demonstrated results Escore by MolDock software showed that most of these compounds 
have higher calculated energy (Escore) than the reference compound 68b which was expected to be 
more potent inhibitors of IMP-1. The survey of results on docking also described feasible 
coordination of the thiolate group of inhibitors to Zn
2+
 centers in the active site of IMP-1 (~2 Å). 
Apart from the binuclear metal center, there was a possibility of π-π stack interaction of phenyl ring 
of inhibitors with both Trp64 and His263 or either of them. Therefore, these compounds were 
synthesized with the yield of ~60% and were examined against IMP-1. All of these compounds 
demonstrated good inhibitory activity against the metallo-β-lactamase IMP-1 ranging 0.086±0.024 
µM to 9.39±4.60 µM. Amongst those, compound 75a showed that the most potent inhibition, with a 
competitive Kic of 0.086±0.024 µM. Although the study of Escore and Kic values showed that the 
calculated energy values (Escore) increases from shorter-chain thioacetic acid-derived to the longer-
chain but the enzyme kinetic studies showed reverse trend with decreasing inhibitory activity from 
shorter-chain thioacetic acid-derived to the longer-chain. This was contrary to the expectation of the 
trend. The only expectation was compound 75a which showed the expected trend of activity and 
Escore. As the crystal structure of these inhibitors co-crystalized with IMP-1 have not obtained, it is 
not possible to find out the reason of this contradiction. The X-ray crystallography can show the 
exact coordination and orientation of these inhibitors into the active site of IMP-1. Therefore, X-ray 
crystallography can help to find out the accuracy of the result of computational modeling and its 
correlation with Escore values. 
2.4 Experimental 
2.4.1 Biological Evaluation 
2.4.1.1 Enzyme Expression and Purification 
The IMP-1 enzyme, lacking the first 21 signal peptide amino acid residues, was expressed and 
purified using the protocol of Vella et al.[26, 27] (The details of the expression of IMP-1 are 
reported in Appendix A). 
2.4.1.2 Kinetic Assays  
Inhibition assays for IMP-1 were performed in 96 well 400 µL UV multi-titre plates using a UV 
multi-plate spectrophotometer. The hydrolysis rate of benzyl penicillin (penicillin G sodium salt) 
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was measured at λ=235 nm [28]. The initial screening assay was performed in duplicate, with 
benzyl penicillin as the substrate and HEPESX (50 mM HEPES, 0.1 M NaCl, 100 mM ZnCl2, pH 
7.0) as the buffer at 25 °C. The final concentrations of enzyme and benzyl penicillin were 10 nM 
and 500 µM respectively. Bovine serum albumin (final concentration of 20 µg/ml) was added to the 
enzyme for stability. For each well, 196 µL substrate and 4 µL inhibitor were added followed by the 
addition of 200 µL of enzyme. The rate of hydrolysis of substrate was recorded for 5 minutes.  
The Kic experimental conditions were the same as the screening conditions with one difference 
being that various inhibitor concentrations were assayed against different substrate concentrations. 
Two to four different inhibitor concentrations were used and the final concentrations of substrate 
were 200, 400, 600, 800 and 1000 µM. The raw kinetic data were analyzed by non-linear regression 
using Win Curve Fit program (Kevin Raner Software) [29]. The substrate hydrolysis rate V is the 
dependent variable while the substrate concentration [S] and inhibitor concentration [I] are 
independent variables. Kic and Kiuc is the competitive and uncompetitive inhibition constant 
respectively. Vmax is the maximum hydrolysis rate and KM is the Michaelis constant. 
 
2.4.2 Synthesis 
2.4.2.1 General  
All chemicals were purchased from Sigma-Aldrich, Merck and Fluka chemical companies. All 
NMR experiments were recorded on Bruker AVANCE 500, 400 or 300 MHz spectrometers. 
Chemical shifts are reported in parts per million (ppm) on a δ scale and referenced to the residual 
solvent peak (
1
H, 7.24 ppm, 
13
C, 77.0 ppm for CDCl3; 
1
H, 2.49 ppm, 
13
C, 39.5 ppm for DMSO-d6; 
1
H, 3.30 ppm, 
13
C, 49.5 ppm for CD3OD). Coupling constants (J) are reported in Hertz. 
Multiplicities of the peaks are abbreviated as follows: s for singlet, sb for broad singlet, d for 
doublet, t for triplet, and q for quartet. Low- and high- resolution EI-MS were measured on a 
Finnigan MAT 900 XL-Trap mass spectrometer in positive and negative ionization mode. LR-ESI 
were recorded on a Bruker HCT 3D Ion Trap and HR-ESI were performed on a BrukerMicrOTof-Q 
with the DIONEX Ultimate 3000 LC in positive and negative electrospray ionization mode, with 
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CH3OH being the solvent. For IR analysis samples were taken as neat by PerkinElmer FT/IR 
Spectrometer Frontier. 
1
H NMR and 
13
C NMR spectra for all compounds are shown in Appendix F. 
2.4.2.2 General procedure 1: Esterification of amino acids 
Compounds 85, 86, 88 and 90 were synthesized using the following general procedure reported by 
Maiti and Banerjee [30]: A solution of amino acid (18.2 mmol) in MeOH (20 ml) was stirred at 
0°C. Thionyl chloride (1.58 ml, 21.8 mmol) was added dropwise over 10 minutes at 0°C. The 
reaction mixture was then allowed to warm to room temperature before being heated under reflux 
for 3 hours. The solvent and excess thionyl chloride evaporated under reduced pressure and the 
product was washed with ethyl acetate to give the methyl ester hydrochloride salt as a colorless 
solid (100%). 
2.4.2.3 General procedure 2: Amide coupling reactions 
The method reported by Gluszok et al. was used.[21] Compounds 87a-c, 89a-c, 91a-c and 93a-c 
were synthesized using the following general procedure: L-Amino acid methyl ester hydrochloride 
85, 86, 88 and 90 (4.50 mmol), thioesters 78a-c (4.95 mmol), HBTU (1.88 g, 4.95 mmol), DIPEA 
(1.75 g, 2.35 ml, 13.50 mmol) in THF (40 ml) was stirred overnight. The THF was evaporated 
under reduced pressure then either DCM or ethyl acetate (40 ml) was added. The organic solution 
was washed with saturated sodium bicarbonate (40 ml) and evaporated to give the crude product, 
which was purified by flash chromatography (30-100% EtOAc in petroleum ether). 
2.4.2.4 General procedure 3: Saponification 
Compounds 72a-c, 73a-c, 74a-c and 75a-c were synthesized using the following general procedure: 
Compounds 87a-c, 89a-c, 91a-c and 93a-c (2.4 mmol) were dissolved in degassed methanol (10 
ml), then degassed sodium hydroxide solution (1 M, 10 ml) was added and the solution was stirred 
under argon for one hour. The organic solvent was evaporated under reduced pressure, then 
degassed water (30 ml) was added and the water phase was washed with degassed ethyl acetate (40 
ml). The pH was adjusted to 1 using concentrated HCl. The solution was extracted with ethyl 
acetate (40 ml) and washed with water (5×50 ml) to remove acetic acid. The organic phase was 
dried over sodium sulfate, filtered and evaporated under reduced pressure to give the pure products. 
2-(Acetylthio)acetic acid (78a) 
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The method reported by Boyer et al. was used.[31] Sodium bicarbonate (15.72 g, 187 mmol) was 
added slowly to a stirred solution of thioacetic acid 76 (8.1 g, 7.5 ml, 106 mmol) and bromoacetic 
acid 77 (11.2 g, 80 mmol) in water (100 ml). The mixture was stirred at room temperature overnight 
and then the solution was acidified to pH 1 with concentrated HCl and extracted with ethyl acetate 
(100 ml). The organic layer was separated and washed with water (3×100 ml), then dried over 
sodium sulfate, filtered and evaporated to give 2-(acetylthio)acetic acid (78a) as a yellow oil (7.05 
g, 65%). 
1
H NMR (300 MHz, CDCl3): δ 3.70 (2H, s, SCH2CO), 2.37 (3H, s, CH3CO).
 13
C NMR (75 
MHz, CDCl3): δ 193.9 (SCO), 174.5 (COOH), 31.2 (CH2), 30.0 (CH3). The NMR spectra are in 
agreement with the literature.[31] 
3-(Acetylthio)propanoic acid (78b) 
 
The method reported by Crich et al. was used.[15] Thioacetic acid 76 (10.8 g, 10 ml, 142 mmol) 
was added with stirring to acrylic acid 79 (7.9 g, 7.5 ml, 110 mmol). The mixture was stirred under 
argon for 30 min at room temperature and then at 100 °C for 90 min. Crystals formed on cooling to 
room temperature. Excess thioacetic acid was removed under reduced pressure then the residue was 
dissolved in ethyl acetate (100 ml). The solution was washed with water (3×100 ml) then dried over 
sodium sulfate, filtered and evaporated to give 3-(acetylthio)propanoic acid (78b) as a yellow 
hygroscopic solid (10.1 g, 62%). 
1
H NMR (400 MHz, CDCl3): δ 3.08 (2H, t, J=6.9 Hz, SCH2), 2.67 
(2H, t, J=6.9 Hz, CH2CO), 2.32 (3H, s, CH3). 
13
C NMR (100 MHz, CDCl3): δ 195.6 (SCO), 177.6 
(COOH), 34.1 (CH2S), 30.5 (CH2CO), 23.8 (CH3). The NMR spectra are in agreement with the 
literature.[15] 
4-(Acetylthio)butanoic acid (78c) 
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The method of Hogg et al. was adapted.[16] Potassium thioacetate80 (1.0 g, 8.8 mmol) was added 
portionwise to a solution of 4-chlorobutyric acid 81 (1.0 g, 8.2 mmol) in dry DMF (5 ml) at room 
temperature. The reaction mixture was stirred under argon for 2 hours then the organic solvent was 
removed under reduced pressure. The residue was taken up in ethyl acetate (50 ml) and washed 
with HCl (5%, 2×50 ml) and water (3×50 ml). The organic phase was dried over sodium sulfate, 
filtered and evaporated to give the product 78c as black oil (0.78 g, 59%). 
1
H NMR (400 MHz, 
CDCl3): δ 2.91 (2H, t, J=7.1 Hz, CH2S), 2.42 (2H, t, J=7.4 Hz, CH2CO), 2.32 (3H, s, CH3), 1.91 
(2H, quintet, J=7.2 Hz, CH2CH2CH2). 
13
C NMR (100 MHz, CDCl3): δ 195.6 (SCO), 178.3 
(COOH), 32.5 (CH2CO), 30.6 (CH2S), 28.2 (CH3), 24.6 (CH2CH2CH2). The NMR spectra are in 
agreement with the literature.[16] 
(S)-Methyl 2-amino-3-phenylpropanoate hydrochloride (86) 
 
White solid, 3.92 g (100%). 
1
H NMR (300 MHz, DMSO-d6): δ 8.83 (3H, bs, NH2.HCl), 7.36-7.18 
(5H, m, Ar-H), 4.20 (1H, dd, J=7.6, 5.5 Hz, CH2CHNH), 3.63 (3H, s, OCH3), 3.23 (1H, dd, 
J=13.4, 5.0 Hz, CHAHBCHNH), 3.09 (1H, dd, J=13.4, 7.4 Hz, CHAHBCHNH).
 13
C NMR (75 MHz, 
DMSO-d6): δ 169.7 (CO), 135.2 (Ar-C), 129.8 (Ar-C), 129.0 (Ar-C), 127.7 (Ar-C), 53.7 
(CH2CHNH), 52.9 (OCH3), 36.2 (CH2CHNH). The NMR spectra are in agreement with the 
literature.[20] 
(S)-Methyl 2-(2-(acetylthio)acetamido)-3-phenylpropanoate (87a) 
 
Orange oil, 1.30 g (98%). IR νmax: 3317, 2953, 1740 (CO2), 1680 (CON), 1662 (COS), 1526, 1215, 
846 cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ 7.33-7.19 (3H, m, Ar-H), 7.11-7.04 (2H, m, Ar-H), 6.63 
(1H, d, J=7.3 Hz, NH), 4.81 (1H, dd, J=7.6, 6.2 Hz, CHNH), 3.72 (3H, s, OCH3), 3.52 (2H, dd, 
J=22.0, 14.9 Hz, CH2S), 3.15 (1H, dd, J=5.6, 14.0 Hz, CHAHBCHNH), 3.06 (1H, dd, J=6.2, 14.0 
Hz, CHAHBCHNH), 2.35 (3H, s, CH3CO). 
13
C NMR (75 MHz, CDCl3): δ 195.2 (COS), 171.5 
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(CO2), 167.6 (CONH), 135.6 (Ar-C), 129.3 (Ar-C), 128.5 (Ar-C), 127.1 (Ar-C), 53.4 (CH2CHNH), 
52.4 (OCH3), 37.6 (CH2CHNH), 32.7 (CH2S), 30.1 (CH3CO). HRMS calculated for 
C14H17NNaO4S [M+Na]
+
 318.0770, found 318.0769. 
(S)-2-(2-Mercaptoacetamido)-3-phenylpropanoic acid (72a) 
 
Brown oil, 0.45 g (79%). IR νmax: 3318, 2947, 2565 (SH), 1719 (CO2), 1632 (CON), 1526, 1208, 
699 cm
-1
. 
1
H NMR (300 MHz, DMSO-d6): δ 8.36 (1H, d, J=9.0 Hz, NH), 7.32-7.12 (5H, m, Ar-H), 
4.48-4.38 (1H, m, CHNH), 3.10 (2H, s, CH2S), 3.05 (1H, dd, J=14.1, 5.3 Hz, CHAHBCHNH), 2.87 
(1H, dd, J=14.1, 8.4 Hz, CHAHBCHNH), 1.76 (1H, s, SH). 
13
C NMR (75 MHz, DMSO-d6): δ 173.1 
(CO2H), 169.9 (CONH), 137.8 (Ar-C), 129.6 (Ar-C), 128.6 (Ar-C), 126.9 (Ar-C), 60.2 (CHNH), 
37.2 (CH2CHNH), 27.2 (CH2S). HRMS calculated for C11H12NO3S [M-H]
-
 238.0543, found 
238.0843. 
(S)-Methyl 2-(3-(acetylthio)propanamido)-3-phenylpropanoate (87b) 
 
Tan solid, 1.34 g (96%). IR νmax: 3292, 2953, 1728 (CO2), 1696 (CON), 1642 (COS), 1545, 1131, 
696 cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ 7.33-7.20 (3H, m, Ar-H), 7.12-7.06 (2H, m, Ar-H), 6.02 
(1H, d, J=7.0 Hz, NH), 4.89 (1H, dt, J=7.8, 5.8 Hz, CHNH), 3.73 (3H, s, OCH3), 3.22-3.02 (4H, m, 
CH2CHNH &CH2S), 2.48 (2H, m, COCH2), 2.32 (3H, s, OCH3C). 
13
C NMR (75 MHz, CDCl3): δ 
195.9 (COS), 171.9 (CONH), 170.1 (CO2), 135.7 (Ar-C), 129.2 (Ar-C), 128.6 (Ar-C), 127.1 (Ar-C), 
53.1 (CHNH), 52.3 (OCH3), 37.8 (CH2CHNH), 36.0 (CH2S), 30.5 (COCH2), 24.7 (CH3CO). 
HRMS calculated for C15H19NNaO4S [M+Na]
+
 332.0937, found 332.0919. The NMR spectra are in 
agreement with those reported for the enantiomer.[9] 
(S)-2-(3-Mercaptopropanamido)-3-phenylpropanoic acid (72b) 
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Brown oil, 0.43 g (70%). IR νmax: 3318, 2973, 2565 (SH), 1712 (CO2), 1656 (CON), 1089, 1047, 
879 cm
-1
. 
1
H NMR (300 MHz, CD3OD): δ 7.32-7.12 (5H, m, Ar-H), 4.68 (1H, dd, J=9.1, 5.1, 
CHNH), 3.20 (1H, dd, J=14.1, 4.8 Hz, CHAHBCHNH), 2.93 (1H, dd, J=14.1, 9.3 Hz, 
CHAHBCHNH), 2.85-2.46 (4H, m, CH2S) 1.80 (1H, s, SH). 
13
C NMR (75 MHz, CD3OD): δ 173.2 
(CO2H), 169.9 (CONH), 137.8 (Ar-C), 129.1 (Ar-C), 128.1 (Ar-C), 126.3 (Ar-C), 53.9 (CHNH), 
37.0 (CH2CHNH), 34.8 (CH2CO), 33.4 (CH2S). HRMS calculated for C24H28N2NaO6S2 [2M+Na]
+
 
527.1281, found 527.1275. The NMR spectra are in agreement with those reported for the 
enantiomer.[9] 
(S)-Methyl 2-(4-(acetylthio)butanamido)-3-phenylpropanoate (87c) 
 
Brown oil, 1.31 g (90%). IR νmax: 3333, 2954, 1737 (CO2), 1680 (CON), 1658 (COS), 1531, 1221, 
847 cm
-1
. 
1
H NMR (500 MHz, CDCl3): δ 7.30-7.20 (3H, m, Ar-H), 7.07 (2H, d, J=7.0 Hz, Ar-H), 
6.01 (1H, d, J=7.7 Hz, NH), 4.87 (1H, dd, J=9.7, 5.0 Hz, CHNH), 3.71 (3H, s, OCH3), 3.15 (1H, 
dd, J=14.0, 5.5 Hz, CHAHBCHNH), 3.05 (1H, dd, J=14.0, 6.5 Hz, CHAHBCHNH), 2.89-2.75 (2H, 
m, CH2S), 2.30 (3H, s, CH3CO), 2.21 (2H, dt, J=7.3, 2.5 Hz, CH2CO), 1.85 (2H, quintet, J=7.2 Hz, 
CH2CH2CH2). 
13
C NMR (125 MHz, CDCl3): δ 195.9 (COS), 172.1 (CONH), 171.4 (CO2), 135.9 
(Ar-C), 129.2 (Ar-C), 128.6 (Ar-C), 127.1 (Ar-C), 53.0 (CHNH), 52.3 (OCH3), 37.9 (CH2CHNH), 
34.8 (CH2CO), 30.6 (CH2S), 28.3 (CH3CO), 25.4 (CH2CH2CH2). HRMS calculated for 
C16H21NNaO4S [M+Na]
+
 346.1083, found 346.1080.  
 (S)-2-(4-mercaptobutanamido)-3-phenylpropanoic acid (72c) 
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Brown viscous oil, 0.42 g (65%). IR νmax: 3318, 2941, 2565 (SH), 1718 (CO2), 1633 (CON), 1531, 
1219, 699 cm
-1
. 
1
H NMR (500 MHz, CD3OD): δ 7.28-7.15 (5H, m, Ar-H), 4.68 (1H, dd, J=9.7, 5.0 
Hz, CHNH), 3.22 (1H, dd, J=14.0, 4.7 Hz, CHAHBCHNH), 2.91 (1H, dd, J=14.0, 10.0 Hz, 
CHAHBCHNH), 2.48 (2H, t, J=7.3 Hz, CH2CO), 2.43 (2H, dt, J=4.7, 7.3 Hz, CH2S), 1.84 (2H, 
quintet, J=7.0 Hz, CH2CH2CH2). 
13
C NMR (125 MHz, CD3OD): δ 175.1 (CO2H), 174.8 (CONH), 
138.5 (Ar-C), 130.2 (Ar-C), 129.5 (Ar-C), 127.8 (Ar-C), 54.9 (CHNH), 38.4 (CH2CHNH), 38.4 
(CH2SH), 35.1 (CH2CO), 26.2 (CH2CH2CH2). HRMS calculated for C13H17NNaO3S [M+Na]
+
 
290.0821, found 290.0827. 
(S)-Methyl 2-amino-3-(1H-indol-3-yl)propanoate hydrochloride (88) 
 
White solid, 4.63 g (100%). 
1
H NMR (400 MHz, CD3OD): δ 7.53 (1H, d, J=7.9 Hz, Ar-H), 7.39 
(1H, d, J=8.1 Hz, Ar-H), 7.22 (1H, s, Ar-H), 7.13 (1H, t, J=7.0 Hz, Ar-H), 7.06 (1H, t, J=7.0 Hz, 
Ar-H), 4.33 (1H, dd, J=7.2, 5.6 Hz, CH2CHNH), 3.77 (3H, s, OCH3), 3.45 (1H, dd, J=15.0, 5.6 Hz, 
CHAHBCHNH), 3.37 (1H, dd, J=15.0, 7.2 Hz, CHAHBCHNH). 
13
C NMR (100 MHz, CD3OD): δ 
171.3 (CO2), 138.8 (Ar-C), 128.7 (Ar-C), 126.2 (Ar-C), 123.4 (Ar-C), 120.8 (Ar-C), 119.3 (Ar-C), 
113.2 (Ar-C), 107.9 (Ar-C), 55.1 (CH2CHNH), 54.1 (OCH3), 28.0 (CH2CHNH). The NMR spectra 
are in agreement with the literature.[32] 
(S)-Methyl 2-(2-(acetylthio)acetamido)-3-(1H-indol-3-yl)propanoate (89a) 
 
Orange oil, 1.44 g (96%). IR νmax: 3349, 2954, 1737 (CO2), 1680 (CON), 1662 (COS), 1524, 1357, 
1222, 847 cm
-1
. 
1
H NMR (500 MHz, CDCl3): δ 8.21 (1H, s, indole-NH), 7.50 (1H, d, J=8.1 Hz, Ar-
H), 7.32 (1H, d, J=8.5 Hz, Ar-H), 7.16 (1H, t, J=7.9 Hz, Ar-H), 7.09 (1H, t, J=7.2 Hz, Ar-H), 6.98 
(1H, d, J=2.4 Hz, Ar-H), 6.64 (1H, d, J=8.8 Hz, CH2CHNH), 4.89 (1H, dd, J=7.0, 5.5 Hz, 
CH2CHNH), 3.67 (3H, s, OCH3), 3.49 (2H, dd, J=19.8, 15 Hz, COCH2S), 3.29 (2H, m, 
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CH2CHNH), 2.22 (3H, s, CH3CO). 
13
C NMR (125 MHz, CDCl3): δ 195.1 (SCOCH3), 172.0 
(COOCH3), 167.7 (CONH), 136.1 (Ar-C), 127.6 (Ar-C), 122.9 (Ar-C), 122.2 (Ar-C), 119.7 (Ar-C), 
118.6 (Ar-C), 111.2 (Ar-C), 109.7 (Ar-C), 53.2 (CHNH), 52.4 (CH3O), 32.9 (CH2S), 30.1 
(CH2CHNH), 27.4 (CH3CO). HRMS calculated for C16H18N2NaO4S [M+Na]
+ 
357.0879, found 
357.0886. 
(S)-3-(1H-indol-3-yl)-2-(2-mercaptoacetamido) propanoic acid (73a) 
 
Yellow waxy solid, 0.47 g (70%). IR νmax: 3379, 2929, 2550 (SH), 1717 (CO2), 1618 (CON), 1530, 
1214, 742 cm
-1
. 
1
H NMR (300 MHz, CD3OD): δ 7.55 (1H, d, J=8.1 Hz, Ar-H), 7.31 (1H, d, J=8.1 
Hz, Ar-H), 7.13-6.92 (3H, m, Ar-H), 4.72 (1H, dd, J=7.0, 5.05 Hz, CHNH), 3.36 (1H, dd, J=14.7, 
5.2 Hz, CHAHBCHNH), 3.22 (1H, dd, J=14.7, 7.2 Hz, CHAHBCHNH), 3.12 (2H, s, CH2S), 1.89 
(1H, s, SH). 
13
C NMR (75 MHz, CD3OD): δ 175.0 (CO2H), 172.9 (CONH), 138.1 (Ar-C), 129.0 
(Ar-C), 124.6 (Ar-C), 122.5 (Ar-C), 119.9 (Ar-C), 119.4 (Ar-C), 112.4 (Ar-C), 110.7 (Ar-C), 55.0 
(CHNH), 28.4 (CH2SH), 28.2 (CH2CHNH). HRMS calculated for C13H13N2O3S [M-H]
- 
277.0652, 
found 277.0658. 
(S)-Methyl 2-(3-(acetylthio)propanamido)-3-(1H-indol-3-yl)propanoate (89b) 
 
Brown viscous oil, 1.49 g (95%). IR νmax: 3323, 2951, 1737 (CO2), 1680 (CON), 1658 (COS), 
1527, 1435, 1216, 745 cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ 8.12 (1H, s, indole-NH), 7.50 (1H, d, 
J=8.1 Hz, Ar-H), 7.34 (1H, d, J=9.6 Hz, Ar-H), 7.18 (1H, t, J=6.9 Hz, Ar-H), 7.09 (1H, t, J=7.8 
Hz, Ar-H), 6.97 (1H, d, J=7.8 Hz, Ar-H), 6.00 (1H, d, J=7.8 Hz, NHCO), 4.94 (1H, dt, J=7.8, 5.4, 
CHNH), 3.68 (3H, s, OCH3), 3.30 (2H, q, J=2.1 Hz, CH2CHNH), 3.09 (2H, t, J=6.9 Hz, CH2S), 
2.45 (2H, t, J=6.9 Hz, CH2CO), 2.30 (3H, s, CH3CO). 
13
C NMR (75 MHz, CDCl3): δ 195.9 (COS), 
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172.2 (CONH), 170.2 (CO2), 136.1 (Ar-C), 127.7 (Ar-C), 122.7 (Ar-C), 122.3 (Ar-C), 119.8 (Ar-
C), 118.5 (Ar-C), 111.3 (Ar-C), 110.0 (Ar-C), 53.0 (CHNH), 52.4 (CH3O), 36.1 (CH2S), 30.5 
(CH2CO), 27.6 (OCH3), 24.6 (CH2CHNH). HRMS calculated for C17H20N2NaO4S [M+Na]
+ 
371.1052, found 371.1036. 
(S)-3-(1H-indol-3-yl)-2-(3-mercaptopropanamido) propanoic acid (73b) 
 
Brown waxy solid, 0.47 g (67%). IR νmax: 3379, 2940, 2550 (SH), 1718 (CO2), 1625 (CON), 1525, 
1210, 742 cm
-1
. 
1
H NMR (300 MHz, DMSO-d6): δ 10.82 (1H, s, indole-NH), 8.20 (1H, d, J=7.7 
Hz, NHCO), 7.52 (1H, d, J=8.1 Hz, Ar-H), 7.31 (1H, d, J=7.7 Hz, Ar-H), 7.13 (1H, d, J=2.2 Hz, 
Ar-H), 7.05 (1H, dt, J=7.3 Hz, 1.3 Hz, Ar-H), 6.96 (1H, dt, J=7.3, 1.3 Hz, Ar-H), 4.47(1H, dt, 
J=7.8, 5.4, CHNH), 3.16 (1H, dd, J=15.0, 5.0 Hz, CHAHBCHNH), 2.99 (1H, dd, J=15.0, 9.0 Hz, 
CHAHBCHNH), 2.69-2.52 (2H, m, CH2S), 2.44-2.30 (2H, m, CH2CO), 2.17 (1H, t, J=9.3 Hz, SH). 
13
C NMR (75 MHz, DMSO-d6): δ 173.4 (CO2H), 170.2 (CONH), 136.0 (Ar-C), 127.2 (Ar-C), 
123.5 (Ar-C), 120.9 (Ar-C), 118.3 (Ar-C), 118.1 (Ar-C), 111.3 (Ar-C), 109.8 (Ar-C), 52.9 (CHNH), 
30.7 (CH2CO), 27.1 (CH2CHNH), 19.8 (CH2SH). HRMS calculated for C14H15N2O3S [M-H]
- 
291.0809, found 291.0812. 
(S)-Methyl 2-(4-(acetylthio)butanamido)-3-(1H-indol-3-yl)propanoate (89c) 
 
Brown viscous oil, 1.47 g (90%). IR νmax: 3313, 2936, 1736 (CO2), 1680 (CON), 1652 (COS), 
1523, 1435, 1214, 744 cm
-1
.
 1
H NMR (400 MHz, CDCl3): δ 8.20 (1H, bs, indole-NH), 7.50 (1H, d, 
J=7.8 Hz, Ar-H), 7.34 (1H, d, J=7.4 Hz, Ar-H), 7.17 (1H, t, J=7.1 Hz, Ar-H), 7.10 (1H, t, J=7.1 
Hz, Ar-H), 6.97 (1H, d, J=2.3 Hz, Ar-H), 6.05 (1H, d, J=7.7 Hz, NHCO), 4.93 (1H, dt, J=7.8, 5.5, 
CHNH), 3.68 (3H, s, OCH3), 3.36-3.23 (2H, m, CH2CHNH), 2.82 (2H, dt, J=2.8, 7.3 Hz, CH2S), 
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2.29 (3H, s, CH3CO), 2.17 (2H, t, J=7.6 Hz, CH2CO), 1.85 (2H, quintet, J=7.2 Hz, CH2CH2CH2). 
13
C NMR (100 MHz, CDCl3): δ 195.9 (COS), 172.4 (CONH), 171.6 (CO2), 136.1 (Ar-C), 127.7 
(Ar-C), 122.7 (Ar-C), 122.3 (Ar-C), 119.7 (Ar-C), 118.5 (Ar-C), 111.3 (Ar-C), 110.1 (Ar-C), 52.9 
(CHNH), 52.4 (CH3O), 34.9 (CH2CO), 30.6 (CH2S), 28.3 (CH3CO), 27.6 (CH2CHNH), 25.3 
(CH2CH2CH2). HRMS calculated for C18H22N2NaO4S [M+Na]
+
 385.1192, found 385.1203. 
 (S)-3-(1H-indol-3-yl)-2-(4-mercaptobutanamido) propanoic acid (73c) 
 
Brown viscous oil, 0.48 g (65%). IR νmax: 3287, 2971, 2901, 2550 (SH), 1735 (CO2), 1634 (CON), 
1527, 1230, 1066, 743 cm
-1
.
 1
H NMR (500 MHz, CD3OD): δ 7.54 (1H, t, J=7.2 Hz, Ar-H), 7.31 
(1H, t, J=7.2 Hz, Ar-H), 7.11-7.03 (2H, m, Ar-H), 6.99 (1H, q, J=7.0 Hz, Ar-H), 4.75 (1H, dt, 
J=7.8, 5.5, CHNH), 3.36 (1H, dd, J=15.0, 4.5 Hz, CHAHBCHNH), 3.13 (1H, dd, J=15.0, 8.3 Hz, 
CHAHBCHNH), 2.42 (2H, t, J=7.2 Hz, CH2CO), 2.27-2.21 (2H, m, CH2S), 1.81 (2H, quintet, J=7.2 
Hz, CH2CH2CH2).
 13
C NMR (125 MHz, CD3OD): δ 175.3 (CO2H), 175.2 (CONH), 138.0 (Ar-C), 
128.8 (Ar-C), 124.4 (Ar-C), 122.4 (Ar-C), 119.8 (Ar-C), 112.3 (Ar-C), 111.1 (Ar-C), 54.6 (CHNH), 
38.3 (CH2CHNH), 35.1 (CH2CO), 28.5 (CH2SH), 26.1 (CH2CH2CH2). HRMS calculated for 
C15H17N2O3S [M-H]
- 
305.0965, found 305.0960.
 
(S)-Methyl 2-amino-3-(4-hydroxyphenyl)propanoate hydrochloride (90) 
 
White solid, 4.21 g (100%). 
1
H NMR (300 MHz, DMSO-d6): δ 9.47 (1H, d, J=8.0 Hz, OH), 8.63 
(3H, bs, NH2.HCl), 7.00 (2H, d, J=8.5 Hz, Ar-H), 6.71 (2H, d, J=8.5 Hz, Ar-H), 4.13 (1H, t, J=5.8 
Hz, CH2CHNH2), 3.65 (3H, s, OCH3), 3.07 (1H, dd, J=15.0, 5.6 Hz, CHAHBCHNH), 2.97 (1H, dd, 
J=15.0, 7.2 Hz, CHAHBCHNH). 
13
C NMR (75 MHz, DMSO-d6): δ 169.4 (CO2), 156.7 (Ar-C), 
130.3 (Ar-C), 124.3 (Ar-C), 115.4 (Ar-C), 53.4 (CH2CHN), 52.5 (CH3O), 35.0 (CH2CHN). The 
NMR spectra are in agreement with the literature.[33] 
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(S)-Methyl 2-(2-(acetylthio)acetamido)-3-(4-hydroxyphenyl)propanoate (91a) 
 
Pale yellow oil, 1.35 g (95%). IR νmax: 3675, 3304, 2989, 2901, 1740 (CO2), 1698 (CON), 1655 
(COS), 1510, 1233, 1109, 737 cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ 6.91 (2H, d, J=8.8 Hz, Ar-H), 
6.70 (2H, d, J=8.4 Hz, Ar-H), 6.66 (1H, d, J=8.9 Hz, NH), 4.82-4.70 (1H, dt, J=7.8, 5.5, CHNH), 
3.71 (3H, s, OCH3), 3.51 (2H, dd, J=25.0, 14.8 Hz, CH2S), 3.06 (1H, dd, J=14.1, 5.7 Hz, 
CHAHBCHNH), 2.93 (1H, dd, J=14.1, 6.7 Hz, CHAHBCHNH), 2.33 (3H, s, CH3CO). 
13
C NMR (75 
MHz, CDCl3): δ 195.4 (COS), 171.7 (CO2), 168.0 (CONH), 155.2 (Ar-C), 130.3 (Ar-C), 127.0 (Ar-
C), 115.5 (Ar-C), 53.6 (CHNH), 52.5 (OCH3), 36.9 (CH2CHNH), 32.7 (CH2S), 30.2 (CH3CO). 
HRMS calculated for C14H17NNaO5S [M+Na]
+
 334.0720, found 334.728. 
(S)-3-(4-hydroxyphenyl)-2-(2-mercaptoacetamido)propanoic acid (74a) 
 
Pale yellow viscous oil, 0.40 g (65%). IR νmax: 3314, 2972, 2550 (SH), 1721 (CO2), 1653 (CON), 
1513, 1186 cm
-1
. 
1
H NMR (400 MHz, CD3OD): δ 7.03 (2H, d, J=8.4 Hz, Ar-H), 6.69 (2H, d, J=8.4 
Hz, Ar-H), 4.59 (1H, dd, J=8.1, 5.2 Hz, CHNH), 3.13 (2H, s, CH2S), 3.10 (1H, dd, J=14.1, 5.2 Hz, 
CHAHBCHNH), 2.91 (1H, dd, J=14.1, 8.3 Hz, CHAHBCHNH), 1.90 (1H, s, SH). 
13
C NMR (100 
MHz, CD3OD): δ 174.5 (CO2H), 172.9 (CONH), 157.4 (Ar-C), 131.4 (Ar-C), 128.7 (Ar-C), 116.2 
(Ar-C), 54.4 (CHNH), 37.5 (CH2CHNH), 27.3 (CH2SH). HRMS calculated for C11H12NO4S [M-H]
-
 
254.0493, found 254.0492. 
(S)-Methyl 2-(3-(acetylthio)propanamido)-3-(4-hydroxyphenyl)propanoate (91b) 
 
 68 
 
Brown viscous oil, 1.35 g (92%). IR νmax: 3675, 3317, 2974, 1736 (CO2), 1680 (CON), 1652 
(COS), 1514, 1221, 844 cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ 6.95-6.86 (2H, d, J=8.5 Hz, Ar-H), 
6.74-6.66 (2H, d, J=8.6 Hz, Ar-H), 6.11 (1H, d, J=8.0 Hz, NH), 4.83 (1H, dt, J=7.7, 6.1 Hz, 
CHNH), 3.71 (3H, s, OCH3), 3.13-3.0 (3H, m, CH2S and CHAHBCHNH), 2.95 (1H, dd, J=14.2, 6.1 
Hz, CHAHBCHNH), 2.51-2.42 (2H, m, CH2CO), 2.29 (3H, s, CH3CO). 
13
C NMR (75 MHz, 
CDCl3): δ 196.2 (COS), 172.1 (CONH), 170.6 (CO2), 155.4 (Ar-C), 130.3 (Ar-C), 127.1 (Ar-C), 
115.6 (Ar-C), 53.3 (CHNH), 52.4 (OCH3), 37.1 (CH2CHNH), 36.0 (CH2S), 30.6 (CH2CO), 24.7 
(CH3CO). HRMS calculated for C15H19NNaO5S [M+Na]
+
 348.0876, found 348.0873. 
(S)-3-(4-hydroxyphenyl)-2-(3-mercaptopropanamido)propanoic acid (74b) 
 
Pale yellow viscous oil, 0.41 g (63%). IR νmax: 3314, 2973, 2550 (SH), 1722 (CO2), 1654 (CON), 
1514, 1190 cm
-1
. 
1
H NMR (300 MHz, DMSO-d6): δ 9.17 (1H, s, OH), 8.16 (1H, d, J=9.5 Hz, NH), 
7.00 (2H, d, J=8.0 Hz, Ar-H), 6.63 (2H, J=8.3 Hz, Ar-H), 4.40-4.26 (1H, m, CHNH), 2.91 (1H, dd, 
J=13.8, 5.2 Hz, CHAHBCHNH), 2.72 (1H, dd, J=13.8, 9.7 Hz, CHAHBCHNH), 2.56 (2H, t, J=7.5 
Hz, CH2S), 2.37 (2H, t, J=7.5 Hz, CH2CO), 2.14 (1H, t, J=8.0 Hz, SH). 
13
C NMR (75 MHz, 
DMSO-d6): δ 172.0 (CO2H), 170.2 (CONH), 155.8 (Ar-C), 130.0 (Ar-C), 127.6 (Ar-C), 114.9 (Ar-
C), 53.7 (CHNH), 38.1 (CH2CHNH), 36.0 (CH2CO), 21.0 (CH2SH). HRMS calculated for 
C12H14NO4S [M-H]
-
 268.0649, found 268.0644. 
(S)-Methyl 2-(4-(acetylthio)butanamido)-3-(4-hydroxyphenyl)propanoate (91c) 
 
Brown viscous oil, 1.37 g (90%). IR νmax: 3676, 3332, 2972, 1737 (CO2), 1680 (CON), 1653 
(COS), 1514, 1223, 841 cm
-1
. 
1
H NMR (500 MHz, CDCl3): δ 6.93 (2H, d, J=8.4 Hz, Ar-H), 6.71 
(2H, d, J=8.4 Hz, Ar-H), 6.12 (1H, d, J=8.1 Hz, NH), 4.84 (1H, dt, J=7.5, 5.5, CHNH), 3.71 (3H, 
s, OCH3), 3.07 (1H, dd, J=13.0, 5.7 Hz, CHAHBCHNH), 2.95 (1H, dd, J=14.0, 6.7 Hz, 
CHAHBCHNH), 2.86-2.76 (2H, m, CH2S), 2.31 (3H, s, CH3CO), 2.24-2.19 (2H, m, CH2CO), 1.84 
(2H, quintet, J=7.2, CH2CH2CH2). 
13
C NMR (125 MHz, CDCl3): δ 196.3 (COS), 172.3 (CONH), 
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171.9 (CO2), 155.3 (Ar-C), 130.3 (Ar-C), 127.3 (Ar-C), 115.6 (Ar-C), 53.2 (CHNH), 52.4 (OCH3), 
37.1 (CH2CHNH), 34.8 (CH2CO), 30.6 (CH2S), 28.3 (CH3CO), 25.4 (CH2CH2CH2). HRMS 
calculated for C16H21NNaO5S [M+Na]
+
 362.1033, found 362.1042. 
 (S)-3-(4-Hydroxyphenyl)-2-(4-mercaptobutanamido)propanoic acid (74c) 
 
Brown viscous oil, 0.41 g, 60%. IR νmax: 3314, 2973, 2550 (SH), 1700 (CO2), 1614 (CON), 1379, 
1045 cm
-1
. 
1
H NMR (500 MHz, CD3OD): δ 7.03 (2H, d, J=8.5 Hz, Ar-H), 6.69 (2H, d, J=8.5 Hz, 
Ar-H), 4.64-4.58 (1H, m, CH2CHNH), 3.11 (1H, dd, J=14.0, 4.9 Hz, CHAHBCHNH), 2.82 (1H, dd, 
J=14.0, 9.6 Hz, CHAHBCHNH), 2.51 (2H, t, J=6.9 Hz, CH2CO), 2.30-2.22 (2H, m, CH2S), 1.87 
(2H, quintet, J=7.2 Hz, CH2CH2CH2). 
13
C NMR (125 MHz, CD3OD): δ 175.2 (CO2H), 175.0 
(CONH), 157.3 (Ar-C), 131.2 (Ar-C), 129.1 (Ar-C), 116.2 (Ar-C), 55.2 (CHNH), 37.6 
(CH2CHNH), 35.2 (CH2CO), 31.2 (CH2SH), 26.2 (CH2CH2CH2). HRMS calculated for 
C13H16NO4S [M-H]
-
 282.0806, found 282.0795. 
(S)-2-((tert-Butoxycarbonyl)amino)-3-(4-hydroxyphenyl)propanoic acid (83) 
 
The method of McIntosh et al. was used.[17] NaOH (0.44 g, 11.04 mmol in 10 ml water) was added 
to a solution of L-tyrosine 82 (1.0 g, 5.52 mmol) in THF (10 ml) and stirred for 10 minutes, then di-
tert-butyl dicarbonate 96 (1.5 g, 1.4 ml, 6.07 mmol) in THF (10 ml) was added and the reaction 
mixture was stirred overnight. The organic solvent was evaporated under reduced pressure, then 
water (20 ml) was added and the solution was acidified to pH 2-3 with phosphoric acid. The 
mixture was extracted with ethyl acetate (50 ml). The organic solvent was washed with 50 ml water, 
dried over sodium sulfate, filtered and evaporated to give the product 83 as a viscous pale yellow oil 
without further purification (1.55 g, 100%). 
1
H NMR (300 MHz, DMSO-d6): δ 9.17 (1H, bs, OH), 
7.01 (2H, d, J=8.5 Hz, Ar-H), 6.95 (1H, d, J=8.1 Hz, NH), 6.64 (2H, d, J=8.5 Hz, Ar-H), 3.90-4.10 
(1H, m, CHNH), 2.87 (1H, dd, J=13.8, 4.8 Hz, CHAHBCHNH), 2.69 (1H, dd, J=14.0, 10.0 Hz, 
CHAHBCHNH), 1.32 (9H, s, CMe3). 
13
C NMR (75 MHz, DMSO-d6): δ 173.7 (COOH), 155.8 
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(CONH), 155.4 (Ar-C), 130.0 (Ar-C), 128.0 (Ar-C), 114.9 (Ar-C), 78.0 (CMe3), 56.6 (CHNH), 
35.7 (CH2CHNH), 28.2 (CMe3). HRMS calculated for C14H18NO5 [M-H]
-
 280.1190, found 
280.1196. The NMR spectra are in agreement with the literature.[17] 
(S)-3-(4-(Benzyloxy)phenyl)-2-((tert-butoxycarbonyl)amino)propanoic acid (84) 
 
The method of Hamada et al. was used.[18] To a solution of N-Boc-L-tyrosine 83 (920 mg, 3.27 
mmol) in dry methanol (5 ml) was added sodium methoxide (376 mg, 6.96 mmol) in dry methanol 
(5 ml). The solution was stirred for 15 min then benzyl bromide97 (0.60 g, 0.39 ml, 3.27 mmol) was 
added dropwise. The mixture was stirred at 40°C for 3 hours then the organic solvent was 
evaporated under reduced pressure. Water (50 ml) was added, followed by phosphoric acid until the 
pH was 5-6. The mixture was extracted with ethyl acetate (50 ml). The organic layer was separated 
and evaporated (water bath less than 40°C) to give the crude product which was purified by flash 
chromatography (20:80% EtOAc in petroleum ether) to give the pure product 84 as pale yellow 
viscous oil (780 mg, 64%). 
1
H NMR (500 MHz, DMSO-d6): δ 7.41 (2H, d, J=7.4 Hz, Ar-H), 7.36 
(2H, t, J=7.4 Hz, Ar-H), 7.30 (1H, t, J=7.2 Hz, Ar-H), 7.02 (2H, d, J=8.5 Hz, Ar-H), 6.81 (2H, d, 
J=8.5 Hz, Ar-H), 5.79 (1H, d, J=6.3 Hz, NH), 5.01 (2H, s, PhCH2O), 3.73(1H, t, J=6.4 Hz, 
CHNH), 2.98 (1H, dd, J=13.2, 5.1 Hz, CHAHBCHNH), 2.86 (1H, dd, J=13.2, 5.1 Hz, 
CHAHBCHNH), 1.32 (9H, s, CMe3).
 13
C NMR (125 MHz, DMSO-d6): δ 173.7 (COOH), 157.0 (Ar-
C), 155.5 (CONH), 137.2 (Ar-C), 130.1 (Ar-C), 128.4 (Ar-C), 127.8 (Ar-C), 127.6 (Ar-C), 114.4 
(Ar-C), 78.0 (CMe3), 69.1 (PhCH2O), 55.4 (CHNH), 35.6 (CH2CHNH), 28.2 (CMe3). The NMR 
spectra are in agreement with the literature.[18] 
(S)-Methyl 2-amino-3-(4-(benzyloxy)phenyl)propanoate hydrochloride (85) 
 
White solid, 5.85 g (100%). 
1
H NMR (300 MHz, DMSO-d6): δ 8.64 (3H, bs, NH2.HCl), 7.47-7.25 
(5H, m, Ar-H), 7.14 (2H, d, J=8.5 Hz, Ar-H), 6.96 (2H, d, J=8.5 Hz, Ar-H), 5.08 (2H, s, PhCH2O), 
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4.20 (1H, t, J=6.9 Hz, CHNH), 3.66 (3H, s, OCH3), 3.06 (2H, m, CH2CHNH). 
13
C NMR (75 MHz, 
DMSO-d6): δ 169.8 (CO2), 158.0 (Ar-C), 137.5 (Ar-C), 131.0 (Ar-C), 128.8 (Ar-C), 128.2 (Ar-C), 
128.1 (Ar-C), 127.0 (Ar-C), 115.3 (Ar-C), 69.6 (CH2O), 53.7 (CHNH), 53.0 (OCH3), 35.4 
(CH2CHNH). The NMR spectra are in agreement with the literature.[19] 
(S)-Methyl 2-(2-(acetylthio)acetamido)-3-(4-(benzyloxy) phenyl)propanoate (93a) 
 
Yellow-brown oil, 1.63 g (90%). IR νmax: 3676, 3269, 2988, 2901, 1733 (CO2), 1700 (CON) 1656 
(COS), 1511, 733 cm
-1
. 
1
H NMR (400 MHz, CDCl3): δ 7.45-7.26 (5H, m, Ar-H), 6.98 (2H, d, J=8.5 
Hz, Ar-H), 6.87 (2H, d, J=8.5 Hz, Ar-H), 6.58 (1H, d, J=7.8 Hz, NH), 5.02 (2H, s, PhCH2O), 4.76 
(1H, dt, J=7.8, 5.8 Hz, CHNH), 3.71 (3H, s, OCH3), 3.51 (2H, dd, J=28.0, 8.0 Hz, CH2S), 2.90-
3.10 (2H, m, CH2CHNH), 2.31 (3H, s, CH3CO). 
13
C NMR (100 MHz, CDCl3): δ 195.2 (COS), 
171.6 (CO2), 167.7 (CONH), 157.9 (Ar-C), 136.9 (Ar-C), 130.3 (Ar-C), 128.6 (Ar-C), 128.0 (Ar-
C), 127.8 (Ar-C), 127.4 (Ar-C), 114.9 (Ar-C), 70.0 (PhCH2O), 53.5 (CH2CHNH), 52.4 (OCH3), 
36.8 (CH2CHNH), 32.7 (CH2S), 30.1 (CH3). HRMS calculated for C21H23NNaO5S [M+Na]
+
 
424.1189, found 424.1202. 
(S)-3-(4-(Benzyloxy)phenyl)-2-(2-mercaptoacetamido) propanoic acid (75a) 
 
Colorless solid, 0.70 g (84%). IR νmax: 3676, 3325, 2989, 2598 (SH), 2901, 1702 (CO2), 1610 
(CON), 1543, 1512, 1235, 736 cm
-1
. 
1
H NMR (400 MHz, DMSO-d6): δ 8.26 (1H, d, J=8.2 Hz, 
NH), 7.46-7.26 (5H, m, Ar-H), 7.13 (2H, d, J=9.2 Hz, Ar-H), 6.90 (2H, d, J=9.2 Hz, Ar-H), 5.05 
(2H, s, PhCH2O), 4.31 (1H, dt, J=7.8, 5.8 Hz, CHNH), 2.97 (1H, dd, J=13.7, 5.0 Hz, 
CHAHBCHNH), 2.80-2.70 (3H, m, CHAHBCHNH and CH2S), 1.75 (1H, s, SH). 
13
C NMR (100 
MHz, DMSO-d6): δ 172.7 (CO2H), 169.4 (CONH), 157.0 (Ar-C), 137.2 (Ar-C), 130.2 (Ar-C), 
129.4 (Ar-C), 128.4 (Ar-C), 127.7 (Ar-C), 127.6 (Ar-C), 114.5 (Ar-C), 69.1 (PhCH2O), 53.8 
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(CHNH), 35.9 (CH2CHNH), 26.8 (CH2SH). HRMS calculated for C18H18NO4S [M-H]
-
 344.0962, 
found 344.0949. 
 
(S)-Methyl 2-(3-(acetylthio)propanamido)-3-(4-(benzyloxy)phenyl)propanoate (93b) 
 
Pale brown oil, 1.50 g (80%). IR νmax: 3675, 3304, 2989, 2901, 1740 (CO2), 1679 (CON), 1650 
(COS), 1510, 1233, 1109, 737 cm
-1
. 
1
H NMR (400 MHz, CDCl3): δ 7.42-7.25 (5H, m, Ar-H), 7.00 
(2H, d, J=8.5 Hz, Ar-H), 6.87 (2H, d, J=8.5 Hz, Ar-H), 6.00 (1H, d, J=7.7 Hz, NH), 5.00 (2H, s, 
ArCH2O), 4.81 (1H, dt, J=7.8, 5.8 Hz, CH2CHNH), 3.69 (3H, s, CH3O), 3.13-2.96 (4H, m, 
SCH2CH2CO &CH2CHNH), 2.49 (2H, dt, J=6.8, 3.0 Hz, SCH2CH2CO), 2.28 (3H, s, CH3CO). 
13
C 
NMR (100 MHz, CDCl3): δ 195.8 (CH3CO), 171.9 (CONH), 170.1 (COOCH3), 157.9 (Ar-C), 
136.9 (Ar-C), 130.2 (Ar-C), 128.5 (Ar-C), 127.9 (Ar-C), 127.9 (Ar-C), 127.4 (Ar-C), 114.9 (Ar-C), 
69.9 (PhCH2O), 53.2 (CH2CHNH), 52.3 (OCH3), 36.9 (CH2CHNH), 35.9 (CH2S), 30.5 (CH2CO), 
24.6 (CH3). HRMS calculated for C22H25NNaO5S [M+Na]
+
 438.1346, found 438.1352. 
(S)-3-(4-(Benzyloxy)phenyl)-2-(3-mercaptopropanamido) propanoic acid (75b) 
 
Pale yellow viscous oil, 071 g (82%). IR νmax: 3676, 3325, 2989, 2598 (SH), 2901, 1702 (CO2), 
1610 (CON), 1543, 1511, 1232, 736 cm
-1
. 
1
H NMR (400 MHz, CD3OD): δ 7.41-7.21 (5H, m, Ar-
H), 7.13 (2H, d, J=9.2 Hz, Ar-H), 6.84 (2H, d, J=9.2 Hz, Ar-H), 4.97 (2H, s, PhCH2O), 4.51 (1H, 
dd, J=7.5, 5.5 Hz, CHNH), 3.14 (1H, dd, J=14.0, 5.0 Hz, CHAHBCHNH), 2.88 (1H, dd, J=14.0, 
7.9 Hz, CHAHBCHNH), 2.62 (2H, dt, J=6.5, 2.6 Hz, CH2S), 2.40 (2H, dt, J=7.5, 2.5 Hz, CH2CO), 
1.80 (1H, s, SH). 
13
C NMR (100 MHz, CD3OD): δ 173.3 (CO2H), 172.8 (CONH), 158.9 (Ar-C), 
138.9 (Ar-C), 131.6 (Ar-C), 131.6 (Ar-C), 128.7 (Ar-C), 128.5 (Ar-C), 115.7 (Ar-C), 115.7 (Ar-C), 
70.9 (PhCH2O), 57.1 (CHNH), 38.3 (CH2CHNH), 37.4 (CH2CO), 28.3 (CH2S). HRMS calculated 
for C19H20NO4S [M-H]
-
 358.1119, found 358.1110. 
(S)-Methyl 2-(4-(acetylthio)butanamido)-3-(4-(benzyloxy) phenyl)propanoate (93c) 
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Brown viscous oil, 1.35 g (70%). IR νmax: 3676, 3292, 2989, 2901, 1749 (CO2), 1736 (CON), 1688 
(COS), 1512, 1242, 697 cm
-1
. 
1
H NMR (400 MHz, CDCl3): δ 7.43-7.26 (5H, m, Ar-H), 6.99 (2H, 
dt, J=8.5, 2.7 Hz, Ar-H), 6.88 (2H, dt, J=8.5, 2.4 Hz, Ar-H), 6.03 (1H, d, J=7.8 Hz, NH), 5.01 (2H, 
s, PhCH2O), 4.82 (1H, dt, J=7.8, 3.9 Hz, CH2CHNH), 3.70 (3H, s, CH3O), 3.08 (1H, dd, J=14.0, 
5.8 Hz, CHAHBCHNH), 2.99 (1H, dd, J=14.0, 6.1 Hz, CHAHBCHNH), 2.90-2.76 (2H, dt, J=7.1, 
4.1 Hz, CH2S), 2.30 (3H, s, CH3CO), 2.22 (2H, td, J=5.4, 1.7 Hz, CH2CO), 1.86 (2H, quintet, 
J=7.2 Hz, CH2CH2CH2). 
13
C NMR (100 MHz, CDCl3): δ 195.9 (COS), 172.2 (CONH), 171.5 
(CO2), 157.9 (Ar-C), 136.9 (Ar-C), 130.2 (Ar-C), 128.5 (Ar-C), 128.1 (Ar-C), 127.9 (Ar-C), 127.4 
(Ar-C), 114.9 (Ar-C), 70.0 (PhCH2O), 53.1 (CHNH), 52.3 (OCH3), 37.0 (CH2CHNH), 34.8 
(CH2CO), 30.6 (CH2S), 28.3 (CH3), 25.4 (CH2CH2CH2). HRMS calculated for C23H27NNaO5S 
[M+Na]
+
452.1502, found 452.1511. 
 (S)-3-(4-(Benzyloxy)phenyl)-2-(4-mercaptobutanamido) propanoic acid (75c) 
 
Brown semisolid, 0.72 g (80%). IR νmax: 3675, 3325, 2989, 2598 (SH), 2925, 1722 (CO2), 1611 
(CON), 1510, 1226, 1176, 695 cm
-1
. 
1
H NMR (500 MHz, CD3OD): δ 7.40 (2H, t, J=7.9 Hz, Ar-H), 
7.35 (2H, t, J=7.1 Hz, Ar-H), 7.28 (1H, t, J=6.5 Hz, Ar-H), 7.12 (2H, t, J=7.8 Hz, Ar-H), 6.90 (2H, 
t, J=8.8 Hz, Ar-H), 5.05 (2H, s, PhCH2O), 4.64 (1H, dd, J=7.2, 4.8 Hz, CHNH), 3.21 (1H, dd, 
J=14.0, 4.4 Hz, CHAHBCHNH), 2.85 (1H, dd, J=14.0, 9.8 Hz, CHAHBCHNH), 2.31 (2H, t, J=7.0 
Hz, CH2CO), 2.28-2.21 (2H, m, CH2S), 1.79-1.70 (2H, m, CH2CH2CH2).
 13
C NMR (125 MHz, 
CD3OD): δ 175.2 (CO2H), 174.9 (CONH), 159.2 (Ar-C), 138.8 (Ar-C), 131.3 (Ar-C), 130.8 (Ar-C), 
129.5 (Ar-C), 128.8 (Ar-C), 128.6 (Ar-C), 115.9 (Ar-C), 71.0 (PhCH2O), 55.0 (CHNH), 37.6 
(CH2CHNH), 35.2 (CH2CO), 31.2 (CH2SH), 24.2 (CH2CH2CH2). HRMS calculated for 
C20H23NO4S [M-H]
- 
372.1275, found 372.1269. 
CENTAsalt (98) 
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The method reported by Bebrone et al.[34] was used. 3-Carboxyl-4-nitrothiophenol 100 (TNB) was 
obtained by dissolving 5,5′-dithio-bis-(2-nitrobenzoic acid) 99 (5.05 mmol, 2 g) in 100 ml of an 
aqueous solution of 0.5 M Tris base, and the pH was adjusted to 8.0 by addition of HCl (6M). 
Dithiothreitol (7.1 mmol, 1.1 g) was added, and the solution turned orange-red. The mixture was 
stirred for 10 min at room temperature and extracted with ethyl acetate (6×25 ml) before being 
acidified to pH=1.5 by addition of HCl (6M). The residual ethyl acetate was eliminated by bubbling 
nitrogen through the solution, which was thereafter left overnight at 4ºC. The precipitate (TNB) was 
collected by filtration, washed, and dried. The sodium salt of cephalothin (2.4 mmol, 1 g) and 1 
equivalent of TNB (478 mg) were dissolved in H2O (19 ml), and the pH was adjusted to 7.0 with 
NaOH (1 M). The solution was stirred for 6 hours at 65°C. The cooled solution was extracted with 
ethyl acetate (10 ml), acidified to pH=2.0 with HCl (1 M), and extracted ethyl acetate (3×15 ml). 
The organic phase was washed water (3×15 ml), dried over sodium sulfate, and evaporated under 
reduced pressure. The sodium salt of CENTA 99 was obtained by dissolving the dry residue in 
water (25 ml) containing 1 equivalent of NaHCO3, and the solution was freeze-dried to give the 
CENTA as light brown solid (1.36 g, 48%).  
1
H NMR for compound 102 (400 MHz, CDCl3): δ 7.89 (1H, d, J=8.5 Hz), 7.75 (1H, d, J=2.0 Hz), 
7.68 (1H, dd, J=8.5, 2.0 Hz), 7.29 (1H, dd, J=5.0, 1.5 Hz), 7.00-6.94 (2H, m), 5.67 (1H, d, J=5.0 
Hz), 5.09 (1H, d, J=5.0 Hz), 4.39-4.25 (2H, m), 3.82 (2H, d, J=3.0 Hz), 3.78-3.57 (2H, m). The 
NMR spectra are in agreement with the literature.[35]  
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3 Chapter 3 
Synthesis of A New Series of L-Benzyl Tyrosine Thiol 
Carboxylic Acid Inhibitors Against IMP-1
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3.1 Introduction 
As already discussed in Chapters 1 and 2, there are no clinically available inhibitors against IMP-1. 
Indeed thiol carboxylic acid compounds have been reported as the most common inhibitors for 
IMP-1.[1-11] In order to design new thiol carboxylic acid inhibitors, the results reported in Chapter 
2 were obtained, and a few potential IMP-1 inhibitors have been designed and synthesized. Despite 
the low Kic value for some of the synthesized compounds in Chapter 2, the market availability and 
cheap price of starting materials made these compounds promising for the further development in 
the future. The aim of the research reported in this chapter is to develop a few potent inhibitors by 
varying the substituents in the benzyl group. 
3.2 Result and Discussion 
As aforementioned, compound 75a showed a potent inhibitory activity with the Kic value of 
0.086±0.024 µM. In order to develop new thiol carboxylic acid inhibitors, a new project was 
designed to develop this compound by including synthesis of more derivatives of benzyl substituted 
groups. Based on commercially available benzyl derivatives, eleven compounds were designed and 
docking results were investigated. These compounds are shown in picture below. 
 
3.2.1 Docking Studies 
For computational modeling, the crystal structure of IMP-1 enzyme (PDB code 1JJT)[12] was 
downloaded from Protein Data Bank (PDB) and Chain B was deleted as the topologies of the active 
sites of both chain A and chain B are identical. The cavity of the active site with two zinc atoms 
was determined by MolDock and it was used for the docking study.[13] The energy results were 
compared with compound 75a as reference. The result of docking showed that all compounds have 
higher calculated energies (Escore) than the reference compound 75a (Table ‎3-1); therefore, It was 
expected that the higher calculated energies Escore to be more potent inhibitors. The prediction of 
interactions of these compounds with the amino acids of the active site was also investigated. The 
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computational modeling showed that the central phenyl ring of compounds 108a-k is flanked by 
Trp64 and His263; therefore, it could be predicted to make a π-π stacking interaction. The chloro, 
bromo, methyl and nitro groups of benzyl ring (108a-k) caused the higher calculated energy (Escore) 
than the reference compound 75a. The modeling also showed that thiolate group of these 
compounds was strongly coordinated to both zinc atoms (~2 Å). Table ‎3-1 shows the predicted 
distances of thiolate with both zinc atoms of the active site of IMP-1. Consequently, compounds 
108a-k were selected for synthesis and screening of IMP-1. Figure ‎3-1 to Figure ‎3-8 show 
interactions of docked ligand 108a, 108d, 108g and 108j into the active site of IMP-1. Two figures 
have been shown for compounds 108a, 108d, 108g and 108j. The first figure shows surface view of 
the IMP-1 active site with compound docked into the active site whereas the second figure shows 
interactions of docked ligand at the active site of IMP-1. The pictures of docking of the other 
molecules are shown in Appendix E. 
Table ‎3-1: Molegro Virtual Docker Escore results for L-benzyl tyrosine derivatives 108a-k (Escore for carboxylate and thiolate) and the 
distances of zinc atoms with thiolate. 
  
Compound 
MolDock Score 
(kcal/mol) 
Distance (Å) between 
Zn1 and S
-
 
Distance (Å) between 
Zn2 and S
- 
75a -190.9 1.93 1.94 
108a -201.1 2.04 1.85 
108b -202.9 1.93 1.96 
108c -194.1 1.94 1.90 
108d -197.3 2.04 1.85 
108e -194.2 1.94 1.90 
108f -195.5 2.03 1.88 
108g -201.9 1.94 1.91 
108h -199.8 1.94 1.90 
108i -207.0 1.94 1.90 
108j -199.5 1.93 1.95 
108k -194.1 1.93 1.94 
*Reference compound   
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Figure ‎3-1: Surface view of the IMP-1 active site with compound 108a docked into the active site. Atom colors on inhibitor are as 
follow: grey–carbon, red-oxygen, blue-nitrogen white-hydrogen, and yellow–sulfur. Zinc atoms of IMP-1 are shown with yellow 
spheres. 
 
Figure ‎3-2: Interaction of docked ligand 108a at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–sulfur (on 
inhibitor). 
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Figure ‎3-3: Surface view of the IMP-1 active site with compound 108d docked into the active site. Atom colors on inhibitor are as 
follow: grey–carbon, red-oxygen, blue-nitrogen, green-chlorine, white-hydrogen, and yellow–sulfur. Zinc atoms of IMP-1 are shown 
with yellow spheres. 
 
Figure ‎3-4: Interaction of docked ligand 108d at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, brown-chlorine, and 
yellow–sulfur (on inhibitor). 
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Figure ‎3-5: Surface view of the IMP-1 active site with compound 108g docked into the active site. Atom colors on inhibitor are as 
follow: grey–carbon, red-oxygen, blue-nitrogen white-hydrogen, and yellow–sulfur. Zinc atoms of IMP-1 are shown with yellow 
spheres. 
 
Figure ‎3-6: Interaction of docked ligand 108g at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–sulfur (on 
inhibitor). 
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Figure ‎3-7: Surface view of the IMP-1 active site with compound 108j docked into the active site. Atom colors on inhibitor are as 
follow: grey–carbon, red-oxygen, blue-nitrogen, brown-bromine, white-hydrogen, and yellow–sulfur. Zinc atoms of IMP-1 are 
shown with yellow spheres. 
 
Figure ‎3-8: Interaction of docked ligand 108d at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, brown-bromine, and 
yellow–sulfur (on inhibitor). 
As the compound 75a was used as the reference compound, having the crystal structure of IMP-1 
co-crystalized with this inhibitor (75a) would be very useful for further investigations and for 
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gauging the accuracy and reliability of the prediction of docking results. As no crystal structure has 
been reported for the reference compound 75a, this compound was also docked into the active site 
of IMP-1 for the prediction of the strength of binding of the designed thiol carboxylic acid 
inhibitors 108a-k into the active site of the enzyme. The study of docking compound 75a into the 
active site of IMP-1 predicted that the thiolate coordinates to both Zn1 and Zn2 with distances of 
1.95 Å and 1.98 Å respectively. The result of computational modeling also predicted that the 
oxygen of amide group of the ligand forms a hydrogen bond (3.19 Å) with the side chain amide 
group of Asn233. As the predicted distances of the central phenyl ring of the ligand 75a with the 
aromatic rings of Trp64 and His263 are around 4 Å, the other prediction was making π-π stacking 
interaction between the central phenyl ring of this ligand with the aromatic rings of either Trp64 and 
His263. 
Analogously, the study of docking showed that all designed compounds 108a-k are coordinated to 
both zinc atoms with the predicted distances in the range of 1.95 to 2.15 Å. Additionally, the 
orientation of the central phenyl ring of inhibitors 108a-k to the aromatic rings of Trp64 and His263 
may also provide π-π stacking. Because of the higher calculated energies (Escore) of compounds 
108a-k than the reference compound 75a as well as the similarity of binding of thiolate to the active 
site of IMP-1 (Figure ‎3-9 and Figure ‎3-10), it was expected that these compounds may show better 
inhibitory activities.  
 
Figure ‎3-9: Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 75a (electrostatic surface view). Atom colors on inhibitor are 
as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. The yellow spheres are zinc atoms. 
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Figure ‎3-10: Interaction of docked ligand 75a at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–sulfur (on 
inhibitor). 
Consequently, these compounds (108a-k) were synthesized with the yield of ~80% (3.2.2) and their 
kinetic activities were measured (3.2.3). Compounds 108a-c with the methyl group in the benzyl 
ring was found as the most potent inhibitors amongst all synthesized compounds (108a-k). The 
inhibitory activities of these inhibitors (108a-c) against IMP-1 were almost ten-fold lower than the 
reference compound 75a. The results of inhibitory activities of compounds 108a-k against IMP-1 
were not the expected outcome. Although the substituents of benzyl ring (108a-k) showed higher 
calculated energies (Escore) than the reference compound 75a which was expected to be better 
inhibitors but they showed less inhibitory activities than the reference compound 75a; therefore, 
adding substituents to the benzyl ring of compound 75a will decrease inhibitory activities against 
IMP-1. 
The study of the modeling of the substituents of benzyl rings (108a-k) shows that they may make a 
barrier of the rotation of benzyl ring or making different orientation of the phenyl ring in the cavity 
of IMP-1 which might decrease the potency of these inhibitors.  
This might be because of the prevention of the rotation of benzyl group in the active site of the 
IMP-1 or because of the repulsion of the substituents of benzyl ring with the amino acids of the 
IMP-1 in the cavity. Also, comparing of substituted chloro (108d-f) and bromo (108j-k) derivatives 
shows that chloro derivatives are more potent than bromo derivatives. Therefore, it seems that the 
smaller the benzyl ring substituents are more active inhibitors against IMP-1. 
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Figure ‎3-11 shows superimposed modeling of compound 75a and 108a-c. The results of modeling 
of compounds 108a-b show that the central phenyl rings of them are tilted than the central phenyl 
ring of compound 75a; therefore, it is predicted that the quality of π-π stacking interaction of 
compounds 108a-b with Trp64 would reduce which may has been the reason of the lower inhibitory 
activity of compounds 108a-b than 75a. 
The modeling result of compound 108c shows that the central phenyl ring of this compound is a 
little further away from His263; therefore, it is predicted that the quality of π-π stacking interaction 
would decrease which may has been the reason of the lower inhibitory activity of compound 108c 
than 75a. 
 
Figure ‎3-11: The superimposed image of inhibitors 108a-c and the reference inhibitor 75a into the active site of IMP-1. 
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3.2.2 Synthesis 
The synthesis pathways for the new developed L-tyrosine IMP-1 inhibitors were similar to what had 
been reported in Chapter 2. However, the Boc protected L-tyrosine methyl ester 103 was used as 
starting material to simplify the process of synthesis from three synthetic steps to two synthetic 
steps. The synthetic routes to compounds 90 and 103 are shown in Scheme 1. The compound L-
tyrosine (82) was bought from Sigma-Aldrich Company. L-Tyrosine methyl ester hydrochloride 90 
was synthesized by refluxing L-tyrosine 82 in methanol containing thionyl chloride.[14] The Boc 
protected L-methyl ester tyrosine 103 was prepared using triethylamine as base and di-tert-butyl 
dicarbonate in DCM with the yield of 90% (Scheme ‎3-1).[15] 
 
Scheme ‎3-1. Reagents and conditions: (a) SOCl2, MeOH, Δ, 2h, 100%; (b) Boc2O, triethylamine, DCM, r.t., overnight, 90%. 
Compounds 105a-k were synthesized by a general procedure (Williamson ether synthesis) by 
refluxing Boc L-tyrosine methyl ester 103, chloro or bromo benzyl derivatives 104a-k and 
potassium carbonate in acetone.[16] The yields were more than 80%. Compounds 106a-k were 
prepared by standard method with TFA in chloroform with the yields of 98%.[17] Compounds 
107a-k were synthesized by amidation of the L-amino acid methyl esters and thioester-acid 
intermediates 78a using HBTU/DIPEA as the coupling reagent.[18] Products were confirmed by 
1
H 
NMR spectroscopy (as observed by the appearance of the characteristic thioacetyl methyl group) 
and HRMS. Hydrolyzed compounds 108a-k were prepared by treatment of intermediates 107a-k 
with degassed sodium hydroxide solution to give the final thiol products (Scheme ‎3-2). The 1H 
NMR spectra for these compounds confirmed the hydrolysis of both ester groups (as evidenced by 
the loss of the thioacetyl methyl and methyl ester signals). Negative mode HRMS also supported 
the successful formation of the compounds. Thiol carboxylic acids 108a-k are sensitive to aerial 
oxidation; therefore, it was necessary to store them in a sealed flask under argon.  
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Scheme ‎3-2: Reagents and conditions: (a) Acetone, K2CO3, Δ, 24h; (b) TFA, CHCl3, r.t, overnight, 98%; (c) 78a, HBTU, DIPEA, 
THF, r.t, overnight; (d) NaOH, H2O/MeOH, r.t, 1 h. 
3.2.3 Enzyme Kinetics Studies 
As discussed in Chapter 2, as CENTA reacts with thiol carboxylic acid compounds; therefore, it is 
not a good substrate for screening of these compounds. Consequently, benzyl penicillin was used 
for assay. The inhibitory activities (IC50 values) of the inhibitors 108a-k against IMP-1 were first 
evaluated by a screening assay which measured the residual activity of the enzyme. The assay 
results showed that all of the thiol compounds 108a-k exhibited more than 50% inhibition at 1-5 
µM. Further kinetic analyses then allowed the determination of Kic values of these compounds. 
Additionally, ortho-substituted benzene compounds showed lower Kic values than meta- and para-
substituted benzene compounds (Table ‎3-2). The complete calculations of the Kic values are shown 
in Appendix D. 
Table ‎3-2: Inhibitory activities of the target compounds 108a-k against IMP-1. 
Compound Kic (µM)
b
 
75a
a 
0.086 ± 0.024 
108a 1.04 ± 0.28 
108b 1.15 ± 0.49 
108c 1.07 ± 0.21 
108d 1.81 ± 0.90 
108e 4.77 ± 2.81 
108f 3.20 ± 0.59 
108g 1.65 ± 0.34 
108h 2.86 ± 1.23 
108i 3.20 ± 0.62 
108j 3.14 ± 0.71 
108k 3.30 ± 0.90 
a Reference compound 
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The results of Kic values of these compounds showed that the inhibitory activity of ortho-, meta- 
and para- methyl derivatives (108a-c) is roughly similar. Therefore, the position of the methyl 
group on the phenyl ring does not have much effect on activity. Approximately, compounds 108j 
and 108k also showed the same activity and the position of bromo on meta- and para- of the phenyl 
ring does not cause a large change in activity. Amongst inhibitors 108d, 108e and 108g, the 
inhibitor with the chloro group in meta position (108d) is the most potent and the other two 
inhibitors (108e and 108f) have roughly same activity. The other inhibitors with the nitro group on 
the phenyl ring also showed the same pattern; the inhibitor with the nitro group in para position 
(108g) is the most potent one whereas the other two inhibitors (108h and 108i) have same activity. 
The calculations of the Kic values of compounds 108a and 108b have been shown in Figure ‎3-12. 
 
Figure ‎3-12: The calculations of the Kic values of compounds 108a and 108b. 
3.3 Conclusions 
A new series of L-benzyl tyrosine thiol carboxylic acid inhibitors has been described. Firstly, the 
docking results were investigated and compared with the reference compound 75a which was 
potent inhibitor with Kic value of 0.086±0.024 µM. The results Escore by MolDock software showed 
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that these compounds have higher calculated energies (Escore) than the reference compound 75a 
which was expected to be better inhibitors of IMP-1. The results of the docking of computational 
modeling also showed feasible coordination to the Zn
2+
 centers in the active site of IMP-1 (~2 Å). 
Apart from the binuclear metal center, there was a possibility of π-π stack interaction of central 
phenyl ring of inhibitors with Trp64 and His263. Although the substituents of benzyl ring (108a-k) 
showed higher Escore values than the reference compound 75a which was expected to be better 
inhibitors but they showed less inhibitory activities than the reference compound 75a. These 
compounds were synthesized with the yield of ~80% and were examined against IMP-1. All of 
these compounds demonstrated inhibitory activities against the metallo-β-lactamase IMP-1 ranging 
1.04±0.28 to 4.77±2.81 µM. Amongst those, compounds 108a-c which have methyl group in the 
benzyl ring showed the highest inhibitory activities. Although these compounds showed good 
inhibition activities but the most potent inhibitors 108a-c were at least ten-fold less active than 
compound 75a. This might be because of the prevention of the rotation of benzyl group in the active 
site of the IMP-1 or because of the repulsion of substituted benzyl ring with the amino acids of the 
IMP-1 in the cavity. Also, comparing of substituted chloro (108d-f) and bromo (108j-k) derivatives 
shows that chloro derivatives are more potent than bromo derivatives. Therefore, it seems the 
smaller substitutes in the benzyl ring are more favorable. The real coordination of these inhibitors 
(75a, 108a-k) can be found by X-ray crystallography which is not carried out in this project. 
Table ‎3-1 indicates that compound 75a has lowest Escore value than compounds 108a-k while its 
inhibitory activity is at least ten-fold more potent than the strongest compounds 108a-c. Although 
the results of Escore were used for the design of these inhibitors but it is not observed an order in the 
trend of the calculated energies (Escore) and inhibitory activities (Kic) of compounds 108a-k.  
3.4 Experimental 
3.4.1 Biological Evaluation 
3.4.1.1 Enzyme Expression and Purification 
As aforementioned in Chapter 2, The IMP-1 enzyme, lacking the first 21 signal peptide amino acid 
residues, was expressed and purified using the protocol of Vella et al.[19, 20] (The details of the 
expression of IMP-1 are reported in Appendix A). 
3.4.1.2 Kinetic Assays  
Inhibition assays for IMP-1 were performed as described in Chapter 2. 
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3.4.2 Synthesis 
1
H NMR and 
13
C NMR spectra are shown in Appendix G. 
General procedure 1: Williamson ether synthesis 
The general method reported by Wolf et al. was used.[16] A mixture of N-Boc-L-tyrosine methyl 
ester (2.0 g, 6.8 mmol), benzyl derivative 104a-k (13.5 mmol), potassium carbonate (1.87 g, 13.5 
mmol) and sodium iodide (100 mg as catalytic amount) in acetone (50 ml) was heated under reflux 
24 hours under nitrogen.The resulting mixture was filtrated and evaporated under vacuum to give 
the crude oil which was purified by f lash chromatography (30-100% EtOAc in petroleum ether). 
General procedure 2: Boc deprotection 
The general method reported by Benthem et al. was used.[17] The L-Boc protected 105a-k (5 
mmol) dissolved in CHCl3 (30 ml) and TFA (1.14 g, 0.76 ml, 10 mmol) was added. The mixture 
stirred at room temperature and the reaction monitored by TLC (typically overnight). The organic 
solution was washed with saturated sodium bicarbonate (30 ml), dried over sodium sulfate and 
evaporated to give the pure product 106a-k. 
General procedure 2: Amide coupling reactions 
The general method reported by Knorr et al. was used.[18] The deprotected Boc 106a-k (4.0 
mmol), 2-(acetylthio)acetic acid (0.59 g, 4.4 mmol), HBTU (1.67 g, 4.4 mmol) and DIPEA (1.56 g, 
2.10 ml, 12.00 mmol) in THF (30 ml) was stirred overnight. The organic solvent was evaporated 
under reduced pressure and the residue was dissolved in DCM (50 ml). The organic phase was 
washed with saturated sodium bicarbonate (50 ml) and evaporated under reduced pressure to give 
the crude oil which was purified by flash chromatography (30-100% EtOAc in petroleum ether) to 
give the products 107a-k. 
General procedure 3: Saponification 
Compounds 108a-k were synthesized using the following general procedure: Compounds 107a-k 
(3.0 mmol) were dissolved in degassed methanol (10 ml), then degassed sodium hydroxide solution 
(1 M, 10 ml) was added and the solution was stirred under argon for one hour. The organic solvent 
was evaporated under reduced pressure, then degassed water (50 ml) was added and the water phase 
was washed with degassed ethyl acetate (50 ml). The pH was adjusted to 1 using concentrated HCl. 
The solution was extracted with ethyl acetate (50 ml) and washed with water (5×50 ml) to remove 
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acetic acid. The organic phase was dried over sodium sulfate, filtered and evaporated under reduced 
pressure to give the pure product 108a-k. 
 (S)-Methyl 2-amino-3-(4-hydroxyphenyl)propanoate hydrochloride (90) 
 
The method reported by Bastiaans et al. was used.[14] To a solution of L-tyrosine 82 (25.0 g, 138 
mmol) and methanol (100 ml) in ice bath was added dropwise thionyl chloride (11 ml, 152 mmol). 
The mixture was heated 3 hours under reflux then the organic solvent was evaporated under 
reduced pressure to give the product as off white solid which was used without further purification 
in the next step (31.97 g, 100%). 
1
H NMR (400 MHz, CD3OD): δ 7.06 (2H, d, J=8.4 Hz, Ar-H), 6.77 (2H, d, J=8.4 Hz, Ar-H), 4.23 
(1H, t, J=6.7 Hz, CH), 3.8 (3H, s, CH3), 3.16 (1H, dd, 14.7, 5.7 Hz, CH2), 3.06 (1H, dd, J=14.7, 7.7 
Hz, CH2). 
13
C NMR (100 MHz, CD3OD): δ 170.6 (CO), 158.4 (Ar-C), 131.5 (Ar-C), 125. (Ar-C), 
116.9 (Ar-C), 55.4 (CH), 53.5 (CH3O), 36.6 (CH2). The NMR spectra are in agreement with the 
literature.[14] 
(S)-Methyl 2-((tert-butoxycarbonyl)amino)-3-(4-hydroxyphenyl)propanoate (103) 
 
The method reported by Rehman et al. was adapted.[15] Di-tert-butyl dicarbonate 96 (29.35 g, 135 
mmol) was added to a solution of L-tyrosine methyl ester hydrochloride 90 (29.66 g, 128 mmol) 
and triethyl amine (53 ml, 384 mmol) in DCM (400 ml). The resulting solution stirred under 
nitrogen overnight at room temperature. Then water (400 ml) was added to wash the organic phase 
then the organic phase was separated and evaporated under reduced and purified by flash 
chromatography (ethyl acetate-petroleum ether 30:70%) to give the product as off white waxy foam 
(34 g, 90%). (The solid was formed during overnight). 
1
H NMR (400 MHz, CDCl3): δ 6.93 (2H, d, J=8.4 Hz, Ar-H), 6.71 (2H, d, J=8.2 Hz, Ar-H), 5.00 
(1H, d, J=8.1 Hz, NH), 4.51 (1H, q, J=7.8 Hz, CH), 3.68 (3H, s, CH3O), 3.01 (1H, dd, J =14.0, 5.4 
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Hz, CHAHB), 2.93 (1H, dd, J =14.0, 6.5 Hz, CHAHB), 1.39 (9H, s, (C(CH3)3). 
13
C NMR (100 MHz, 
CDCl3): δ 172.7 (CHCO), 155.3 (NHCO), 155.2 (Ar-C), 130.3 (Ar-C), 127.4 (Ar-C), 115.51 (Ar-
C), 80.2 (C(CH3)3), 54.6 (CH), 52.3 (CH3O), 37.5 (CH2), 28.3 (C(CH3)3). The NMR spectra are in 
agreement with the literature.[21]  
 (S)-Methyl 2-((tert-butoxycarbonyl)amino)-3-(4-((2-methylbenzyl)oxy)phenyl)propanoate (105a) 
 
Pale yellow viscous oil, 2.17 g (80%).
 1
H NMR (500 MHz, CDCl3): δ 7.34 (1H, d, J=7.1 Hz, Ar-
H), 7.26-7.16 (3H, m, Ar-H), 7.03 (2H, d, J=8.5 Hz, Ar-H), 6.89 (2H, d, J=8.5 Hz, Ar-H), 4.98 
(2H, s, CH2O), 4.96 (1H, d-broad, J=7.5 Hz, NH), 4.54 (1H, quartet, J=6.9 Hz, CH2CHNH), 3.70 
(3H, s, CH3O), 3.04 (1H, dd, J =13.8, 5.8 Hz, CHAHBCHNH), 2.99 (1H, dd, J =13.8, 5.8 Hz, 
CHAHBCHNH), 2.35 (3H, s, CH3Ph), 1.40 (9H, s, C(CH3)3). 
13
C NMR (125 MHz, CDCl3): δ 172.4 
(COOCH3), 158.0 (COOBoc), 155.1 (Ar-C), 136.7 (Ar-C), 134.7 (Ar-C), 130.4 (Ar-C), 130.2 (Ar-
C), 128.6 (Ar-C), 128.2 (Ar-C), 128.2 (Ar-C), 126.0 (Ar-C), 114.8 (Ar-C), 79.9 (C(CH3)3), 68.6 
(CH2O), 54.5 (CH2CHNH), 52.1 (CH3OCO), 37.5 (CH2CHNH), 28.3 (C(CH3)3), 18.8 (CH3Ph). 
HRMS calculated for C23H29NNaO5 [M+Na]
+
 422.1938, found 422.1939. 
(S)-Methyl 2-amino-3-(4-((2-methylbenzyl)oxy)phenyl)propanoate (106a) 
 
Orange solid, 1.47 g (98%). 
1
H NMR (500 MHz, CDCl3): δ 7.39 (1H, d, J=7.1 Hz, Ar-H), 7.27-
7.17 (3H, m, Ar-H), 7.11 (2H, d, J=8.5 Hz, Ar-H), 6.93 (2H, d, J=8.5 Hz, Ar-H), 5.00 (2H, s, 
CH2O), 3.71 (1H, t, J=6.6 Hz, CH2CHNH), 3.71 (3H, s, CH3O), 3.04 (1H, dd, J =13.8, 5.2 Hz, 
CHAHBCHNH), 2.84 (1H, dd, J =13.8, 7.7 Hz, CHAHBCHNH), 2.36 (3H, s, CH3Ph), 1.97 (2H, bs, 
NH2). 
13
C NMR (125 MHz, CDCl3): δ 175.3 (CO), 157.9 (Ar-C), 136.6 (Ar-C), 134.7 (Ar-C), 130.3 
(Ar-C), 130.3 (Ar-C), 129.2 (Ar-C), 128.6 (Ar-C), 128.2 (Ar-C), 126.0 (Ar-C), 114.8 (Ar-C), 68.6 
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(CH2O), 55.8 (CH2CHNH), 52.0 (CH3O), 39.9 (CH2CHNH), 18.8 (CH3Ph). HRMS calculated for 
C18H22NO3 [M+H]
+
 300.1594, found 300.1595. 
(S)-Methyl 2-(2-(acetylthio)acetamido)-3-(4-((2-methylbenzyl)oxy)phenyl)propanoate (107a) 
 
Pale yellow viscous oil, 1.33 g (80%). 
1
H NMR (400 MHz, CDCl3): δ 7.37 (1H, d, J=7.1 Hz, Ar-
H), 7.27-7.17 (3H, m, Ar-H), 6.99 (2H, d, J=8.5 Hz, Ar-H), 6.88 (2H, d, J=8.5 Hz, Ar-H), 6.60 
(1H, d, J=7.7 Hz, NH), 4.98 (2H, s, CH2O), 4.77 (1H, dt, J =7.7, 5.8 Hz, CH2CHNH), 3.71 (3H, s, 
CH3O), 3.52 (2H, dd, J=25.0, 15.0 Hz, CH2S), 3.08 (1H, dd, J =13.8, 5.5 Hz, CHAHBCHNH), 3.00 
(1H, dd, J =13.8, 6.1 Hz, CHAHBCHNH), 2.35 (3H, s, CH3CO), 2.32 (3H, s, CH3Ph). 
13
C NMR 
(100 MHz, CDCl3): δ 195.2 (COS), 171.6 (COO), 167.6 (CONH), 158.0 (Ar-C), 136.6 (Ar-C), 
134.7 (Ar-C), 130.4 (Ar-C), 130.3 (Ar-C), 128.6 (Ar-C), 128.3 (Ar-C), 127.8 (Ar-C), 126.0 (Ar-C), 
114.8 (Ar-C), 68.5 (CH2O), 53.5 (CH2CHNH), 52.3 (CH3O), 36.7 (CH2CHNH), 32.7 (CH2S), 30.1 
(CH3CO), 18.8 (CH3Ph). HRMS calculated for C22H25NNaO5S [M+Na]
+
 438.1346, found 
438.1349. 
(S)-2-(2-Mercaptoacetamido)-3-(4-((2-methylbenzyl)oxy)phenyl)propanoic acid (108a) 
 
Colorless solid, 0.66 g (61%).
 1
H NMR (400 MHz, CD3OD): δ 7.34 (1H, d, J=7.3 Hz, Ar-H), 7.24-
7.10 (5H, m, Ar-H), 6.99 (2H, d, J=8.5 Hz, Ar-H), 5.00 (2H, s, ArCH2O), 4.62 (1H, dd, J =8.3, 5.3 
Hz, CH2CHNH), 3.19-3.10 (3H, m, CHAHBCHNH & COCH2SH), 2.95 (1H, dd, J =14.0, 8.2 Hz, 
CHAHBCHNH), 2.33 (3H, s, CH3), 1.90 (1H, s, SH). 
13
C NMR (100 MHz, CD3OD): δ 174.4 
(COOH), 172.9 (CONH), 159.3 (Ar-C), 138.0 (Ar-C), 136.4 (Ar-C), 131.5 (Ar-C), 131.3 (Ar-C), 
130.3 (Ar-C), 129.7 (Ar-C), 129.2 (Ar-C), 126.9 (Ar-C), 115.8 (Ar-C), 69.7 (PhCH2O), 55.3 
(CH2CHNH), 37.5 (CH2CHNH), 28.0 (COCH2SH), 18.9 (CH3). HRMS calculated for C19H20NO4S 
[M-H]
- 
358.1119, found 358.1125. 
(S)-Methyl 2-((tert-butoxycarbonyl)amino)-3-(4-((3-methylbenzyl)oxy)phenyl)propanoate (105b) 
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Pale yellow viscous oil, 2.17 g (80%).
 1
H NMR (500 MHz, CDCl3): δ 7.28-7.17 (3H, m, Ar-H), 
7.12 (1H, d, J=7.4 Hz, Ar-H), 7.02 (2H, d, J=8.5 Hz, Ar-H), 6.88 (2H, d, J=8.5 Hz, Ar-H), 4.98 
(2H, s, CH2O), 4.94 (1H, d-broad, J=7.5 Hz, NH), 4.33 (1H, quartet, J=6.9 Hz, CH2CHNH), 3.69 
(3H, s, CH3O), 3.07-2.93 (2H, m, CH2CHNH), 2.35 (3H, s, CH3Ph), 1.40 (9H, s, C(CH3)3). 
13
C 
NMR (125 MHz, CDCl3): δ 172.4 (COOCH3), 158.0 (COOBoc), 155.1 (Ar-C), 138.3 (Ar-C), 
136.9 (Ar-C), 130.3 (Ar-C), 128.7 (Ar-C), 128.5 (Ar-C), 128.2 (Ar-C), 128.2 (Ar-C), 124.6 (Ar-C), 
114.9 (Ar-C), 79.9 (C(CH3)3), 70.1 (CH2O), 54.5 (CH2CHNH), 52.2 (CH3OCO), 37.5 
(CH2CHNH), 28.3 (C(CH3)3), 21.4 (CH3Ph). HRMS calculated for C23H29NNaO5 [M+Na]
+
 
422.1938, found 422.1935. 
(S)-Methyl 2-amino-3-(4-((3-methylbenzyl)oxy)phenyl)propanoate (106b) 
 
Olive green solid, 1.47 g (98%). 
1
H NMR (500 MHz, CDCl3): δ 7.91 (2H, bs, NH2), 7.24 (1H, t, 
J=7.6 Hz, Ar-H), 7.20 (1H, s, Ar-H), 7.17 (1H, d, J=7.6 Hz, Ar-H), 7.11 (1H, d, J=7.4 Hz, Ar-H), 
7.07 (2H, d, J=8.5 Hz, Ar-H), 6.91 (2H, d, J=8.5 Hz, Ar-H), 4.94 (2H, s, CH2O), 4.23 (1H, dd, 
J=7.7, 5.2 Hz, CH2CHNH), 3.73 (3H, s, CH3O), 3.23 (1H, dd, J =13.8, 5.2 Hz, CHAHBCHNH), 
3.13 (1H, dd, J =13.8, 7.7 Hz, CHAHBCHNH), 2.34 (3H, s, CH3Ph). 
13
C NMR (125 MHz, CDCl3): 
δ 169.2 (CO), 158.8 (Ar-C), 138.3 (Ar-C), 136.5 (Ar-C), 130.3 (Ar-C), 128.9 (Ar-C), 128.5 (Ar-C), 
128.3 (Ar-C), 124.6 (Ar-C), 124.6 (Ar-C), 115.6 (Ar-C), 70.1 (CH2O), 54.5 (CH2CHNH), 53.4 
(CH3O), 35.2 (CH2CHNH), 21.4 (CH3Ph). HRMS calculated for C18H22NO3 [M+H]
+
 300.1594, 
found 300.1592. 
(S)-Methyl 2-(2-(acetylthio)acetamido)-3-(4-((3-methylbenzyl)oxy)phenyl)propanoate (107b) 
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Viscous yellow oil, 1.33 g (80%). 
1
H NMR (500 MHz, CDCl3): δ 7.29-7.16 (3H, m, Ar-H), 7.12 
(1H, d, J=7.4 Hz, Ar-H), 6.98 (2H, d, J=8.5 Hz, Ar-H), 6.86 (2H, d, J=8.5 Hz, Ar-H), 6.62 (1H, bs, 
NH), 4.97 (2H, s, CH2O), 4.75 (1H, quartet, J=6.5 Hz, CH2CHNH), 3.71 (3H, s, CH3O), 3.52 (2H, 
dd, J=32.0, 15.1 Hz, CH2S), 3.07 (1H, dd, J =13.8, 5.5 Hz, CHAHBCHNH), 2.99 (1H, dd, J =13.8, 
6.1 Hz, CHAHBCHNH), 2.35 (3H, s, CH3CO), 2.31 (3H, s, CH3Ph). 
13
C NMR (125 MHz, CDCl3): 
δ 195.2 (COS), 171.6 (COO), 167.7 (CONH), 158.0 (Ar-C), 138.3 (Ar-C), 136.8 (Ar-C), 130.3 (Ar-
C), 128.7 (Ar-C), 128.5 (Ar-C), 128.2 (Ar-C), 127.7 (Ar-C), 124.6 (Ar-C), 114.9 (Ar-C), 70.0 
(CH2O), 53.5 (CH2CHNH), 52.4 (CH3O), 36.7 (CH2CHNH), 32.7 (CH2S), 30.1 (CH3CO), 21.4 
(CH3Ph). HRMS calculated for C22H25NNaO5S [M+Na]
+
 438.1346, found 438.1343. 
(S)-2-(2-Mercaptoacetamido)-3-(4-((3-methylbenzyl)oxy)phenyl)propanoic acid (108b) 
 
Off white solid, 0.70 g (65%). 
1
H NMR (400 MHz, CD3OD): δ 7.25-7.16 (3H, m, Ar-H), 7.15-7.08 
(3H, m, Ar-H), 6.89 (2H, d, J=8.5 Hz, Ar-H), 4.99 (2H, s, ArCH2O), 4.61 (1H, dd, J =8.3, 5.3 Hz, 
CH2CHNH), 3.18-3.07 (3H, m, CHAHBCHNH & COCH2SH), 2.93 (1H, dd, J =14.0, 8.2 Hz, 
CHAHBCHNH), 2.33 (3H, s, CH3), 1.90 (1H, s, SH). 
13
C NMR (100 MHz, CD3OD): δ 174.4 
(COOH), 172.9 (CONH), 159.3 (Ar-C), 139.3 (Ar-C), 138.7 (Ar-C), 131.4 (Ar-C), 130.3 (Ar-C), 
129.5 (Ar-C), 129.4 (Ar-C), 129.1 (Ar-C), 125.6 (Ar-C), 115.9 (Ar-C), 71.0 (PhCH2O), 55.3 
(CH2CHNH), 37.5 (CH2CHNH), 28.0 (COCH2SH), 21.4 (CH3). HRMS calculated for C19H20NO4S 
[M-H]
- 
358.1119, found 358.1129. 
(S)-Methyl 2-((tert-butoxycarbonyl)amino)-3-(4-((4-methylbenzyl)oxy)phenyl)propanoate (105c) 
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Off white solid, 2.44 g (90%). 
1
H NMR (400 MHz, CDCl3): δ 7.29 (2H, d, J=7.9 Hz, Ar-H), 7.17 
(2H, d, J=7.9 Hz, Ar-H), 7.01 (2H, d, J=8.5 Hz, Ar-H), 6.87 (2H, d, J=8.5 Hz, Ar-H), 4.97 (2H, s, 
CH2O), 4.94 (1H, bs, NH), 4.61-4.44 (1H, m, CH2CHNH), 3.68 (3H, s, CH3O), 3.02-2.92 (2H, m, 
CH2CHNH), 2.34 (3H, s, CH3Ph), 1.40 (9H, s, C(CH3)3). 
13
C NMR (100 MHz, CDCl3): δ 172.4 
(COOCH3), 158.0 (COOBoc), 155.1 (Ar-C), 137.7 (Ar-C), 133.9 (Ar-C), 130.3 (Ar-C), 129.3 (Ar-
C), 128.1 (Ar-C), 127.6 (Ar-C), 114.9 (Ar-C), 79.9 (C(CH3)3), 69.9 (CH2O), 54.5 (CH2CHNH), 
52.2 (CH3OCO), 37.5 (CH2CHNH), 28.3 (C(CH3)3), 21.2 (CH3Ph). HRMS calculated for 
C23H29NNaO5 [M+Na]
+
 422.1938, found 422.1936. 
(S)-Methyl 2-amino-3-(4-((4-methylbenzyl)oxy)phenyl)propanoate (106c) 
 
Pale yellow viscous oil, 1.47 g (98%). 
1
H NMR (400 MHz, CDCl3): δ 7.29 (2H, d, J=7.9 Hz, Ar-
H), 7.17 (2H, d, J=7.9 Hz, Ar-H), 7.07 (2H, d, J=8.5 Hz, Ar-H), 6.89 (2H, d, J=8.5 Hz, Ar-H), 4.97 
(2H, s, CH2O), 3.74 (1H, dd, J =7.3, 5.3 Hz, CH2CHNH), 3.70 (3H, s, CH3O), 3.03 (1H, dd, J 
=13.8, 5.2 Hz, CHAHBCHNH), 2.84 (1H, dd, J =13.8, 7.7 Hz, CHAHBCHNH), 2.68 (2H, bs, NH2), 
2.34 (3H, s, CH3Ph). 
13
C NMR (100 MHz, CDCl3): δ 174.5 (CO), 158.0 (Ar-C), 137.7 (Ar-C), 
133.9 (Ar-C), 130.3 (Ar-C), 129.3 (Ar-C), 128.6 (Ar-C), 127.6 (Ar-C), 115.0 (Ar-C), 69.9 (CH2O), 
55.6 (CH2CHNH), 52.2 (CH3O), 39.4 (CH2CHNH), 21.2 (CH3Ph). HRMS calculated for 
C18H22NO3 [M+H]
+
 300.1594, found 300.1591. 
(S)-Methyl 2-(2-(acetylthio)acetamido)-3-(4-((4-methylbenzyl)oxy)phenyl)propanoate (107c) 
 
Off white solid, 1.36 g (82%).
 1
H NMR (500 MHz, CDCl3): δ 7.28 (2H, d, J=7.9 Hz, Ar-H), 7.17 
(2H, d, J=7.9 Hz, Ar-H), 6.97 (2H, d, J=8.6 Hz, Ar-H), 6.86 (2H, d, J=8.6 Hz, Ar-H), 6.57 (1H, d, 
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J=7.7 Hz, NH), 4.97 (2H, s, CH2O), 4.75 (1H, dt, J =7.8, 5.5 Hz, CH2CHNH), 3.70 (3H, s, CH3O), 
3.51 (2H, dd, J=31.0, 14.8 Hz, CH2S), 3.06 (1H, dd, J =13.8, 5.5 Hz, CHAHBCHNH), 2.99 (1H, dd, 
J =13.8, 6.1 Hz, CHAHBCHNH), 2.34 (3H, s, CH3CO), 2.31 (3H, s, CH3Ph). 
13
C NMR (125 MHz, 
CDCl3): δ 195.2 (COS), 171.6 (COO), 167.6 (CONH), 158.0 (Ar-C), 137.8 (Ar-C), 133.9 (Ar-C), 
130.3 (Ar-C), 129.3 (Ar-C), 127.7 (Ar-C), 127.6 (Ar-C), 114.9 (Ar-C), 69.9 (CH2O), 53.5 
(CH2CHNH), 52.3 (CH3O), 36.8 (CH2CHNH), 32.8 (CH2S), 30.1 (CH3CO), 21.2 (CH3Ph). HRMS 
calculated for C22H25NNaO5S [M+Na]
+
 438.1346, found 438.1342. 
(S)-2-(2-Mercaptoacetamido)-3-(4-((4-methylbenzyl)oxy)phenyl)propanoic acid (108c) 
 
Off white solid, 0.73 g (68%). 
1
H NMR (500 MHz, CD3OD): δ 7.26 (2H, d, J=9.0 Hz, Ar-H), 7.19-
7.06 (4H, m, Ar-H), 6.88 (2H, d, J=8.5 Hz, Ar-H), 4.96 (2H, s, ArCH2O), 4.61 (1H, dd, J =8.3, 5.3 
Hz, CH2CHNH), 3.17-3.07 (3H, m, CHAHBCHNH & COCH2SH), 2.93 (1H, dd, J =14.0, 8.2 Hz, 
CHAHBCHNH), 2.31 (3H, s, CH3), 1.9 (1H, s, SH). 
13
C NMR (125 MHz, CD3OD): δ 174.4 
(COOH), 172.9 (CONH), 159.2 (Ar-C), 138.7 (Ar-C), 135.7 (Ar-C), 131.4 (Ar-C), 130.2 (Ar-C), 
130.1 (Ar-C), 128.7 (Ar-C), 115.9 (Ar-C), 70.9 (PhCH2O), 55.3 (CH2CHNH), 37.5 (CH2CHNH), 
28.0 (COCH2SH), 21.2 (CH3), 1.90 (1H, s, SH). HRMS calculated for C19H20NO4S [M-H]
- 
358.1119, found 358.1132. 
(S)-Methyl 2-((tert-butoxycarbonyl)amino)-3-(4-((2-chlorobenzyl)oxy)phenyl)propanoate (105d) 
 
Off white solid, 2.34 g (82 %).
 1
H NMR (500 MHz, CDCl3): δ 7.53 (1H, dd, J =7.1, 1.4 Hz, Ar-H), 
7.38 (1H, dd, J =7.1, 1.4 Hz, Ar-H), 7.30-7.20 (2H, m, Ar-H), 7.03 (2H, d, J=8.5 Hz, Ar-H), 6.88 
(2H, d, J=8.5 Hz, Ar-H), 5.12 (2H, s, CH2O), 4.96 (1H, d, J=6.7 Hz, NH), 4.53 (1H, quartet, J=7.0 
Hz, CH2CHNH), 3.69 (3H, s, CH3O), 3.04 (1H, dd, J =13.8, 5.8 Hz, CHAHBCHNH), 2.97 (1H, dd, 
J =13.8, 6.0 Hz, CHAHBCHNH), 1.40 (9H, s, C(CH3)3). 
13
C NMR (125 MHz, CDCl3): δ 172.4 
(COOCH3), 157.6 (NHCOO), 155.1 (Ar-C), 134.7 (Ar-C), 132.5 (Ar-C), 130.4 (Ar-C), 129.3 (Ar-
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C), 128.9 (Ar-C), 128.7 (Ar-C), 128.5 (Ar-C), 126.9 (Ar-C), 114.9 (Ar-C), 79.9 (C(CH3)3), 67.1 
(CH2O), 54.5 (CH2CHNH), 52.2 (CH3O), 37.5 (CH2CHNH), 28.3 (C(CH3)3). HRMS calculated for 
C22H26ClNNaO5 [M+Na]
+
 442.1392, found 442.1397. 
(S)-Methyl 2-amino-3-(4-((2-chlorobenzyl)oxy)phenyl)propanoate (106d) 
 
Green viscous oil, 1.57 g (98%). 
1
H NMR (500 MHz, CDCl3): δ 7.53 (1H, dd, J =7.1, 1.4 Hz, Ar-
H), 7.37 (1H, dd, J =7.1, 1.4 Hz, Ar-H), 7.28-7.20 (2H, m, Ar-H), 7.10 (2H, d, J=8.5 Hz, Ar-H), 
6.90 (2H, d, J=8.5 Hz, Ar-H), 5.12 (2H, s, CH2O), 3.69 (4H, s: 1H for CH2CHNH and 3H for 
CH3O), 3.01 (1H, dd, J =13.6, 5.1 Hz, CHAHBCHNH), 2.81 (1H, dd, J =13.7, 7.7 Hz, 
CHAHBCHNH), 1.67 (2H, bs, NH2). 
13
C NMR (125 MHz, CDCl3): δ 175.3 (CO), 157.4 (Ar-C), 
134.7 (Ar-C), 132.5 (Ar-C), 130.3 (Ar-C), 129.6 (Ar-C), 129.3 (Ar-C), 128.9 (Ar-C), 128.7 (Ar-C), 
126.9 (Ar-C), 114.9 (Ar-C), 67.1 (CH2O), 55.8 (CH2CHNH), 51.9 (CH3O), 40.0 (CH2CHNH). 
HRMS calculated for C17H19ClNO3 [M+H]
+
 320.1048, found 320.1049. 
(S)-Methyl 2-(2-(acetylthio)acetamido)-3-(4-((2-chlorobenzyl)oxy)phenyl)propanoate (107d) 
 
Yellow viscous oil, 1.43 g (82%). 
1
H NMR (500 MHz, CDCl3): δ 7.53 (1H, dd, J =7.1, 1.4 Hz, Ar-
H), 7.37 (1H, dd, J =7.1, 1.4 Hz, Ar-H), 7.28-7.20 (2H, m, Ar-H), 7.00 (2H, d, J=8.5 Hz, Ar-H), 
6.88 (2H, d, J=8.5 Hz, Ar-H), 6.60 (1H, d, J=7.7 Hz, NH), 5.12 (2H, s, CH2O), 4.75 (1H, quartet, 
J=6.4 Hz, CH2CHNH), 3.70 (3H, s, CH3O), 3.51 (2H, dd, J=32.0, 15.0 Hz, CH2S), 3.07 (1H, dd, J 
=13.8, 5.5 Hz, CHAHBCHNH), 2.99 (1H, dd, J =13.8, 6.1 Hz, CHAHBCHNH), 2.32 (3H, s, 
CH3CO). 
13
C NMR (125 MHz, CDCl3): δ 195.1 (COS), 171.6 (COO), 167.6 (CONH), 157.6 (Ar-
C), 134.6 (Ar-C), 132.5 (Ar-C), 130.3 (Ar-C), 129.3 (Ar-C), 129.0 (Ar-C), 128.7 (Ar-C), 128.1 (Ar-
C), 126.9 (Ar-C), 114.8 (Ar-C), 67.1 (CH2O), 53.5 (CH2CHNH), 52.3 (CH3O), 36.7 (CH2CHNH), 
32.7 (CH2S), 30.1 (CH3CO). HRMS calculated for C21H22ClNNaO5S [M+Na]
+
 458.0799, found 
458.0803. 
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(S)-3-(4-((2-Chlorobenzyl)oxy)phenyl)-2-(2-mercaptoacetamido)propanoic acid (108d) 
 
Tan solid, 0.79 g (69%). 
1
H NMR (500 MHz, CD3OD): δ 7.52 (1H, m, Ar-H), 7.40 (1H, m, Ar-H), 
7.31-7.25 (2H, m, Ar-H), 7.14 (2H, d, J=8.5 Hz, Ar-H), 6.90 (2H, d, J=8.5 Hz, Ar-H), 5.10 (2H, s, 
CH2O), 4.62 (1H, dd, J =8.0, 5.4 Hz, CH2CHNH), 3.15 (1H, dd, J =13.8, 5.5 Hz, CHAHBCHNH), 
3.12 (2H, s, CH2SH), 2.95 (1H, dd, J =13.8, 6.1 Hz, CHAHBCHNH), 1.90 (1H, s, SH). 
13
C NMR 
(125 MHz, CD3OD): δ 174.3 (COOH), 172.9 (CONH), 159.0 (Ar-C), 136.1 (Ar-C), 134.0 (Ar-C), 
131.5 (Ar-C), 130.6 (Ar-C), 130.4 (Ar-C), 130.4 (Ar-C), 130.3 (Ar-C), 128.1 (Ar-C), 115.9 (Ar-C), 
68.3 (PhCH2O), 55.3 (CH2CHNH), 37.5 (CH2CHNH), 28.0 (COCH2SH). HRMS calculated for 
C18H17ClNO4S [M-H]
- 
378.0572, found 378.0566. 
 (S)-Methyl 2-((tert-butoxycarbonyl)amino)-3-(4-((3-chlorobenzyl)oxy)phenyl)propanoate (105e) 
 
Pale yellow oil, 2.28 g (80%). 
1
H NMR (500 MHz, CDCl3): δ 7.41 (1H, s, Ar-H), 7.28 (3H, s, Ar-
H), 7.02 (2H, d, J=8.5 Hz, Ar-H), 6.86 (2H, d, J=8.5 Hz, Ar-H), 4.99 (2H, s, CH2O), 4.96 (1H, d, 
J=7.5 Hz, NH), 4.53 (1H, quartet, J=7.2 Hz, CH2CHNH), 3.69 (3H, s, CH3O), 3.03 (1H, dd, J 
=13.8, 5.8 Hz, CHAHBCHNH), 2.98 (1H, dd, J =13.8, 6.0 Hz, CHAHBCHNH), 1.40 (9H, s, 
C(CH3)3). 
13
C NMR (125 MHz, CDCl3): δ 172.4 (COOCH3), 157.5 (NHCOO), 155.1 (Ar-C), 139.1 
(Ar-C), 134.5 (Ar-C), 130.3 (Ar-C), 129.8 (Ar-C), 128.6 (Ar-C), 128.0 (Ar-C), 127.4 (Ar-C), 125.3 
(Ar-C), 114.9 (Ar-C), 79.9 (C(CH3)3), 69.1 (CH2O), 54.5 (CH2CHNH), 52.2 (CH3O), 37.5 
(CH2CHNH), 28.3 (C(CH3)3). HRMS calculated for C22H26ClNNaO5 [M+Na]
+
 442.1392, found 
442.1394. 
(S)-Methyl 2-amino-3-(4-((3-chlorobenzyl)oxy)phenyl)propanoate (106e) 
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Yellow solid, 1.57 g (98%). 
1
H NMR (500 MHz, CDCl3): δ 7.40 (1H, s, Ar-H), 7.26 (3H, s, Ar-H), 
7.08 (2H, d, J=8.6 Hz, Ar-H), 6.87 (2H, d, J=8.6 Hz, Ar-H), 4.97 (2H, s, CH2O), 3.68 (3H, s, 
CH3O), 3.66 (1H, m, CH2CHNH), 3.00 (1H, dd, J =13.6, 5.1 Hz, CHAHBCHNH), 2.80 (1H, dd, J 
=13.6, 7.7 Hz, CHAHBCHNH), 1.65 (2H, bs, NH2). 
13
C NMR (125 MHz, CDCl3): δ 175.3 (CO), 
157.3 (Ar-C), 139.0 (Ar-C), 134.4 (Ar-C), 130.2 (Ar-C), 129.7 (Ar-C), 129.6 (Ar-C), 127.9 (Ar-C), 
127.3 (Ar-C), 125.2 (Ar-C), 114.8 (Ar-C), 69.0 (CH2O), 55.7 (CH2CHNH), 51.8 (CH3O), 40.0 
(CH2CHNH). HRMS calculated for C17H19ClNO3 [M+H]
+
 320.1048, found 320.1047. 
(S)-Methyl 2-(2-(acetylthio)acetamido)-3-(4-((3-chlorobenzyl)oxy)phenyl)propanoate (107e) 
 
Brown viscous oil, 1.45 g (83%). 
1
H NMR (500 MHz, CDCl3): δ 7.40 (1H, s, Ar-H), 7.29 (3H, s, 
Ar-H), 6.99 (2H, d, J=8.6 Hz, Ar-H), 6.85 (2H, d, J=8.6 Hz, Ar-H), 6.59 (1H, d, J=7.7 Hz, NH), 
4.99 (2H, s, CH2O), 4.76 (1H, dt, J=7.7, 5.9 Hz, CH2CHNH), 3.70 (3H, s, CH3O), 3.51 (2H, dd, 
J=27.5, 14.8 Hz, CH2S), 3.07 (1H, dd, J =13.8, 5.5 Hz, CHAHBCHNH), 2.99 (1H, dd, J =13.8, 6.1 
Hz, CHAHBCHNH), 2.32 (3H, s, CH3CO). 
13
C NMR (125 MHz, CDCl3): δ 195.2 (COS), 171.5 
(COO), 167.6 (CONH), 157.6 (Ar-C), 139.0 (Ar-C), 134.5 (Ar-C), 130.4 (Ar-C), 129.9 (Ar-C), 
128.2 (Ar-C), 128.1 (Ar-C), 127.4 (Ar-C), 125.3 (Ar-C), 114.8 (Ar-C), 69.1 (CH2O), 53.5 
(CH2CHNH), 52.4 (CH3O), 36.8 (CH2CHNH), 32.8 (CH2S), 30.1 (CH3CO). HRMS calculated for 
C21H22ClNNaO5S [M+Na]
+
 458.0799, found 458.0800. 
(S)-3-(4-((3-chlorobenzyl)oxy)phenyl)-2-(2-mercaptoacetamido)propanoic acid (108e) 
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Tan solid, 0.77 g (68%). 
1
H NMR (500 MHz, CD3OD): δ 7.42 (1H, s, Ar-H), 7.33-7.26 (3H, m, Ar-
H), 7.13 (2H, d, J=8.6 Hz, Ar-H), 6.89 (2H, d, J=8.6 Hz, Ar-H), 5.02 (2H, s, ArCH2O), 4.62 (1H, 
dd, J =8.2, 5.2 Hz, CH2CHNH), 3.18-3.10 (3H, m, CHAHBCHNH & COCH2SH), 2.94 (1H, dd, J 
=14.0, 8.0 Hz, CHAHBCHNH), 1.90 (1H, s, SH). 
13
C NMR (125 MHz, CD3OD): δ 174.3 (COOH), 
172.9 (CONH), 158.9 (Ar-C), 141.2 (Ar-C), 135.4 (Ar-C), 131.5 (Ar-C), 131.0 (Ar-C), 130.6 (Ar-
C), 128.8 (Ar-C), 128.3 (Ar-C), 126.6 (Ar-C), 115.9 (Ar-C), 70.0 (PhCH2O), 55.3 (CH2CHNH), 
37.5 (CH2CHNH), 28.0 (COCH2SH). HRMS calculated for C18H17ClNO4S [M-H]
- 
378.0572, found 
378.0569. 
 (S)-Methyl 2-((tert-butoxycarbonyl)amino)-3-(4-((4-chlorobenzyl)oxy)phenyl)propanoate (105f) 
 
Yellow solid, 2.28 g (82%). 
1
H NMR (400 MHz, CDCl3): δ 7.33 (4H, s, Ar-H), 7.02 (2H, d, J=8.5 
Hz, Ar-H), 6.85 (2H, d, J=8.5 Hz, Ar-H), 4.98 (2H, s, CH2O), 4.94 (1H, d, J=7.5 Hz, NH), 4.59-
4.46 (1H, m, CH2CHNH), 3.69 (3H, s, CH3O), 3.05 (1H, dd, J =13.8, 5.8 Hz, CHAHBCHNH), 2.95 
(1H, dd, J =13.8, 6.0 Hz, CHAHBCHNH), 1.40 (9H, s, C(CH3)3). 
13
C NMR (100 MHz, CDCl3): δ 
172.4 (COOCH3), 157.6 (NHCOO), 155.1 (Ar-C), 135.5 (Ar-C), 133.7 (Ar-C), 130.3 (Ar-C), 128.7 
(Ar-C), 128.5 (Ar-C), 128.2 (Ar-C), 114.9 (Ar-C), 79.9 (C(CH3)3), 69.2 (CH2O), 54.5 
(CH2CHNH), 52.2 (CH3O), 37.5 (CH2CHNH), 28.3 (C(CH3)3). HRMS calculated for 
C22H26ClNNaO5 [M+Na]
+
 442.1392, found 442.1395. 
(S)-Methyl 2-amino-3-(4-((4-chlorobenzyl)oxy)phenyl)propanoate (106f) 
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Brown solid, 1.57 g (98%). 
1
H NMR (500 MHz, CDCl3): δ 7.33 (4H, s, Ar-H), 7.08 (2H, d, J=8.6 
Hz, Ar-H), 6.87 (2H, d, J=8.6 Hz, Ar-H), 4.98 (2H, s, CH2O), 3.69 (4H, s, (1H for CH2CHNH and 
3H for CH3O)), 3.01 (1H, dd, J =13.8, 5.8 Hz, CHAHBCHNH), 2.80 (1H, dd, J =13.8, 6.0 Hz, 
CHAHBCHNH), 1.71 (2H, s, NH2). 
13
C NMR (125 MHz, CDCl3): δ 175.3 (CO), 157.5 (Ar-C), 
135.5 (Ar-C), 133.7 (Ar-C), 130.3 (Ar-C), 129.6 (Ar-C), 128.9 (Ar-C), 128.7 (Ar-C), 114.9 (Ar-C), 
69.2 (CH2O), 55.8 (CH2CHNH), 52.0 (CH3O), 40.0 (CH2CHNH). HRMS calculated for 
C17H19ClNO3 [M+H]
+
 320.1048, found 320.1046. 
(S)-Methyl 2-(2-(acetylthio)acetamido)-3-(4-((4-chlorobenzyl)oxy)phenyl)propanoate (107f) 
 
Brown viscous oil, 1.39 g (80%). 
1
H NMR (500 MHz, CDCl3): δ 7.33 (4H, s, Ar-H), 6.98 (2H, d, 
J=8.7 Hz, Ar-H), 6.84 (2H, d, J=8.7 Hz, Ar-H), 6.59 (1H, d, J=7.7 Hz, NH), 4.98 (2H, s, CH2O), 
4.75 (1H, dt, J =7.8, 5.5 Hz, CH2CHNH), 3.70 (3H, s, CH3O), 3.51 (2H, dd, J=27.5, 14.2 Hz, 
CH2S), 3.07 (1H, dd, J =13.8, 5.5 Hz, CHAHBCHNH), 2.98 (1H, dd, J =13.8, 6.1 Hz, 
CHAHBCHNH), 2.32 (3H, s, CH3CO). 
13
C NMR (125 MHz, CDCl3): δ 195.2 (COS), 171.6 (COO), 
167.7 (CONH), 157.7 (Ar-C), 135.4 (Ar-C), 133.8 (Ar-C), 130.4 (Ar-C), 130.3 (Ar-C), 128.7 (Ar-
C), 128.1 (Ar-C), 114.9 (Ar-C), 69.2 (CH2O), 53.5 (CH2CHNH), 52.4 (CH3O), 36.8 (CH2CHNH), 
32.7 (CH2S), 30.1 (CH3CO). HRMS calculated for C21H22ClNNaO5S [M+Na]
+
 458.0799, found 
458.0806. 
(S)-3-(4-((4-Chlorobenzyl)oxy)phenyl)-2-(2-mercaptoacetamido)propanoic acid (108f) 
 
Off white soild. 0.80 g (70%). 
1
H NMR (500 MHz, CD3OD): δ 7.39 (2H, d, J=8.5 Hz, Ar-H), 7.34 
(2H, d, J=8.5 Hz, Ar-H), 7.13 (2H, d, J=8.5 Hz, Ar-H), 6.89 (2H, d, J=8.5 Hz, Ar-H), 5.02 (2H, s, 
ArCH2O), 4.61 (1H, dd, J =8.3, 5.3 Hz, CH2CHNH), 3.18-3.08 (3H, m, CHAHBCHNH & 
COCH2SH), 2.94 (1H, dd, J =14.0, 8.2 Hz, CHAHBCHNH), 1.90 (1H, s, SH). 
13
C NMR (125 MHz, 
CD3OD): δ 174.3 (COOH), 172.9 (CONH), 159.0 (Ar-C), 137.6 (Ar-C), 134.6 (Ar-C), 131.5 (Ar-
C), 130.5 (Ar-C), 130.1 (Ar-C), 129.6 (Ar-C), 115.9 (Ar-C), 70.1 (PhCH2O), 55.3 (CH2CHNH), 
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37.5 (CH2CHNH), 28.00 (COCH2SH). HRMS calculated for C18H17ClNO4S [M-H]
- 
378.0572, 
found 378.0557. 
(S)-Methyl 2-((tert-butoxycarbonyl)amino)-3-(4-((2-nitrobenzyl)oxy)phenyl)propanoate (105g) 
 
Pale yellow viscous oil, 2.78 g (95%). 
1
H NMR (500 MHz, CDCl3): δ 8.13 (1H, d, J=8.0 Hz, Ar-
H), 7.85 (1H, d, J=7.8 Hz, Ar-H), 7.65 (1H, t, J=7.6 Hz, Ar-H), 7.44 (1H, t, J=8.0 Hz, Ar-H), 7.03 
(2H, d, J=8.5 Hz, Ar-H), 6.88 (2H, d, J=8.5 Hz, Ar-H), 5.44 (2H, s, CH2O), 4.97 (1H, d, J=6.7 Hz, 
NH), 4.52 (1H, quartet, J=7.0 Hz, CH2CHNH), 3.69 (3H, s, CH3O), 3.04 (1H, dd, J =13.8, 5.8 Hz, 
CHAHBCHNH), 2.97 (1H, dd, J =13.8, 6.0 Hz, CHAHBCHNH), 1.39 (9H, s, C(CH3)3). 
13
C NMR 
(125 MHz, CDCl3): δ 172.3 (COOCH3), 157.2 (NHCOO), 155.0 (Ar-C), 146.8 (Ar-C), 134.0 (Ar-
C), 133.9 (Ar-C), 130.4 (Ar-C), 128.9 (Ar-C), 128.5 (Ar-C), 128.3 (Ar-C), 124.9 (Ar-C), 114.9 (Ar-
C), 79.9 (C(CH3)3), 66.8 (CH2O), 54.5 (CH2CHNH), 52.2 (CH3O), 37.4 (CH2CHNH), 28.3 
(C(CH3)3). HRMS calculated for C22H26N2NaO7 [M+Na]
+ 
453.1632, found 453.1635. 
(S)-Methyl 2-amino-3-(4-((2-nitrobenzyl)oxy)phenyl)propanoate (106g) 
 
Tan yellow viscous oil, 1.62 g (98%). 
1
H NMR (500 MHz, CDCl3): δ 8.13 (1H, d, J=8.0 Hz, Ar-H), 
7.86 (1H, d, J=7.8 Hz, Ar-H), 7.65 (1H, t, J=7.6 Hz, Ar-H), 7.46 (1H, t, J=8.0 Hz, Ar-H), 7.10 
(2H, d, J=8.5 Hz, Ar-H), 6.90 (2H, d, J=8.5 Hz, Ar-H), 5.44 (2H, s, CH2O), 3.69 (4H, s: 1H for 
CH2CHNH and 3H for CH3O), 3.01 (1H, dd, J =13.6, 5.1 Hz, CHAHBCHNH), 2.82 (1H, dd, J 
=13.7, 7.7 Hz, CHAHBCHNH), 1.95 (2H, bs, NH2). 
13
C NMR (125 MHz, CDCl3): δ 175.2 (CO), 
157.1 (Ar-C), 148.3 (Ar-C), 134.0 (Ar-C), 133.9 (Ar-C), 130.4 (Ar-C), 129.9 (Ar-C), 128.5 (Ar-C), 
128.3 (Ar-C), 124.9 (Ar-C), 115.0 (Ar-C), 66.8 (CH2O), 55.7 (CH2CHNH), 52.0 (CH3O), 39.9 
(CH2CHNH). HRMS calculated for C17H19N2O5 [M+H]
+
 331.1288, found 331.1290. 
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(S)-Methyl 2-(2-(acetylthio)acetamido)-3-(4-((2-nitrobenzyl)oxy)phenyl)propanoate (107g) 
 
Pale yellow solid, 1.48g (83%). 
1
H NMR (500 MHz, CDCl3): δ 8.13 (1H, d, J=8.0 Hz, Ar-H), 7.86 
(1H, d, J=7.8 Hz, Ar-H), 7.66 (1H, t, J=7.6 Hz, Ar-H), 7.47 (1H, t, J=8.0 Hz, Ar-H), 7.00 (2H, d, 
J=8.5 Hz, Ar-H), 6.88 (2H, d, J=8.5 Hz, Ar-H), 6.59 (1H, d, J=7.6 Hz, NH), 5.43 (2H, s, CH2O), 
4.76 (1H, dt, J=7.8, 5.8 Hz, CH2CHNH), 3.70 (3H, s, CH3O), 3.51 (2H, dd, J=28.2, 15.0 Hz, 
CH2S), 3.08 (1H, dd, J =13.8, 5.5 Hz, CHAHBCHNH), 2.99 (1H, dd, J =13.8, 6.1 Hz, 
CHAHBCHNH), 2.33 (3H, s, CH3CO). 
13
C NMR (125 MHz, CDCl3): δ 195.2 (COS), 171.5 (COO), 
167.6 (CONH), 157.3 (Ar-C), 146.9 (Ar-C), 134.0 (Ar-C), 133.8 (Ar-C), 130.5 (Ar-C), 128.5 (Ar-
C), 128.5 (Ar-C), 128.3 (Ar-C), 125.0 (Ar-C), 114.9 (Ar-C), 66.8 (CH2O), 53.5 (CH2CHNH), 52.4 
(CH3O), 36.8 (CH2CHNH), 32.8 (CH2S), 30.2 (CH3CO). HRMS calculated for C21H22N2NaO7S 
[M+Na]
+ 
469.1040, found 469.1045. 
(S)-2-(2-Mercaptoacetamido)-3-(4-((2-nitrobenzyl)oxy)phenyl)propanoic acid (108g) 
 
Pale yellow solid, 0.79 g (67%). 
1
H NMR (500 MHz, CDCl3): δ 8.22 (1H, bs, OH), 8.12 (1H, d, 
J=8.0 Hz, Ar-H), 7.84 (1H, d, J=7.8 Hz, Ar-H), 7.64 (1H, t, J=7.6 Hz, Ar-H), 7.45 (1H, t, J=8.0 
Hz, Ar-H), 7.13 (1H, d, J=7.6 Hz, NH), 7.00 (2H, d, J=8.5 Hz, Ar-H), 6.89 (2H, d, J=8.5 Hz, Ar-
H), 5.41 (2H, s, CH2O), 4.80 (1H, quartet, J=6.4 Hz, CH2CHNH), 3.20 (2H, d, J=9.1 Hz, CH2SH), 
3.16 (1H, dd, J =13.8, 5.5 Hz, CHAHBCHNH), 3.07 (1H, dd, J =13.8, 6.1 Hz, CHAHBCHNH), 1.83 
(3H, t, J=9.1 Hz, SH). 
13
C NMR (125 MHz, CDCl3): δ 177.0 (COOH), 170.0 (CONH), 157.4 (Ar-
C), 146.9 (Ar-C), 134.0 (Ar-C), 133.7 (Ar-C), 130.6 (Ar-C), 128.5 (Ar-C), 128.3 (Ar-C), 128.3 (Ar-
C), 124.9 (Ar-C), 115.1 (Ar-C), 66.8 (PhCH2O), 53.5 (CH2CHNH), 36.4 (CH2CHNH), 28.1 
(COCH2SH). HRMS calculated for C18H17N2O6S [M-H]
- 
389.0813, found 389.0809. 
(S)-Methyl 2-((tert-butoxycarbonyl)amino)-3-(4-((3-nitrobenzyl)oxy)phenyl)propanoate (105h) 
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Yellow viscous oil, 2.63 g (90%). 
1
H NMR (500 MHz, CDCl3): δ 8.27 (1H, s, Ar-H), 8.15 (1H, d, 
J=8.2 Hz, Ar-H), 7.72 (1H, d, J=7.6 Hz, Ar-H), 7.52 (1H, t, J=7.9 Hz, Ar-H), 7.03 (2H, d, J=8.5 
Hz, Ar-H), 6.86 (2H, d, J=8.5 Hz, Ar-H), 5.09 (2H, s, CH2O), 4.98 (1H, d, J=7.9 Hz, NH), 4.51 
(1H, quartet, J=7.0 Hz, CH2CHNH), 3.67 (3H, s, CH3O), 3.03 (1H, dd, J =13.8, 5.8 Hz, 
CHAHBCHNH), 2.96 (1H, dd, J =13.8, 6.0 Hz, CHAHBCHNH), 1.38 (9H, s, C(CH3)3). 
13
C NMR 
(125 MHz, CDCl3): δ 172.3 (COOCH3), 157.2 (NHCOO), 155.0 (Ar-C), 148.3 (Ar-C), 139.2 (Ar-
C), 133.0 (Ar-C), 130.4 (Ar-C), 129.5 (Ar-C), 128.9 (Ar-C), 122.8 (Ar-C), 122.0 (Ar-C), 114.8 (Ar-
C), 79.8 (C(CH3)3), 68.5 (CH2O), 54.4 (CH2CHNH), 52.1 (CH3O), 37.4 (CH2CHNH), 28.2 
(C(CH3)3). HRMS calculated for C22H26N2NaO7 [M+Na]
+ 
453.1632, found 453.1639. 
(S)-Methyl 2-amino-3-(4-((3-nitrobenzyl)oxy)phenyl)propanoate (106h) 
 
Brown Solid, 1.62 g (98%). 
1
H NMR (400 MHz, CDCl3): δ 8.26 (1H, s, Ar-H), 8.12 (1H, d, J=8.2 
Hz, Ar-H), 7.72 (1H, d, J=7.6 Hz, Ar-H), 7.52 (1H, t, J=7.9 Hz, Ar-H), 7.09 (2H, d, J=8.5 Hz, Ar-
H), 6.87 (2H, d, J=8.5 Hz, Ar-H), 5.08 (2H, s, CH2O), 3.72 (1H, dd, J =7.4, 5.1 Hz, CH2CHNH), 
3.67 (3H, s, CH3O), 3.02 (1H, dd, J =13.6, 5.1 Hz, CHAHBCHNH), 2.84 (1H, dd, J =13.7, 7.7 Hz, 
CHAHBCHNH), 2.75 (2H, bs, NH2). 
13
C NMR (100 MHz, CDCl3): δ 174.5 (CO), 157.1 (Ar-C), 
148.3 (Ar-C), 139.1 (Ar-C), 133.0 (Ar-C), 130.4 (Ar-C), 129.5 (Ar-C), 122.8 (Ar-C), 122.0 (Ar-C), 
121.2 (Ar-C), 114.8 (Ar-C), 68.5 (CH2O), 55.4 (CH2CHNH), 52.0 (CH3O), 39.3 (CH2CHNH). 
HRMS calculated for C17H19N2O5 [M+H]
+
 331.1288, found 331.1286. 
(S)-Methyl 2-(2-(acetylthio)acetamido)-3-(4-((3-nitrobenzyl)oxy)phenyl)propanoate (107h) 
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Yellow solid, 1.45 g (81%). 
1
H NMR (400 MHz, CDCl3): δ 8.28 (1H, s, Ar-H), 8.15 (1H, d, J=8.2 
Hz, Ar-H), 7.73 (1H, d, J=7.6 Hz, Ar-H), 7.54 (1H, t, J=7.9 Hz, Ar-H), 7.00 (2H, d, J=8.5 Hz, Ar-
H), 6.88 (2H, d, J=8.5 Hz, Ar-H), 6.62 (1H, d, J=7.6 Hz, NH), 5.10 (2H, s, CH2O), 4.74 (1H, dt, 
J=7.8, 5.8 Hz, CH2CHNH), 3.69 (3H, s, CH3O), 3.51 (2H, dd, J=22.8, 14.9 Hz, CH2S), 3.07 (1H, 
dd, J =13.8, 5.5 Hz, CHAHBCHNH), 2.98 (1H, dd, J =13.8, 6.1 Hz, CHAHBCHNH), 2.33 (3H, s, 
CH3CO). 
13
C NMR (100 MHz, CDCl3): δ 195.2 (COS), 171.5 (COO), 167.6 (CONH), 157.3 (Ar-
C), 148.4 (Ar-C), 139.1 (Ar-C), 133.1 (Ar-C), 130.5 (Ar-C), 129.5 (Ar-C), 128.6 (Ar-C), 122.9 (Ar-
C), 122.1 (Ar-C), 114.8 (Ar-C), 68.6 (CH2O), 53.5 (CH2CHNH), 52.4 (CH3O), 36.8 (CH2CHNH), 
32.7 (CH2S), 30.1 (CH3CO). HRMS calculated for C21H22N2NaO7S [M+Na]
+ 
469.1040, found 
469.1045. 
(S)-2-(2-Mercaptoacetamido)-3-(4-((3-nitrobenzyl)oxy)phenyl)propanoic acid (108h) 
 
Pale yellow solid, 0.82 g (70%). 
1
H NMR (400 MHz, CDCl3): δ 10.56 (1H, bs, OH), 8.25 (1H, s, 
Ar-H), 8.13 (1H, d, J=8.2 Hz, Ar-H), 7.71 (1H, d, J=7.6 Hz, Ar-H), 7.52 (1H, t, J=7.9 Hz, Ar-H), 
7.20 (1H, d, J=7.8 Hz, NH), 7.09 (2H, d, J=8.5 Hz, Ar-H), 6.88 (2H, d, J=8.5 Hz, Ar-H), 5.07 (2H, 
s, CH2O), 4.80 (1H, dt, J=7.8, 5.2 Hz, CH2CHNH), 3.20 (2H, d, J=9.1 Hz, CH2SH), 3.16 (1H, dd, 
J =13.8, 5.5 Hz, CHAHBCHNH), 3.07 (1H, dd, J =13.8, 6.1 Hz, CHAHBCHNH), 1.84 (3H, t, J=9.1 
Hz, SH). 
13
C NMR (100 MHz, CDCl3): δ 174.8 (COOH), 170.3 (CONH), 157.4 (Ar-C), 148.3 (Ar-
C), 139.0 (Ar-C), 133.1 (Ar-C), 130.5 (Ar-C), 129.5 (Ar-C), 128.2 (Ar-C), 122.9 (Ar-C), 122.1 (Ar-
C), 114.9 (Ar-C), 68.5 (PhCH2O), 53.5 (CH2CHNH), 36.3 (CH2CHNH), 28.0 (COCH2SH). 
HRMS calculated for C18H17N2O6S [M-H]
- 
389.0813, found 389.0805. 
(S)-Methyl 2-((tert-butoxycarbonyl)amino)-3-(4-((4-nitrobenzyl)oxy)phenyl)propanoate (105i) 
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Brown viscous oil, 2.69 g (92%). 
1
H NMR (500 MHz, CDCl3): δ 8.21 (2H, d, J=8.7 Hz, Ar-H), 
7.56 (2H, d, J=8.7 Hz, Ar-H), 7.03 (2H, d, J=8.5 Hz, Ar-H), 6.86 (2H, d, J=8.5 Hz, Ar-H), 5.12 
(2H, s, CH2O), 4.96 (1H, d, J=7.3 Hz, NH), 4.50 (1H, quartet, J=7.6 Hz, CH2CHNH), 3.68 (3H, s, 
CH3O), 3.03 (1H, dd, J =13.8, 5.8 Hz, CHAHBCHNH), 2.97 (1H, dd, J =13.8, 6.0 Hz, 
CHAHBCHNH), 1.38 (9H, s, C(CH3)3). 
13
C NMR (125 MHz, CDCl3): δ 172.3 (COOCH3), 157.2 
(NHCOO), 155.0 (Ar-C), 147.5 (Ar-C), 144.5 (Ar-C), 130.4 (Ar-C), 129.0 (Ar-C), 127.5 (Ar-C), 
123.8 (Ar-C), 114.8 (Ar-C), 79.9 (C(CH3)3), 68.6 (CH2O), 54.5 (CH2CHNH), 52.2 (CH3O), 37.4 
(CH2CHNH), 28.2 (C(CH3)3). HRMS calculated for C22H26N2NaO7 [M+Na]
+ 
453.1632, found 
453.1636. 
 (S)-Methyl 2-amino-3-(4-((4-nitrobenzyl)oxy)phenyl)propanoate (106i) 
 
Dark brown solid, 1.62 g (98%). 
1
H NMR (400 MHz, CDCl3): δ 8.16 (2H, d, J=8.7 Hz, Ar-H), 7.80 
(2H, bs, NH2), 7.53 (2H, d, J=8.7 Hz, Ar-H), 7.08 (2H, d, J=8.5 Hz, Ar-H), 6.87 (2H, d, J=8.5 Hz, 
Ar-H), 5.05 (2H, s, CH2O), 4.28 (1H, t, J=6.4 Hz, CH2CHNH), 3.77 (3H, s, CH3O), 3.26 (1H, dd, J 
=13.6, 5.1 Hz, CHAHBCHNH), 3.12 (1H, dd, J =13.7, 7.7 Hz, CHAHBCHNH). 
13
C NMR (100 
MHz, CDCl3): δ 169.5 (CO), 158.1 (Ar-C), 147.4 (Ar-C), 144.3 (Ar-C), 130.4 (Ar-C), 127.5 (Ar-
C), 125.1 (Ar-C), 123.8 (Ar-C), 115.5 (Ar-C), 68.5 (CH2O), 54.7 (CH2CHNH), 53.6 (CH3O), 35.2 
(CH2CHNH). HRMS calculated for C17H19N2O5 [M+H]
+
 331.1288, found 331.1287. 
(S)-Methyl 2-(2-(acetylthio)acetamido)-3-(4-((4-nitrobenzyl)oxy)phenyl)propanoate (107i) 
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Brown viscous oil, 1.48 g (83%). 
1
H NMR (400 MHz, CDCl3): δ 8.21 (2H, d, J=8.7 Hz, Ar-H), 
7.57 (2H, d, J=8.7 Hz, Ar-H), 7.00 (2H, d, J=8.5 Hz, Ar-H), 6.85 (2H, d, J=8.5 Hz, Ar-H), 6.60 
(1H, d, J=7.7 Hz, NH), 5.11 (2H, s, CH2O), 4.75 (1H, dt, J=7.8, 5.2 Hz, CH2CHNH), 3.69 (3H, s, 
CH3O), 3.51 (2H, dd, J=19.9, 14.8 Hz, CH2S), 3.07 (1H, dd, J =13.8, 5.5 Hz, CHAHBCHNH), 2.97 
(1H, dd, J =13.8, 6.1 Hz, CHAHBCHNH), 2.33 (3H, s, CH3CO). 
13
C NMR (100 MHz, CDCl3): δ 
195.1 (COS), 171.5 (COO), 167.5 (CONH), 157.2 (Ar-C), 147.5 (Ar-C), 144.4 (Ar-C), 130.4 (Ar-
C), 128.6 (Ar-C), 127.5 (Ar-C), 123.8 (Ar-C), 114.8 (Ar-C), 68.6 (CH2O), 53.5 (CH2CHNH), 52.3 
(CH3O), 36.8 (CH2CHNH), 32.7 (CH2S), 30.1 (CH3CO). HRMS calculated for C21H22N2NaO7S 
[M+Na]
+ 
469.1040, found 469.1042.  
(S)-2-(2-Mercaptoacetamido)-3-(4-((4-nitrobenzyl)oxy)phenyl)propanoic acid (108i) 
 
Brown solid, 0.84 g (72%). 
1
H NMR (400 MHz, CDCl3): δ 9.43 (1H, bs, OH), 8.21 (2H, d, J=8.7 
Hz, Ar-H), 7.57 (2H, d, J=8.7 Hz, Ar-H), 7.09 (2H, d, J=8.5 Hz, Ar-H), 6.88 (2H, d, J=8.5 Hz, Ar-
H), 5.12 (2H, s, ArCH2O), 4.81 (1H, dd, J =7.6, 6.0 Hz, CH2CHNH), 3.21 (2H, d, J=8.9 Hz, 
COCH2SH), 3.17 (1H, dd, J =14.0, 5.7 Hz, CHAHBCHNH), 3.08 (1H, dd, J =14.0, 8.0 Hz, 
CHAHBCHNH), 1.81 (1H, t, J=9.1 Hz, SH). 
13
C NMR (100 MHz, CDCl3): δ 175.4 (COOH), 169.9 
(CONH), 157.4 (Ar-C), 147.6 (Ar-C), 144.3 (Ar-C), 130.6 (Ar-C), 128.3 (Ar-C), 127.6 (Ar-C), 
123.8 (Ar-C), 115.0 (Ar-C), 68.6 (PhCH2O), 53.5 (CH2CHNH), 36.4 (CH2CHNH), 28.1 
(COCH2SH). HRMS calculated for C18H17N2O6S [M-H]
- 
389.0813, found 389.0809. 
(S)-Methyl 3-(4-((3-bromobenzyl)oxy)phenyl)-2-((tert-butoxycarbonyl)amino)propanoate (105j) 
 
Tan viscous oil, 2.84 g (90%). 
1
H NMR (500 MHz, CDCl3): δ 7.56 (1H, s, Ar-H), 7.43 (1H, d, 
J=8.0 Hz, Ar-H), 7.32 (1H, d, J=7.7 Hz, Ar-H), 7.22 (1H, t, J=8.0 Hz, Ar-H), 7.02 (2H, d, J=8.5 
Hz, Ar-H), 6.86 (2H, d, J=8.5 Hz, Ar-H), 4.98 (2H, s, CH2O), 4.94 (1H, d, J=7.5 Hz, NH), 4.53 
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(1H, quartet, J=7.2 Hz, CH2CHNH), 3.68 (3H, s, CH3O), 3.03 (1H, dd, J =13.8, 5.8 Hz, 
CHAHBCHNH), 2.97 (1H, dd, J =13.8, 6.0 Hz, CHAHBCHNH), 1.40 (9H, s, C(CH3)3). 
13
C NMR 
(125 MHz, CDCl3): δ 172.4 (COOCH3), 157.5 (NHCOO), 155.1 (Ar-C), 139.3 (Ar-C), 131.0 (Ar-
C), 130.4 (Ar-C), 130.3 (Ar-C), 130.1 (Ar-C), 128.6 (Ar-C), 125.8 (Ar-C), 122.6 (Ar-C), 114.9 (Ar-
C), 79.9 (C(CH3)3), 69.1 (CH2O), 54.5 (CH2CHNH), 52.2 (CH3O), 37.5 (CH2CHNH), 28.3 
(C(CH3)3). HRMS calculated for C22H26BrNNaO5 [M+Na]
+
 486.0887, found 486.0893. 
(S)-Methyl 2-amino-3-(4-((3-bromobenzyl)oxy)phenyl)propanoate (106j) 
 
Brown solid, 1.78 g (98%). 
1
H NMR (500 MHz, CDCl3): δ 7.56 (1H, s, Ar-H), 7.42 (1H, d, J=8.0 
Hz, Ar-H), 7.32 (1H, d, J=7.7 Hz, Ar-H), 7.22 (1H, t, J=7.8 Hz, Ar-H),7.09 (2H, d, J=8.6 Hz, Ar-
H), 6.87 (2H, d, J=8.6 Hz, Ar-H), 4.98 (2H, s, CH2O), 3.69 (4H: 3H-singlet for CH3O and 1H-
multiplet for CH2CHNH), 3.01 (1H, dd, J =13.6, 5.1 Hz, CHAHBCHNH), 2.82 (1H, dd, J =13.7, 7.7 
Hz, CHAHBCHNH), 1.90 (2H, bs, NH2). 
13
C NMR (125 MHz, CDCl3): δ 175.2 (CO), 157.4 (Ar-C), 
139.3 (Ar-C), 130.9 (Ar-C), 130.3 (Ar-C), 130.3 (Ar-C), 130.1 (Ar-C), 129.6 (Ar-C), 125.8 (Ar-C), 
122.6 (Ar-C), 114.9 (Ar-C), 69.0 (CH2O), 55.7 (CH2CHNH), 52.0 (CH3O), 39.9 (CH2CHNH). 
HRMS calculated for C17H19BrNO3 [M+H]
+
 364.0543, found 364.0547. 
(S)-Methyl 2-(2-(acetylthio)acetamido)-3-(4-((3-bromobenzyl)oxy)phenyl)propanoate (107j) 
 
Tan viscous oil, 1.63 g (85%). 
1
H NMR (400 MHz, CDCl3): δ 7.56 (1H, s, Ar-H), 7.42 (1H, d, 
J=8.0 Hz, Ar-H), 7.31 (1H, d, J=7.7 Hz, Ar-H), 7.22 (1H, t, J=7.8 Hz, Ar-H), 6.98 (2H, d, J=8.6 
Hz, Ar-H), 6.84 (2H, d, J=8.6 Hz, Ar-H), 6.61 (1H, d, J=7.7 Hz, NH), 4.97 (2H, s, CH2O), 4.75 
(1H, dt, J=7.8, 5.9 Hz, CH2CHNH), 3.69 (3H, s, CH3O), 3.51 (2H, dd, J=24.1, 14.8 Hz, CH2S), 
3.07 (1H, dd, J =13.8, 5.5 Hz, CHAHBCHNH), 2.98 (1H, dd, J =13.8, 6.1 Hz, CHAHBCHNH), 2.32 
(3H, s, CH3CO). 
13
C NMR (100 MHz, CDCl3): δ 195.2 (COS), 171.5 (COO), 167.6 (CONH), 157.5 
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(Ar-C), 139.3 (Ar-C), 131.0 (Ar-C), 130.3 (Ar-C), 130.3 (Ar-C), 130.1 (Ar-C), 128.2 (Ar-C), 125.8 
(Ar-C), 122.6 (Ar-C), 114.8 (Ar-C), 69.0 (CH2O), 53.5 (CH2CHNH), 52.3 (CH3O), 36.7 
(CH2CHNH), 32.7 (CH2S), 30.1 (CH3CO). HRMS calculated for C21H22BrNNaO5S [M+Na]
+ 
502.0294, found 502.0291. 
(S)-3-(4-((3-bromobenzyl)oxy)phenyl)-2-(2-mercaptoacetamido)propanoic acid (108j) 
 
Off white solid, 0.89 g (70%). 
1
H NMR (400 MHz, CD3OD): δ 7.57 (1H, s, Ar-H), 7.43 (1H, d, 
J=8.0 Hz, Ar-H), 7.37 (1H, d, J=7.7 Hz, Ar-H), 7.25 (1H, t, J=7.8 Hz, Ar-H),7.13 (2H, d, J=8.6 
Hz, Ar-H), 6.89 (2H, d, J=8.6 Hz, Ar-H), 5.01 (2H, s, ArCH2O), 4.61 (1H, dd, J =8.2, 5.2 Hz, 
CH2CHNH), 3.18-3.08 (3H, m, CHAHBCHNH & COCH2SH), 2.94 (1H, dd, J =14.0, 8.0 Hz, 
CHAHBCHNH), 1.90 (1H, s, SH). 
13
C NMR (100 MHz, CD3OD): δ 174.3 (COOH), 172.9 (CONH), 
158.9 (Ar-C), 141.5 (Ar-C), 131.8 (Ar-C), 131.5 (Ar-C), 131.3 (Ar-C), 131.3 (Ar-C), 130.6 (Ar-C), 
127.1 (Ar-C), 123.4 (Ar-C), 115.9 (Ar-C), 69.9 (PhCH2O), 55.3 (CH2CHNH), 37.5 (CH2CHNH), 
28.0 (COCH2SH). HRMS calculated for C18H17BrNO4S [M-H]
- 
422.0067, found 422.0071. 
(S)-Methyl 3-(4-((4-bromobenzyl)oxy)phenyl)-2-((tert-butoxycarbonyl)amino)propanoate (105k) 
 
Off white solid, 2.90 g (92%). 
1
H NMR (500 MHz, CDCl3): δ 7.48 (2H, d, J=8.3 Hz, Ar-H), 7.27 
(2H, d, J=8.3 Hz, Ar-H), 7.01 (2H, d, J=8.5 Hz, Ar-H), 6.85 (2H, d, J=8.5 Hz, Ar-H), 4.96 (2H, s, 
CH2O), 4.94 (1H, d, J=7.5 Hz, NH), 4.57-4.48 (1H, m, CH2CHNH), 3.68 (3H, s, CH3O), 3.03 (1H, 
dd, J=13.8, 5.8 Hz, CHAHBCHNH), 2.97 (1H, dd, J=13.8, 6.0 Hz, CHAHBCHNH), 1.39 (9H, s, 
C(CH3)3). 
13
C NMR (125 MHz, CDCl3): δ 172.4 (COOCH3), 157.6 (NHCOO), 155.1 (Ar-C), 136.0 
(Ar-C), 131.7 (Ar-C), 130.3 (Ar-C), 129.0 (Ar-C), 128.5 (Ar-C), 121.8 (Ar-C), 114.9 (Ar-C), 79.9 
(C(CH3)3), 69.2 (CH2O), 54.5 (CH2CHNH), 52.2 (CH3O), 37.5 (CH2CHNH), 28.3 (C(CH3)3). 
HRMS calculated for C22H26BrNNaO5 [M+Na]
+
 486.0887, found 486.0896. 
 112 
 
(S)-Methyl 2-amino-3-(4-((4-bromobenzyl)oxy)phenyl)propanoate (106k) 
 
Brown solid, 1.78 g (98%). 
1
H NMR (500 MHz, CDCl3): δ 7.50 (2H, d, J=8.3 Hz, Ar-H), 7.30 (2H, 
d, J=8.4 Hz, Ar-H), 7.10 (2H, d, J=8.5 Hz, Ar-H), 6.88 (2H, d, J=8.5 Hz, Ar-H), 4.96 (2H, s, 
CH2O), 3.69 (4H: 3H-singlet for CH3O and 1H for CH2CHNH),, 3.01 (1H, dd, J=13.6, 5.1 Hz, 
CHAHBCHNH), 2.81 (1H, dd, J=13.7, 7.7 Hz, CHAHBCHNH). 
13
C NMR (125 MHz, CDCl3): δ 
175.6 (CO), 157.6 (Ar-C), 136.2 (Ar-C), 131.8 (Ar-C), 130.5 (Ar-C), 129.8 (Ar-C), 129.2 (Ar-C), 
122.0 (Ar-C), 115.1 (Ar-C), 69.4 (CH2O), 56.0 (CH2CHNH), 52.1 (CH3O), 40.2 (CH2CHNH). 
HRMS calculated for C17H19BrNO3 [M+H]
+
 364.0543, found 364.0546. 
(S)-Methyl 2-(2-(acetylthio)acetamido)-3-(4-((4-bromobenzyl)oxy)phenyl)propanoate (107k) 
 
Tan viscous oil, 1.59 g (83%). 
1
H NMR (400 MHz, CDCl3): δ 7.48 (2H, d, J=8.3 Hz, Ar-H), 7.27 
(2H, d, J=8.3 Hz, Ar-H), 6.97 (2H, d, J=8.5 Hz, Ar-H), 6.83 (2H, d, J=8.5 Hz, Ar-H), 6.60 (1H, d, 
J=7.5 Hz, NH), 4.96 (2H, s, CH2O), 4.75 (1H, dt, J=7.6, 5.9 Hz, CH2CHNH), 3.70 (3H, s, CH3O), 
3.51 (2H, dd, J=23.1, 14.8 Hz, CH2S), 3.06 (1H, dd, J=13.8, 5.5 Hz, CHAHBCHNH), 2.97 (1H, dd, 
J=13.8, 6.1 Hz, CHAHBCHNH), 2.31 (3H, s, CH3CO). 
13
C NMR (100 MHz, CDCl3): δ 195.2 
(COS), 171.5 (COO), 167.6 (CONH), 157.6 (Ar-C), 135.9 (Ar-C), 131.7 (Ar-C), 130.3 (Ar-C), 
129.0 (Ar-C), 128.1 (Ar-C), 121.8 (Ar-C), 114.8 (Ar-C), 69.2 (CH2O), 53.5 (CH2CHNH), 52.4 
(CH3O), 36.7 (CH2CHNH), 32.7 (CH2S), 30.1 (CH3CO). HRMS calculated for C21H22BrNNaO5S 
[M+Na]
+ 
502.0294, found 502.0289. 
(S)-3-(4-((4-Bromobenzyl)oxy)phenyl)-2-(2-mercaptoacetamido)propanoic acid (108k) 
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Off white solid, 0.87 g (68%). 
1
H NMR (500 MHz, CD3OD): δ 7.50 (2H, d, J=8.3 Hz, Ar-H), 7.33 
(2H, d, J=8.3 Hz, Ar-H), 7.13 (2H, d, J=8.5 Hz, Ar-H), 6.89 (2H, d, J=8.5 Hz, Ar-H), 5.01 (2H, s, 
ArCH2O), 4.61 (1H, dd, J=8.3, 5.3 Hz, CH2CHNH), 3.19-3.09 (3H, m, CHAHBCHNH & 
COCH2SH), 2.94 (1H, dd, J=14.0, 8.0 Hz, CHAHBCHNH), 1.90 (1H, s, SH). 
13
C NMR (125 MHz, 
CD3OD): δ 174.4 (COOH), 172.9 (CONH), 159.0 (Ar-C), 138.2 (Ar-C), 132.6 (Ar-C), 131.5 (Ar-
C), 130.6 (Ar-C), 130.4 (Ar-C), 122.5 (Ar-C), 116.0 (Ar-C), 70.2 (PhCH2O), 55.3 (CH2CHNH), 
37.5 (CH2CHNH), 28.0 (COCH2SH). HRMS calculated for C18H17BrNO4S [M-H]
- 
422.0067, 
found 422.0073. 
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4 Chapter 4 
Synthesis of Putative Inhibitors of IMP-1 Identified Through 
Virtual Screening
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4.1 Introduction 
As mentioned previously in Chapter 1, the active site of IMP-1 has two zinc ions which hold a 
bridging water molecule which is responsible for β-lactam hydrolysis. The next approach in IMP-1 
inhibitor discovery was to screen virtual compounds from the ZINC Database Library 
(www.zinc.docking.org) for their affinity towards the enzyme. ZINC website is a free database of 
commercially-available compounds for virtual screening. ZINC contains over 35 million 
purchasable compounds in ready-to-dock, 3D formats.[1] 
This project was initiated by Peter Vella [2] (Graduated PhD student from the McGeary group). 
Among the 10000 compounds investigated, four molecules were selected for their high ranking 
docking scores and their feasibility of synthesis (Figure ‎4-1). 
 
Figure ‎4-1: Structures of virtually docked compounds for IMP-1. 
4.2 Result and Discussion 
Due to the lower price and commercial availability of cyclohexanoyl chloride, benzoyl chloride and 
its nitro derivatives, the cyclopropyl, cyclobutyl, cyclopentylcarboxamide substituents of 
compounds 109-112 were replaced with the corresponding benzamide and 
cyclohexanecarboxamide side groups (Figure ‎4-2). Consequently compounds 113-116 were 
designed, docked, synthesized and assayed against IMP-1. 
 
Figure ‎4-2: Structures of designed inhibitors for MBLs. 
4.2.1 Docking Studies 
As already discussed in Chapter 2, MolDock software has been used for docking studies regarding 
highest accuracy than other software. For computational modeling, the crystal structure of IMP-1 
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enzyme (PDB code 1JJT) was downloaded from the Protein Data Bank (PDB) and Chain B was 
deleted as the topologies of the active sites of both chain A and chain B are identical. The cavity of 
the active site with two zinc atoms was determined by MolDock and it was used for the docking 
study. The designed molecules 113-116 as well as the reference compounds 109-112 were docked 
into the active site of IMP-1. The value of the results of docking was compared with the reference 
compounds 109-112. The achieved results Escore for compounds 113-116 showed that they have 
lower energy value than the reference compounds 109-112 (Table ‎4-1). Therefore, it was expected 
that compounds 113-116 show better inhibition activity than compounds 109-112.  
Table ‎4-1: Molegro Virtual Docker Escore results for compounds 109-116. 
Compound MolDock Score (kcal/mol) 
109 -106.6 
110 -62.2 
111 -98.9 
112 -97.7 
113 -117.5 
114 -119.1 
115 -129.6 
116 -131.5 
The study of docking in the active site of IMP-1 showed that compounds 113 (Figure ‎4-3 and 
Figure ‎4-4), 114 (Figure ‎4-5 and Figure ‎4-6), 115 (Figure ‎4-7 and Figure ‎4-8) and 116 (Figure ‎4-9 
and Figure ‎4-10) are coordinated (loosely) to the zinc ions via the oxygen of the tertiary amide 
group. The docking also showed that compounds 113, 114 and 116 formed a hydrogen bond with 
Gly232 through the pyrimidone carbonyl group which makes inhibitors more rigid in the active site. 
It was also predicted that the aromatic ring of compounds 113-116 which faces Trp64 could make a 
π-π stacking interaction (The predicted distance of the aromatic ring and Trp64 is around 4 Å). 
Although the obtained results of Escore for compounds 113-116 were better than compounds 109-112 
but these values were very lower than the obtained Escore values of the reported compounds of 
Chapters 2 and 3. Because the structures of compounds 109-116 were different from the reported 
compounds of Chapters 2 and 3, their obtained Escore values could not be compared together. In 
addition, the reported compounds 109-116 were a totally new class of possible IMP-1 inhibitors; 
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therefore, there were not any reported inhibitors in literatures for comparison with the designed 
compounds 109-116. 
 
Figure ‎4-3: Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 113 (electrostatic surface view). Atom colors on inhibitor are 
as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. Zinc atoms are shown as yellow spheres. 
 
Figure ‎4-4: Interaction of docked ligand 113 at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–sulfur (on 
inhibitor). 
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Figure ‎4-5: Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 114 (electrostatic surface view). Atom colors on inhibitor are 
as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. Zinc atoms are shown as yellow spheres. 
 
Figure ‎4-6: Interaction of docked ligand 114 at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–sulfur (on 
inhibitor). 
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Figure ‎4-7: Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 115 (electrostatic surface view). Atom colors on inhibitor are 
as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. Zinc atoms are shown as yellow spheres. 
 
Figure ‎4-8: Interaction of docked ligand 115 at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–sulfur (on 
inhibitor). 
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Figure ‎4-9: Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 116 (electrostatic surface view). Atom colors on inhibitor are 
as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. Zinc atoms are shown as yellow spheres. 
 
Figure ‎4-10: Interaction of docked ligand 116 at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–sulfur (on 
inhibitor). 
Finally, compounds 113-116 were synthesized in the yield of 65% to 80% (section 4.2.2) and their 
inhibitory activities (section 4.2.3) were measured against IMP-1. None of compounds 109-112 
 123 
 
showed inhibitory activities against this enzyme; therefore, this class of compounds is not 
recommended as leads for the further development. 
The achieved results in ZINC Database Library not necessary means that their outcome compounds 
are potent inhibitors. For validation, they must be synthesized and their inhibition activities should 
be assayed. Sometimes, some compounds are insoluble in DMSO and the assay cannot be carried 
out and also compouns might also bind to the other part of the enzyme. If a compound is good 
inhibitor, it is easier to find out the orientation of the binding of the inhibitor into the active site of 
the enzyme by X-ray crystallography. In contrast, for those compounds which are not inhibitors, the 
prediction of inactivity is not easy because it is not clear whether the compounds are bounded to 
another part of the enzyme or they are inactive at all. In this case, it is not possible to say that 
compounds 113-116 were coordinated to another part of the IMP-1 or they are inactive at all; 
therefor, further investigation can be carried out by X-ray crystallography to understand the exact 
behavior of compounds 113-116 when they are involved with enzyme. 
4.2.2 Synthesis 
Scheme ‎4-1 shows the retrosynthesis of compounds 113-116. 
 
Scheme ‎4-1: The retrosynthesis of compounds 113-116. 
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Compounds 113-116 could be synthesized with the reaction between acyl chloride and amine group 
of compound 125. These compounds were new and no NMR and high resolution mass spectra have 
been reported for them. Compound 125 could be synthesized with debenzylation of compound 124. 
The procedures of synthesis of compounds 124, 123, 120, 119 have been reported in literatures and 
were used in the appropriate project. 
Compounds 113-116 were synthesized in five steps each. Scheme ‎4-2 shows the synthetic pathway. 
All the compounds were synthesized in good yields and their structures were confirmed by NMR 
and high resolution mass spectra. 
 
Scheme ‎4-2: a) MeOH, reflux, 99%. b) Toluene, NaOCH3, 45%. c) Ethanol, Na, 62%. d) Ethanol, Pd/C (5%), H2, 100%. e) THF, 
DMAP, triethyl amine, rt. 
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The reported experimental procedure by Vafina et al.[3] was used for the synthesis of compound 
119. Compound 119 was synthesized using a double Michael addition of benzylamine to methyl 
acrylate. Refluxing these two compounds together in methanol solution gave compound 119 in 99% 
yield. This reaction can also be carried out without solvent.[3, 4] 
1
H NMR and 
13
C NMR spectra 
have been recorded for this compound and were in agreement with the literature.[3] The 
1
H NMR 
shows 5H of the phenyl ring in the aromatic region and 6H for two methyl groups at 3.61 ppm. The 
methylene group of the benzyl ring appears at 3.55 ppm and the other four methylene groups appear 
at 2.76 and 2.43 ppm. 
A modification of the reported experimental procedure by Vafina et al.[3] was used for the 
synthesis of compound 120. The reaction was modified by changing the organic solvent from 
benzene (because of its toxicity) to toluene and increasing the amount of organic solvent five-fold. 
The reported yield was 93% whereas the achieved yield was 54%. No NMR and high resolution 
mass spectra have been reported for compound 120 by the original authors, therefore, the successful 
synthesis was proved by recording its 
1
H-NMR and 
13
C-NMR spectra as well as high-resolution 
mass spectrum. In comparison to compound 119, the 
1
H-NMR spectrum of compound 120 shows 
the five hydrogens of the phenyl ring in the aromatic region split into two peaks which integrate for 
two hydrogens and three hydrogens. This compound also has 11 aliphatic protons as well as 1 
proton as the enol-OH form. Those 11 protons appear in the aliphatic region but the proton of enol-
OH form does not appear in NMR. 
Compound 122 was synthesized from benzonitrile by treatment with sodium in methanol for 48 
hours, followed by adding ammonium chloride to produce compound 123 with the yield of 55%.[5] 
The 
1
H NMR and 
13
C NMR spectra have been recorded for this compound and were in agreement 
with the literature.[5] The 
1
H NMR spectrum of this compound shows that 5H of the phenyl ring  
appear in 2H, 1H and 2H separately in the aromatic region. The other 4H of two amine groups 
appear at 8.40 ppm as a broad signal. 
Compound 124 was prepared from intermediates 120 and 123 in ethanol with sodium based on the 
work done by Huber et al.[6] 
1
H-NMR and 
13
C-NMR spectra were recorded for this compound and 
were in agreement with the literature.[6] The appearance of 10H in the aromatic region and 8H in 
the aliphatic region (four methylene groups) confirmed the successful synthesis of compound 124. 
Although two experimental procedures have been reported for the synthesis of compound 125, 
neither of them was successful unless acid was omitted from the reaction mixture. The reported 
experimental procedure by Huber et al.[6] was first used and data were recorded and analyzed. The 
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NMR and low resolution mass spectra showed that the benzyl group was removed but a methyl 
group was added to the nitrogen. As hydrochloric acid would protonate methanol, after 
debenzylation of compound 124, the amine would attack protonated methanol and would be 
methylated. Therefore, it was not a desirable product. The second reported method by Lazar et 
al.[7] was also tried but the NMR and low resolution mass spectral data showed that no 
debenzylation occurred. The conditions of two methods were similar but in the second method 
acetic acid was used instead of hydrochloric acid. 
 
Figure ‎4-11: Different tried conditions for the debenzylation of compound 124. 
Finally, the debenzylation of compound 125 was obtained without the presence of acid. 
1
H-NMR 
and 
13
C-NMR spectra as well as the high resolution mass spectrum were recorded for this 
compound. 
1
H-NMR spectrum showed 5H at aromatic region whereas it was 10H for compound 
124. The methylene group of the benzyl group was also absent in the 
1
H-NMR spectrum and 
protons of two NH groups appeared at 1.68 ppm as a broad signal. 
13
C-NMR spectrum also showed 
that the benzyl group was removed. The other factor which also confirmed the successful synthesis 
of compound 125 was the accuracy of the mass of the molecular ion observed in the mass spectrum 
(HRMS calculated for C13H14N3O [M+H]
+
 228.1131, found 228.1132). 
The next compounds (113-116) were new and synthesized by coupling of intermediate 125 and acyl 
chloride (126-129). The 
1
H-NMR spectra have been recorded for compounds 113-116. Broad peaks 
were observed in the aliphatic region; therefore, additional experiments were performed in order to 
clarify why. Because of the availability of the amide bond, the existence of rotamers was predicted. 
Accordingly, 
1
H-NMR spectra were recorded at different temperatures to demonstrate the existence 
of rotamers. The 
1
H-NMR spectra of compounds 113 and 114 were recorded at 25 
o
C and 50 
o
C 
whereas compounds 115 and 116 were recorded at 25 
o
C and 80 
o
C. For recording 
1
H-NMR spectra 
of compounds 113 and 114, CDCl3 was used whereas DMSO-d6 was used for compounds 115 and 
116 because of the lower solubility in CDCl3. 
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The recorded 
1
H-NMR spectra showed that two methylene groups appear as four separate signals at 
25 
o
C while these signals merge and appear as two signals at higher temperature. The reason for the 
merging of signals at higher temperature (50 
o
C and 80 
o
C) is the faster rotation of the acyl group 
that causes the signals of the methylene groups to become coincident. Figure ‎4-12 and Figure ‎4-13 
Show 
1
H-NMR spectra of compound 115 at two different temperatures (25 °C and 80 °C). 
Methylene groups and related signals are shown with blue and red arrows and the green arrow also 
shows the rotation of amide group.  
 
Figure ‎4-12: 1H-NMR spectrum for compound 115 at 25 °C. 
 
Figure ‎4-13: 1H-NMR spectrum for compound 115 at 80 °C. 
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Apart from methylene groups, the recorded 
1
H-NMR spectra showed 5H in the aromatic region of 
intermediate 125 whereas there were 10H, 9H and 9H for compounds 113, 115 and 116 
respectively. Compound 114 presented 5H of the phenyl ring in the aromatic region and 11H for 
cyclohexyl group in aliphatic area between (1-3 ppm); 10H of the methylene groups of the 
cyclohexyl group appeared between 1-2 ppm and 1H of the methine group appeared in 2.61 ppm.  
Because of the low solubility of compounds 113-116 in CDCl3, DMSO-d6 and CD3OD, 
13
C NMR 
spectra could not be recorded, as much longer time would be needed for collecting 
13
C NMR data 
(three days or more). Therefore, only 
1
H-NMR and high resolution mass spectra have been recorded 
for compounds 113-116 which were enough to prove the successful synthesis of these compounds. 
4.2.3 Enzyme Kinetic Studies 
Compounds 113-116 were assayed against IMP-1 with CENTA as substrate. Because these 
compounds were insoluble at 10 mM DMSO stock solution, they were prepared in lower 
concentration (1 mM) and the assay was carried out only at two lower concentrations (100 µM and 
10 µM). The assay results are shown in Table ‎4-2. None of these compounds showed good activity 
against IMP-1, therefore the kinetic experiments were not performed. (The details of assay are 
discussed in section 4.4.1.2). 
Table ‎4-2: Screening results of compounds 113-116 against IMP-1. 
Compound Inhibition% (100 µM) Inhibition% (10 µM) MolDock Score (kcal/mol) 
125 8 9 Not determined 
113 24
 
11 -117.5 
114 6
 
2
 
-119.1 
115 0 0 -129.6 
116 12
 
9 -131.5 
 
4.3 Conclusions 
The ZINC Database Library (www.zinc.docking.org) was used for screening of virtual compounds 
as inhibitors for IMP-1 based on their affinity towards the enzyme. Subsequently, compounds 109-
112 were ranked highest out of a library of 10000 compounds. Analogs 113-116 were chosen to 
facilitate synthesis and because reagents were available commercially. Therefore, compounds 113-
116 were designed and docked. The Escore values of these compounds were found by docking and 
compared with compounds 109-112. The predicted results of computational modeling showed that 
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the obtained Escore values of compounds 113-116 were higher than compounds 109-112 which 
expected to show better inhibitory activity. Although the obtained results of Escore for compounds 
113-116 were better than compounds 109-112 but these values were very lower than the obtained 
Escore values of the reported compounds of Chapters 2 and 3. Because the structures of compounds 
109-116 were different from the reported compounds of Chapters 2 and 3, their obtained Escore 
values could not be compared together. In addition, the reported compounds 109-116 were a totally 
new class of possible IMP-1 inhibitors; therefore, there were not any reported inhibitors in 
literatures for comparison with the designed compounds 109-116. The results of docking study 
predicted that these compounds could coordinate to either or both zinc via the oxygen of the tertiary 
amide group. The computational modeling also predicted that the central phenyl rings of 
compounds 109-112 could make π-π stacking interaction with the aromatic ring of Trp64 of IMP-1. 
Finally, these compounds were synthesized in the yield of 65% to 80% and their inhibitory 
activities were measured against IMP-1. None of compounds 109-112 showed inhibitory activities 
against this enzyme; therefore, this class of compounds is not recommended as leads for the further 
development. 
4.4 Experimental 
4.4.1 Biological Evaluation 
4.4.1.1 Enzyme Expression and Purification 
As already discussed in Chapter 2, the IMP-1 enzyme, lacking the first 21 signal peptide amino acid 
residues, was expressed and purified using the protocol of Vella et al.[2, 8] (The details of the 
expression of IMP-1 are reported in Appendix A). 
4.4.1.2 Kinetic Assays  
Inhibition assays for IMP-1 were performed in 96 well 400 µL multi-titre plates using a multi-plate 
spectrophotometer. The hydrolysis rate of CENTA was measured at λ=405 nm.[9] The initial 
screening assay was performed in duplicate, with CENTA as the substrate and HEPESX (50 mM 
HEPES, 0.1 M NaCl, 100 mM ZnCl2, pH 7.0) as the buffer at 25 °C. The final concentrations of 
enzyme and CENTA were 5 nM and 70 nM respectively. Bovine serum albumin (final 
concentration of 20 µg/ml) was added to the enzyme for stability. For each well, 196 µL substrate 
and 4 µL inhibitor were added followed by the addition of 200 µL of enzyme. The rate of 
hydrolysis of substrate was recorded for 5 minutes. Because none of compounds 113-116 were 
potent, Kic values were not measured. 
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4.4.2 Synthesis 
1
H NMR and 
13
C NMR spectra are shown in Appendix H. 
Dimethyl 3,3'-(benzylazanediyl)dipropanoate (119)  
 
The method reported by Vafina et al.[3] was used. A solution of benzylamine 117 (0.49 g, 0.5 ml, 
4.6 mmol), methyl acrylate 118 (1.58 g, 1.65 ml, 18.3 mmol) and methanol (10 ml) was heated 
under reflux overnight. The residue was concentrated under reduced pressure to give the product 
119 as yellow oil (1.27 g, 99%). 
1
H NMR (300 MHz, CDCl3): δ 7.29-7.17 (5H, m, Ar-H), 3.61 (6H, s, OCH3), 3.55 (2H, s, 
NCH2Ph), 2.76 (4H, t, J＝7.2 Hz, NCH2), 2.43 (4H, t, J＝7.2 Hz, COCH2). 
13
C NMR (75 MHz, 
CDCl3): δ 172.9 (CO), 139.0 (Ar-C), 128.7 (Ar-C), 128.2 (Ar-C), 127.0 (Ar-C), 58.3 (NCH2Ph), 
51.5 (OCH3), 49.2 (NCH2CH2), 32.6 (COCH2). Rf= 0.82 (20/80 ethyl acetate – petroleum ether). 
The NMR spectra are in agreement with the literature.[3, 4] 
Methyl 1-benzyl-4-oxopiperidine-3-carboxylate (120) 
 
The method reported by Vafina et al.[3] was used. Amine 119 (1.147 g, 4.1 mmol) was added 
dropwise during 15 minutes under vigorous stirring to a suspension of sodium methoxide (0.334 g, 
6.18 mmol) in 250 ml of dry toluene. The mixture was stirred for 48 hours under reflux, cooled to 0
 
o
C and poured into water (250 ml). The mixture was stirred until the β-keto ester sodium salt 
dissolved completely, the organic phase was separated and the aqueous phase was neutralized with 
acetic acid and extracted with toluene (50 ml). The combined toluene extracts were evaporated 
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under reduced pressure and purified by flash chromatography* to give the pure product 120 as 
yellow solid (0.46 g, 45%). 
* The product 120 can also be used for the next step without purification by flash chromatography 
but for recording NMR data, purification was necessary. 
1
H NMR (300 MHz, CDCl3): δ 7.71-7.60 (dd, 2H, J=2.5, 7.5 Hz, Ar-H), 7.48-7.38 (m, 3H, Ar-H), 
4.34-4.16 (m, 2H, PhCH2N), 4.01-3.88 (db, 1H), 3.75 (s, 3H, OCH3), 3.58-3.44 (m, 2H), 3.35-3.17 
(m, 1H), 3.07-2.91 (m, 1H), 2.49 (dt, 1H, J=18.6, 4.6 Hz). 
13
C NMR (75 MHz, CDCl3): δ 169.4 
(CH2COCH), 168.0 (CHCOOCH3), 131.3 (Ar-C), 130.4 (Ar-C), 129.4 (Ar-C), 127.9 (Ar-C), 91.5 
(NCH2Ph), 59.2 (CHCH2N), 52.1 (COCHCO), 46.9 (CH2CH2N), 46.5 (OCH3), 25.4 (CH2CO). 
The NMR spectra are in agreement with the literature.[3] 
Benzamidine hydrochloride (123) 
 
The method reported by Thompson et al.[5] was used. A three-neck 250 ml round-bottom ﬂask was 
equipped with a mechanical stirrer. It was charged with a catalytic amount of sodium metal (0.1 g) 
and dry MeOH (50 ml). Once sodium dissolved completely, benzonitrile 121 (3.7 ml, 36.2 mmol) 
was added and the reaction was stirred under nitrogen for 48 hours at 35-40 
0
C then ammonium 
chloride (2.0 g, 36.8 mmol) was added, and stirring was continued for an additional 24 hours at 35-
40 
0
C. The reaction mixture was concentrated under reduced pressure and the crude residue was 
washed with diethyl ether (2×100 ml) then ethanol (100 ml) was added and stirred for 15 minutes 
and ﬁltered off to remove impurity. The organic solvent was removed under reduced pressure to 
give the product 123 as a white solid. (3.4 g, 55%). 
1
H NMR (400 MHz, DMSO-d6): δ 8.40 (4H, bs, NH.HCl, NH2), 7.87 (2H, d, J=7.6 Hz, Ar-H), 7.72 
(1H, t, J=7.3 Hz, Ar-H), 7.59 (2H, t, J=7.7 Hz, Ar-H). 
13
C NMR (100 MHz, DMSO-d6): δ 165.8, 
133.8, 129.0, 128.1, 128.0. The NMR spectra are in agreement with the literature.[5] 
6-Benzyl-2-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one (124) 
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The method reported by Huber et al.[6] was used. Methyl 1-benzyl-4-oxopiperidine-3-carboxylate 
120 (3.24 g, 13.10 mmol) and benzamidine hydrochloride 123 (2.05 g, 13.10 mmol) were dissolved 
in dry ethanol (10 ml) then a solution of dissolved metallic sodium (0.91 g, 39.66 mmol) in dry 
ethanol (10 ml) was added. The mixture was heated under reflux for 24 hours, evaporated to 
dryness and the residue was suspended in water (200 ml) overnight, filtered off and washed with 
water (200 ml). The residue was recrystallized from ethanol to give the pure product 124 as white 
solid (2.60 g, 62%). 
1
H NMR (300 MHz, CDCl3): δ 7.99 (2H, d, J=8.2 Hz, Ar-H), 7.55-7.26 (8H, m, Ar-H), 3.73 (2H, s, 
PhCH2N(CH2)CH2), 3.51 (2H, s, BnNCH2C), 2.89-2.82 (2H, m, NCH2CH2C), 2.82-2.73 (2H, m, 
NCH2CH2C). 
13
C NMR (75 MHz, CDCl3): δ 162.6 (NCNH), 160.7 (CO), 154.0 (NCCH2), 138.0 
(Ar-C), 132.2 (Ar-C), 131.7 (Ar-C), 129.2 (Ar-C), 129.0 (Ar-C), 128.5 (Ar-C), 127.4 (Ar-C), 127.2 
(Ar-C), 118.4 (Ar-C), 62.6 (NCH2Ph), 49.5 (CCH2N), 49.4 (CH2CH2N), 32.1 (CH2CH2N). HRMS 
calculated for C20H20N3O [M+H]
+
 318.1601, found 318.1603. m.p. 246-247 °C (lit. [6] m.p. 245-
247 °C). The NMR spectra are in agreement with the literature.[6] 
2-Phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one (125) 
 
The method reported by Huber et al.[6] was adapted by omitting hydrochloric acid. The N-benzyl 
derivative 124 (1.0 g, 3.2 mmol) was dissolved in ethanol (100 ml). The catalyst Pd/C 5% (100 mg) 
was added and the solution was hydrogenated (under a balloon) at atmospheric pressure under 
reflux for 24 hours. After removing the catalyst by filtration, the solution was dried over sodium 
sulfate and evaporated under reduced pressure to give the pure product 125 as white solid (0.72 g, 
100%).  
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1
H NMR (300 MHz, CDCl3): δ 8.06-7.99 (2H, m, Ar-H), 7.45- 7.43 (3H, m, Ar-H), 3.87 (2H, s, 
NHCH2C), 3.16 (2H, t, J=5.9 Hz, NHCH2CH2C), 2.74 (2H, t, J=5.9 Hz, NHCH2CH2C), 1.68 (2H, 
bs, CONH and CH2NH).
 13
C NMR (75 MHz, CDCl3): δ 162.3 (NCNH), 160.8 (CO), 153.7 
(NCCH2), 132.2 (Ar-C), 131.8 (Ar-C), 129.1 (Ar-C), 127.1 (Ar-C), 119.8 (Ar-C), 43.1 (CCH2NH), 
42.2 (CH2CH2N), 32.0 (CH2CH2N). HRMS calculated for C13H14N3O [M+H]
+
 228.1131, found 
228.1132. m.p. 185-190
 
°C (lit. [6] m.p. not reported). 
General procedure of amidation 
Compounds 113-116 were synthesized using the following general procedure. The amine 125 (20 
mg, 88 µmol), compounds 126-129 (176 µmol), triethylamine (0.037 ml, 264 µmol) and DMAP (1 
mg, 8.19 µmol) in THF (10 ml) were stirred 12 hours at room temperature. The organic solvent was 
evaporated under reduced pressure. The reaction was quenched with 5 ml potassium hydroxide (1 
M), extracted with ethyl acetate, dried over sodium sulfate and evaporated under reduced pressure 
to give the products 113-116. 
6-Benzoyl-2-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one (113) 
 
White solid, 23 mg (80%). 
1
H NMR (400 MHz, CDCl3, 298 K): δ 8.06 (2H, d, J=6.9 Hz, Ar-H), 
7.58-7.40 (8H, m, Ar-H), 4.74 (1H, bs, CONCH2C), 4.48 (1H, bs, CONCH2C), 4.06 (1H, bs, 
CONCH2CH2C), 3.70 (1H, bs, CONCH2CH2C) 2.91 (2H, bs, CONCH2CH2C). 
1
H NMR (400 
MHz, CDCl3, 313 K): δ 8.06 (2H, d, J=7.5 Hz, Ar-H), 7.57-7.38 (8H, m, Ar-H), 4.57 (2H, bs, 
CONCH2C), 3.92 (2H, bs, CONCH2CH2C), 2.89 (2H, s, CONCH2CH2C). HRMS calculated for 
C20H17N3NaO2 [M+Na]
+
 354.1204, found 354.1213. m.p. The compound did not melt below 300 
°C. 
Cyclohexanecarbonyl chloride (127) 
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The general method reported by Lange et al.[10] was used. Thionyl chloride (1.7 ml, 23.4 mmol) 
was added slowly to a solution of cyclohexanecarboxylic acid 130 (1.0 g, 7.8 mmol) in chloroform 
(10 ml). The solution was heated under reflux for 2 hours then chloroform (40 ml) was added and 
the organic solution washed with water (2×50 ml) and dried over sodium sulfate and evaporated 
under reduced pressure to give the product 127 as colorless oil (1.13 g, 99%).  
1
H NMR (300 MHz, CDCl3): δ 2.78-2.62 (1H, m, CH), 2.12-1.98 (2H, m), 1.85-1.70 (2H, m), 1.70-
1.57 (1H, m), 1.57-1.40 (2H, m), 1.38-1.12 (3H, m). 
13
C NMR (75 MHz, CDCl3): δ 176.9 (CO), 
54.9 (CHCO), 29.1 (CH2CH), 25.4 (CH2 CH2 CH2 CH2 CH2), 25.0 (CH2 CH2 CH2 CH2 CH2). The 
NMR spectra are in agreement with the literature.[10] 
6-(Cyclohexanecarbonyl)-2-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one (114) 
 
White solid, 21 mg (70%). 
1
H NMR (300 MHz, CDCl3, 298 K): δ 8.00-8.13 (2H, m, Ar-H), 7.47-
7.60 (3H, m, Ar-H), 4.60 (1H, s, CONCH2C), 4.50 (1H, s, CONCH2C), 3.88 (1H, t, J=5.2 Hz, 
CONCH2CH2C), 3.77 (1H, bs, CONCH2CH2C), 2.75-2.90 (2H, m, CONCH2CH2C), 2.61 (1H, bt, 
J=10.5 Hz, CHCO), 1.62-1.88 (5H, m, cyclohexane), 1.10-1.40 (4H, m, cyclohexane). 
1
H NMR (75 
MHz, CDCl3, 313 K): δ 8.37 (2H, b, Ar-H), 7.48-7.60 (3H, m, Ar-H), 4.53 (2H, bs, CONCH2C), 
3.86 (2H, bs, CONCH2CH2C), 2.82 (2H, bs, CONCH2CH2C), 2.61 (1H, bt, J=10.5 Hz, CHCO), 
1.55-1.90 (5H, m, cyclohexane), 1.15-1.40 (4H, m, cyclohexane). HRMS calculated for 
C20H23N3NaO2 [M+Na]
+
 360.1682, found 360.1666. m.p. The compound decomposed higher than 
300 °C. 
6-(3-Nitrobenzoyl)-2-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one (115) 
 
Yellow solid, 23 mg (70%). 
1
H NMR (400 MHz, DMSO-d6, 298 K): δ 8.38-8.23 (m, 2H, Ar-H), 
8.06 (bs, 2H, Ar-H), 7.96 (1H, d, J=7.6 Hz, Ar-H), 7.78 (1H, t, J=7.9 Hz, Ar-H), 7.60-7.46 (3H, m, 
Ar-H), 4.51 (1H, s, CONCH2C), 4.25 (1H, s, CONCH2C), 3.94 (1H, s, CONCH2CH2C), 3.59 (1H, 
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s, CONCH2CH2C), 2.78 (2H, s, CONCH2CH2C).
 1
H NMR (400 MHz, DMSO-d6, 353 K): δ 8.33-
8.25 (2H, m, Ar-H), 8.09 (d, 2H, J=6.8, Ar-H), 7.93 (dt, 1H, J=7.8, 1.4 Hz, Ar-H), 7.78 (1H, t, 
J=8.4 Hz, Ar-H), 7.60-7.44 (m, 3H, Ar-H), 4.41 (s, 2H, CONCH2C), 3.76 (s, 2H, CONCH2CH2C), 
2.80 (2H, t, J=8.4 Hz, CONCH2CH2C).
 
HRMS calculated for C20H16KN4O4 [M+K]
+
 415.0785, 
found 415.0791. m.p. The compound did not melt below 300 °C.
 
4-Nitrobenzoyl chloride (129) 
 
The method reported by Wang et al.[11] was used. Thionyl chloride (1.30 ml, 17.94 mmol) was 
added slowly to a solution of 4-Nitrobenzoic acid 131 (1.0 g, 5.98 mmol) in chloroform (10 ml). 
The solution was heated under reflux for 2 hours then chloroform (40 ml) was added and the 
organic solution washed with water (2×50 ml) and dried over sodium sulfate and evaporated under 
reduced pressure to give the product 129 as white solid (1.13 g, 99%). 
1
H NMR (300 MHz, DMSO-d6): δ 8.28 (2H, d, J=8.6 Hz, Ar-H), 8.13 (2H, d, J=8.6 Hz, Ar-H).
 13
C 
NMR (75 MHz, DMSO-d6): δ 165.8 (CO), 150.1 (Ar-C), 136.4 (Ar-C), 130.7 (Ar-C), 123.7 (Ar-C). 
The NMR spectra are in agreement with the literature.[11] 
6-(4-Nitrobenzoyl)-2-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one (116) 
 
Yellow solid, 22 mg (65%). 
1
H NMR (400 MHz, DMSO-d6, 298 K): δ 8.35-8.15 (4H, m, Ar-H), 
7.72 (2H, t, J=9.0 Hz, Ar-H), 7.30 (3H, bs, Ar-H), 4.38 (1H, s, CONCH2C), 4.07 (1H, s, 
CONCH2C), 3.88 (1H, t, J=5.9 Hz, CONCH2CH2C), 3.46 (1H, t, J=5.4 Hz, CONCH2CH2C), 2.68-
2.54 (2H, m, CONCH2CH2C).
 1
H NMR (400 MHz, DMSO-d6, 353 K): δ 8.35-8.05 (4H, m, Ar-H), 
7.69 (2H, d, J=8.7 Hz, Ar-H), 7.36-7.22 (3H, m, Ar-H), 4.24 (2H, bs, CONCH2C), 3.72 (2H, bs, 
CONCH2CH2C), 2.61 (2H, t, J=10.9 Hz, CONCH2CH2C).
 
HRMS calculated for C20H16KN4O4 
[M+K]
+
 415.0785, found 415.0791. m.p. The compound did not melt below 300 °C.  
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5 Chapter 5 
Synthesis and Assay of Imidazole Derivatives Against IMP-1
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5.1 Introduction 
As already discussed in Chapter 1, there are no IMP-1 inhibitors used in the clinic. It was also 
discussed that different classes of inhibitors have been reported for IMP-1.[1-19] Thiol carboxylic 
acid compounds were introduced as the most common category of IMP-1 inhibitors.[1-4] 
Dicarboxylate compounds were also introduced as the second common category.[5-8] Different 
compounds have also been reported as inhibitors against IMP-1 which include 
trifluoromethylketones and alcohols,[15, 16] hydroxamates,[17] tetrazoles,[18] sulfonamides[19] 
and sulfonyl hydrazones.[19]  
Like Chapters 2, 3 and 4, the crystal structure of IMP-1 (PDB Code: 1JJT) as well as MolDock 
software have been used for the prediction of the binding of imidazole derivatives into the active 
site of the enzyme (IMP-1). As already discussed in Chapter 2, IMP-1 (PDB Code: 1JJT) is a 
functionally monomer protein but crystallized as a dimer with 221 amino acids in each chain A and 
B. Both chain A and chain B have identical amino acid residues and two zinc atoms at the active 
site. The topologies of the active sites of both chain A and chain B are identical and hence, chain B 
was deleted and chain A was used for the docking study. 
In Chapters 2 and 3, the syntheses of some thiol carboxylic acid compounds were reported as IMP-1 
inhibitors. In the work described in Chapter 4, screening using the ZINC Database Library was the 
starting point for the synthesis of candidate compounds as putative inhibitors of IMP-1. For the 
reported project in this chapter, two imidazole derivatives were used as leads for the synthesis of 
possible inhibitors of IMP-1.  
5.2 Results and Discussion 
The design of this project was based on two lead compounds 152 and 154 which were reported by 
Vella et al.[20] Compounds 152 and 154 show 53% and 50% inhibition at 1 mM against IMP-1 
(Figure ‎5-1). These two compounds are not potent inhibitors as their IC50 values are in the range of 
mM. However, the modification of these compounds may lead to potent inhibitors. Therefore, these 
compounds were selected as two references for further development. 
 
Figure ‎5-1: Lead compounds with IC50=1 mM reported by Vella et al.[20] 
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Figure ‎5-2 shows the designed compounds as well as the reference compounds 152 and 154. All 
compounds were subjected to in silico docking as before and the results of Escore were compared to 
the reference compounds 152 and 154. This class of inhibitors is not included in any reported 
inhibitors in Chapter 1. Apart from docking study, these compounds (132-157) were synthesized 
randomly to find out the possibility of better inhibitory activities of IMP-1. At the beginning of 
design, it was predicted that compounds 132- 151 may bind to both zinc atoms via the N3 of the 
imidazole group. Although the prediction was largely correct, but molecules with nitro substituent 
groups showed different coordination to zinc atoms in computational modeling. The study of 
computational modeling showed that these compounds (142-147) were coordinated to zinc atoms 
via their nitro groups. 
On the other hand, compounds 152-157 were synthesized in acidic condition which cause the N3 of 
these compounds being protonated, therefore, it was predicted that these molecules will coordinate 
to zinc atoms via their amine group.  
 
Figure ‎5-2: Designed compounds against IMP-1 as inhibitor. Compounds 152 and 154 are reference compounds. 
5.2.1 Docking Studies 
As already discussed in Chapter 2, computational modeling can assist in identifying the mode of 
binding of an inhibitor when compared with the known reference compound (a compound which is 
reported and activity is known). In this project compounds 152 and 154 were chosen as the 
references. It also gives possible binding interactions (hydrogen bonding, ionic interactions, etc). It 
was also discussed in Chapter 2 that among different docking software, MolDock (within the 
Molegro program) [21] is the most accurate method for determining the correct binding of flexible 
 140 
 
small molecules when compared to experimental data.[22] In order to compare different inhibitors, 
the effectiveness of the binding interaction is represented as a relative value (MolDock score), 
which is calculated by the addition of calculated intra- (internal energy of the inhibitor) and inter-
molecular (inhibitor-protein interaction) energies (Equation 2.1). Lower Escore values indicate a 
prediction of stronger binding of the inhibitor into the enzyme. As mentioned in Chapter 1, the 
active site (which contains the di- zinc center) is situated in a pocket.[23-24] The cavity of the 
active site of IMP-1 with two zinc atoms was determined by MolDock and it was used for the 
docking study. All of the compounds as well as the reference compounds 152 and 154 were docked 
to IMP-1. The results of Escore docking are shown in Table ‎5-1. Compounds 152-157 were docked 
as salt structures because their N3 are protonated as they were synthesized in acidic condition. 
The reference compounds 152 and 154 which are docked as N3 protonated showed Escore= -82.3 
kcal/mol and Escore= -80.6 kcal/mol respectively. The Escore values of computational modeling 
showed that only nine compounds have higher calculated energy (Escore) than the reference 
compounds 152 and 154. These compounds include 143, 144, 145, 147, 148, 149, 153, 155 and 
157. The Escore results are shown in Table ‎5-1.  
Table ‎5-1: Molegro Virtual Docker Escore results for compound 132-157. N3 of compounds 152-157 are protonated. 
Compound MolDock Score (kcal/mol)  Compound MolDock Score (kcal/mol) 
132 -69.0  145 -94.9 
133 -73.7  146 -80.9 
134 -76.8  147 -97.0 
135 -74.0  148 -90.8 
136 -72.5  149 -90.5 
137 -80.6  150 -80.5 
138 -66.7  151 -76.5 
139 -74.2   152
* -82.3 
140 -80.1  153 -85.1 
141 -74.8   154
* -80.6 
142 -82.3  155 -84.3 
143 -86.1  156 -72.4 
144 -92.0  157 -88.3 
*Reference compounds 
Table ‎5-1 also shows that compounds 145 and 147 have the highest ranked docking score (Escore), 
therefore, the strongest binding to the active site of the enzyme was predicted for these two 
compounds.  
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Figure ‎5-3 and Figure ‎5-4 show the results of docking of compound 147 as the highest ranked 
docking score (Escore) into the active site of IMP-1. The modeling predicted that compound 147 has 
close contact to zinc atoms via one of the oxygen atoms of nitro group (Zn1, 3.36 Å and Zn2, 5.10 
Å). They also predicted that the other oxygen atom of the nitro group forms hydrogen bonds with 
Gly232 and Lys224. 
 
Figure ‎5-3: Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 145 (electrostatic surface view). Atom colors on inhibitor are 
as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. The yellow spheres are zinc atoms. 
 
Figure ‎5-4: Interaction of docked ligand 145 at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–sulfur (on 
inhibitor). 
Figure ‎5-5 and Figure ‎5-6 show the docked compound 147 into the active site of IMP-1 as the 
second highest ranked docking score (Escore). The computational modeling predicted that the 
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orientation of this ligand is similar to compound 145. It was also predicted that one of the oxygen 
atoms of nitro group is coordinated to both zinc atoms with the predicted distances of 4.93 Å (Zn1) 
and 3.18 Å (Zn2). The other oxygen of nitro group was also predicted to form hydrogen bonds with 
Gly232 and Lys224. 
 
Figure ‎5-5: Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 147 (electrostatic surface view). Atom colors on inhibitor are 
as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. The yellow spheres are zinc atoms. 
 
Figure ‎5-6: Interaction of docked ligand 147 at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–sulfur (on 
inhibitor). 
As already discussed, compounds 152-157 are N3 protonated. Amongst them, compound 157 was 
predicted as the highest ranked docking score (Escore) into the active site of IMP-1. Figure ‎5-7 and 
Figure ‎5-8 show the computational modeling of compound 157 into the active site of IMP-1. As the 
N3 is protonated, the appropriate molecule was predicted to coordinate to zinc atoms via the amine 
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group. The predicted distances of binding of the nitrogen group of amine to Zn1 and Zn2 atoms are 
3.73 Å and 3.19 Å respectively. As the predicted distances of the indole ring of Trp64 to the 
aromatic ring of N3 protonated ligands (152-157) are between 6 and 7 Å, making π-π stacking 
interaction is not predicted. 
 
Figure ‎5-7: Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 132 (electrostatic surface view). Atom colors on inhibitor are 
as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. The yellow spheres are zinc atoms. 
 
 
Figure ‎5-8: Interaction of docked ligand 132 at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–sulfur (on 
inhibitor). 
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Finally, compounds 132-157 were synthesized (section 5.2.2) and their inhibitory activities (5.2.3) 
were measured against IMP-1. Although the synthesized compounds showed roughly 50% 
inhibitory activities at 100 µM but they were not potent enough to measure Kic values of them. 
IMP-1 inhibitors with the inhibitory activities of less than 2 µM are worthwhile. Compounds 145 
and 148 were identified as the most potent inhibitors amongst compounds 132-157. Compound 145 
showed 71±5% inhibition at 100 µM whereas compound 148 showed 68±6% inhibition at the same 
concentration. Although compounds 145 and 148 were not potent enough but they can be used as 
leads for further investigation of IMP-1 inhibitors. 
Table ‎5-2 shows the predicted distances of binding of N3 of imidazole of compounds 132-141 and 
148-151 with zinc atoms of IMP-1 which are obtained by computational modeling. The results 
predicted that these compounds are loosely coordinated to zinc atoms. Also computational 
modeling predicted that there is no π-π stacking interaction for the designed molecules in the active 
site of IMP-1. 
Table ‎5-2: The predicted distances of binding of N3 of imidazole of compounds 132-141 and 148-151 with zinc atoms of IMP-1 
Compound N3-Imidazole to Zn1(Å) N3-Imidazole to Zn2 (Å) 
132 3.38 4.22 
133 3.39 4.35 
134 3.45 4.12 
135 3.52 4.26 
136 3.17 4.12 
137 3.68 4.17 
138 3.27 3.47 
139 3.37 3.68 
140 3.26 3.84 
141 3.45 3.94 
148 3.90 5.21 
149 3.50 5.10 
150 3.18 3.26 
151 3.20 3.34 
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5.2.2 Synthesis 
Compounds 132-149 were synthesized with the general method which was reported by Salvio et 
al.[25] The synthetic route is shown in Scheme ‎5-1. The NMR spectra as well as low and high 
resolution mass spectra were recorded and confirmed the successful synthesis of compounds 132-
149. 
 
Scheme ‎5-1: Reagents and conditions: Dry CH3CN, K2CO3, reflux, overnight, yield: 55-93%. 
Compounds 150-151 were synthesized in one step based on the general method of Vallée et al.[26] 
Both compounds are known and the NMR spectra are in agreement with the reported data. The 
synthetic pathway is shown in Scheme ‎5-2. 
 
Scheme ‎5-2: Reagents and conditions: 160 °C, 30 min, yield: 80-90%. 
Compounds 152-157 were synthesized in one step based on the general method using Pd/C, HCl, 
H2 in ethanol. The NMR spectra as well as the high resolution mass spectra were recorded and 
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confirmed the successful synthesis of these compounds. The synthetic pathway is shown in 
Scheme ‎5-3. 
 
Scheme ‎5-3: Reagents and conditions: Pd/C (5%), H2, ethanol, HCl, reflux, 24h, yield: 80-92%. 
5.2.3 Enzyme Kinetic Studies 
Compounds 132-157 were assayed against IMP-1 with CENTA as substrate. Inhibition percentage 
values were measured at two different concentrations. The assay results are shown in Table ‎5-3. 
Some assays are shown as cloudy in the Table because the precipitation was observed when the 
enzyme was added at the time of assay. 
Table ‎5-3: Inhibition percentage values of compounds 132-157 against IMP-1. 
Compound Inhibition (1 mM) Inhibition (100 µM)  Compound Inhibition (1 mM) Inhibition (100 µM) 
132 50±8% 30±6%  145 Cloudy 71±5% 
133 53±9% 35±3%  146 Cloudy 32±3% 
134 Cloudy
 
47±5%  147 Cloudy 31±2% 
135 69±6% 52±4%  148 Cloudy 68±6% 
136 Cloudy 48±3%  149 Cloudy 40±4% 
137 Cloudy 52±6%  150 81±4% 49±3% 
138 Cloudy 52±4%  151 Cloudy 51±5% 
139 Cloudy 53±5%   152
a 
53±8% 35±6% 
140 Cloudy 49±4%  153 Cloudy 59±4% 
141 63±4% 53±5%   154
a 
53±9% 35±4% 
142 Cloudy 46±6%  155 Cloudy 59±5% 
143 72±4% 53±3%  156 Cloudy 38±3% 
144 Cloudy 43±4%  157 Cloudy 32±4% 
a: Reference compounds 
Table ‎5-3 shows that the inhibition activities of the most new designed compounds could not be 
measured at 10 mM as they were cloudy during the assay. The inhibition activities of these 
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compounds are between 30±6% and 71±5% at 100 µM. As discussed in Chapter 2, compounds with 
50% inhibition at lower concentration than 10 µM are considered as potent inhibitors. Therefore, 
Kic values of these imidazole derivatives were not recorded as they are not potent enough. The table 
also shows that compounds 145 and 148 are the most potent compounds with 71±5% and 68±6% 
inhibition at the concentration of 100 µM.  
Table ‎5-4 compares the inhibition activities of compounds 132-157 at 100 µM with their Escore 
values which were obtained in computational modeling. The result of table shows that there is not 
an order between Escore values and the measured inhibition activities. However, compound 145 as 
the second highest ranked docking score (Escore) showed expected prediction and its activity was 
71±5% at 100 µM. 
Table ‎5-4: Inhibition activities and Escore of compounds 132-157 
Compound Inhibition (100 µM) 
MolDock Score 
(kcal/mol) 
 Compound Inhibition (100 µM) 
MolDock Score 
(kcal/mol) 
132 30±6% -69.0  145 71±5% -94.9 
133 35±3% -73.7  146 32±3% -80.9 
134 47±5% -76.8  147 31±2% -97.0 
135 52±4% -74.0  148 68±6% -90.8 
136 48±3% -72.5  149 40±4% -90.5 
137 52±6% -80.6  150 49±3% -80.5 
138 52±4% -66.7  151 51±5% -76.5 
139 53±5% -74.2   152
a 
35±6% -82.3 
140 49±4% -80.1  153 59±4% -85.1 
141 53±5% -74.8   154
a 
35±4% -80.6 
142 46±6% -82.3  155 59±5% -84.3 
143 53±3% -86.1  156 38±3% -72.4 
144 43±4% -92.0  157 32±4% -88.3 
a
 Reference compounds 
5.3 Conclusions 
Two reference compounds 152 and 154 were used as two leads for designing of twenty-four 
imidazole derivatives. Their docking behavior was investigated with MolDock software and Escore 
values were used for the prediction of inhibition activity. All compounds were synthesized with 
yields higher than 80%. Their inhibition activities were measured at two concentrations (1 mM and 
100 µM). The assay results showed that compounds 145 and 147 are the most potent inhibitors 
amongst the compounds. Consequently, these two compounds can be used as leads for the future 
plan and development of new inhibitors. Additionally, in this Chapter, the results of computational 
modeling did not show an order between the Escore and inhibitory activities. 
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5.4 Experimental 
5.4.1 Biological Evaluation 
5.4.1.1 Enzyme Expression and Purification 
As already discussed in Chapter 2, the IMP-1 enzyme, lacking the first 21 signal peptide amino acid 
residues, was expressed and purified using the protocol of Vella et al.[20, 28] (The details of the 
expression of IMP-1 are reported in Appendix A). 
5.4.1.2 Kinetic Assays  
Inhibition assays for IMP-1 were performed in 96 well 400 µL multi-titre plates using a multi-plate 
spectrophotometer. The hydrolysis rate of CENTA was measured at λ=405 nm [29]. The initial 
screening assay was performed in duplicate, with CENTA as the substrate and HEPESX (50 mM 
HEPES, 0.1 M NaCl, 100 mM ZnCl2, pH 7.0) as the buffer at 25 °C. The final concentration of 
enzyme and CENTA was 5 nM and 70 nM respectively. Bovine serum albumin (final concentration 
of 20 µg/ml) was added to the enzyme for stability. For each well, 196 µL substrate and 4 µL 
inhibitor were added followed by the addition of 200 µL of enzyme. The rate of hydrolysis of 
substrate was recorded for 5 minutes. Because IC50 values of compounds 132-157 were in the range 
of 1 mM and 100 µM, it was realized that they are not potent enough to measure Kic values. As 
different inhibitors have been reported in the range of 10 µM to 2.7 nM, therefore, the IC50 values 
higher than this range are not considered as potent. However, they can be used as leads for further 
development of new inhibitors. 
5.4.2 Synthesis 
1
H NMR and 
13
C NMR spectra are shown in Appendix I. 
General procedure 1: 
Compounds 132-149 were synthesized using the following general procedure reported by Salvio et 
al.[25] Potassium carbonate (2.0 g, 14.4 mmol), imidazole derivatives 158-159 (32.9 mmol) and 
compounds 160-168 (4.7 mmol) were added to dry acetonitrile (50 ml). The mixture was heated 
under reflux and the progress of the reaction was monitored by TLC. The organic solvent was 
removed under vacuum and the residue was dissolved in DCM (100 ml)
*
. The organic phase was 
washed with saturated sodium bicarbonate aqueous solution (2×50 ml), dried over sodium sulfate 
and evaporated to give the products 132-149.
** 
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*Note 1: Ethyl acetate (200 ml) was used for compounds 146 and 147. 
**Note 2: Compounds 146 and 147 were purified by flash column chromatography (ethyl acetate-
methanol 0-100%) 
General procedure 2: 
Compounds 150-151 were synthesized using the following general procedure reported by Vallée et 
al.[26] Imidazole derivatives 158-159 (40 mmol) were mixed with 4-hydroxybenzyl alcohol 169 
(1.0 g, 8.0 mmol). The reaction mixture was heated at 160
0
 C for half an hour resulting in dark 
brown oil that was added to 100 ml of hot water resulting in a brown solid which was ﬁltered. Then 
the residue was transferred to round bottom flask and ethyl acetate (50 ml) was added and stirred 
for 10 min to wash the product which was filtered off and dried in the oven at 40 °C to give the 
products 150-151. 
General procedure 3: 
The general procedure reported by Roumen et al.[27] was modified (HCl 2M was added in the 
reaction) for the synthesis of hydrochloride salt of compounds 152-157. Compounds 142-147 (4.6 
mmol), HCl 2M (4 ml), Pd/C 5% (100 mg) in ethanol (20 ml) was hydrogenated (under a balloon) 
at atmospheric pressure under reflux 24 hours. The organic solvent was evaporated under vacuum 
and water (50 ml) was added and stirred for 10 minutes and the solid impurity was filtered off then 
water phase was washed with ethyl acetate (50 ml) and evaporated under vacuum and dried in oven 
at 40 °C to give the products 152-157. 
General procedure 4: 
Intermediates 171, 173, 175, 177, 180 and 183 were synthesized using the following general 
procedure reported by Jiang et al.[9] Aldehyde 170, 172, 174, 176, 179 and 182 (20.0 mmol) were 
dissolved in methanol (50 ml) and sodium borohydride (0.76 g, 20.0 mmol) was added portionwise 
with cooling in ice bath. The mixture was stirred at room temperature for one hour. The solvent 
evaporated under reduced pressure and DCM (100 ml) was added and the organic layer was washed 
with HCl 5% (2×50 ml). The organic layer was separated, dried over sodium sulfate and evaporated 
to give the products 171, 173, 175, 177, 180 and 183. 
General procedure 5: 
Intermediates 161-168 were synthesized using the following general procedure reported by Ding et 
al.[30] To a solution of compound 171, 173, 175, 177, 178, 180, 181 and 183 (15.6 mmol) and 
pyridine (0.5 ml) in DCM (15 ml) in ice bath was added dropwise a solution of thionyl chloride 
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(1.36 ml, 18.8 mmol) in DCM (15 ml). The mixture was stirred at room temperature overnight then 
DCM (50 ml) was added. The organic layer was washed with saturated sodium bicarbonate aqueous 
solution (2×50 ml), dried over sodium sulfate and evaporated to give the products 161-168. 
1-Benzyl-1H-imidazole (132) 
 
Pale yellow solid, 0.61 g (82 %). 
1
H NMR (300 MHz, CDCl3): δ 7.51 (1H, s, NCHN), 7.37-7.25 
(3H, m, Ph-H), 7.16-7.08 (2H, m, Ph-H), 7.06 (1H, s, NCHCHNCH2), 6.87 (1H, s, NCHCHNCH2), 
5.08 (2H, s, CH2). 
13
C NMR (75 MHz, CDCl3): δ 137.4 (Ar-C), 136.1 (Ar-C), 129.7 (Ar-C), 128.9 
(Ar-C), 128.2 (Ar-C), 127.2 (Ar-C), 119.2 (Ar-C), 50.7 (CH2). HRMS calculated for C10H11N2 
[M+H]
+
 159.0922, found 159.0924. m.p. 71-73 °C (lit. [25] m.p. 71-72 °C). The NMR spectra are 
in agreement with the literature.[25] 
1-Benzyl-2-methyl-1H-imidazole (133) 
 
Pale yellow oil, 0.65 g
 
(80 %). 
1
H NMR (400 MHz, CDCl3): δ 7.30-7.17 (3H, m, Ph-H), 6.98 (2H, 
d, J=1.5 Hz, Ph-H), 6.88 (1H, d, J=1.3 Hz, NCHCHNCH2), 6.76 (1H, d, J=1.4 Hz, 
NCHCHNCH2), 4.95 (2H, s, CH2), 2.45 (3H, s, CH3). 
13
C NMR (100 MHz, CDCl3): δ 144.5 (Ar-
C), 136.1 (Ar-C), 128.6 (Ar-C), 127.6 (Ar-C), 126.9 (Ar-C), 126.3 (Ar-C), 119.6 (Ar-C), 49.3 
(CH2), 12.8 (CH3). HRMS calculated for C11H13N2 [M+H]
+
 173.1073, found 173.1077. The NMR 
spectra are in agreement with the literature.[31] 
p-Tolylmethanol (171) 
 
Colorless solid, 2.39 g (98%). 
1
H NMR (300 MHz, CDCl3): δ 7.24 (2H, d, J=8.0 Hz, Ar-H), 7.16 
(2H, d, J=8.0 Hz, Ar-H), 4.63 (2H, s, CH2), 2.34 (3H, s, CH3), 1.61 (1H, s, OH). 
13
C NMR (75 
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MHz, CDCl3): δ 137.9 (Ar-C), 137.4 (Ar-C), 129.2 (Ar-C), 127.1 (Ar-C), 65.3 (CH2), 21.1 (CH3). 
The NMR spectra are in agreement with the literature.[32] 
1-(Chloromethyl)-4-methylbenzene (161) 
 
Dark brown oil, 2.15 g (98%). 
1
H NMR (500 MHz, CDCl3): δ 7.24 (2H, d, J=8.1 Hz, Ar-H), 7.16 
(2H, d, J=7.9 Hz, Ar-H), 4.55 (2H, s, CH2), 2.34 (3H, s, CH3). 
13
C NMR (125 MHz, CDCl3): δ 
138.3 (Ar-C), 134.5 (Ar-C), 129.4 (Ar-C), 128.5 (Ar-C), 46.3 (CH2), 21.2 (CH3). The NMR spectra 
are in agreement with the literature.[30] 
1-(4-Methylbenzyl)-1H-imidazole (134) 
 
Brown solid, 0.66 g (81%). 
1
H NMR (300 MHz, CDCl3): δ 7.44 (1H, s, NCHN), 7.08 (2H, d, J=7.9 
Hz, Ph-H), 7.04-6.94 (3H, m, Ph-H & NCHCHNCH2), 6.81 (1H, t, J=1.2 Hz, NCHCHNCH2), 4.97 
(2H, s, CH2), 2.27 (3H, s, CH3). 
13
C NMR (75 MHz, CDCl3): δ 137.7 (Ar-C), 137.1 (Ar-C), 132.9 
(Ar-C), 129.4 (Ar-C), 129.3 (Ar-C), 127.0 (Ar-C), 118.9 (Ar-C), 50.2 (CH2), 20.8 (CH3). HRMS 
calculated for C11H13N2 [M+H]
+
 173.1073, found 173.1076. m.p. 49-50 °C (lit. [33] m.p. 49-50 °C). 
The NMR spectra are in agreement with the literature.[33] 
2-Methyl-1-(4-methylbenzyl)-1H-imidazole (135) 
 
Brown oil, 0.69 g (79%). 
1
H NMR (500 MHz, CDCl3): δ 7.09 (2H, d, J=7.9 Hz, Ph-H), 6.94-6.86 
(3H, m, Ph-H & NCHCHNCH2), 6.77 (1H, d, J=1.3 Hz, NCHCHNCH2), 4.94 (2H, s, CH2), 2.28 
(6H, s, both CH3). 
13
C NMR (125 MHz, CDCl3): δ 144.7 (Ar-C), 137.5 (Ar-C), 133.2 (Ar-C), 129.4 
(Ar-C), 127.1 (Ar-C), 126.5 (Ar-C), 119.7 (Ar-C), 49.3 (CH2), 20.9 (Ar-Me), 13.0 (Imidazole-Me). 
HRMS calculated for C12H15N2 [M+H]
+
 187.1230, found 187.1227. 
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(2-Chlorophenyl)methanol (173) 
 
Yellow solid, 2.28 g (80%). 
1
H NMR (300 MHz, CDCl3): δ 7.46 (1H, d, J=7.3 Hz, Ar-H), 7.34 
(1H, d, J=7.5 Hz, Ar-H), 7.30-7.17 (2H, m, Ar-H), 4.76 (2H, s, CH2), 2.77 (1H, s, OH). 
13
C NMR 
(75 MHz, CDCl3): δ 138.1 (Ar-C), 132.7 (Ar-C), 129.3 (Ar-C), 128.8 (Ar-C), 128.7 (Ar-C), 127.0 
(Ar-C), 62.8 (CH2). Rf= 0.68 (20/80 ethyl acetate/petroleum ether). The NMR spectra are in 
agreement with the literature.[34] 
1-Chloro-2-(chloromethyl)benzene (162) 
 
Pale yellow liquid, 2.01 g (80%). 
1
H NMR (300 MHz, CDCl3): δ 7.48-7.42 (1H, m, Ar-H), 7.41-
7.34 (1H, m, Ar-H), 7.29-7.22 (2H, m, Ar-H), 4.69 (2H, s, CH2). 
13
C NMR (75 MHz, CDCl3): δ 
135.0 (Ar-C), 134.0 (Ar-C), 130.8 (Ar-C), 129.9 (Ar-C), 129.8 (Ar-C), 127.2 (Ar-C), 43.5 (CH2). 
Rf= 0.38 (20/80 ethyl acetate/petroleum ether). The NMR spectra are in agreement with the 
literature.[35] 
1-(2-Chlorobenzyl)-1H-imidazole (136) 
 
Brown oil, 0.78 g (86%). 
1
H NMR (300 MHz, CDCl3): δ 7.48 (1H, s, NCHN), 7.35-7.29 (1H, m, 
Ph-H), 7.25-7.11 (2H, m, Ph-H), 7.01 (1H, t, J=1.1 Hz, NCHCHNCH2), 6.90-6.84 (2H, m, Ph-H & 
NCHCHNCH2), 5.14 (2H, s, CH2). 
13
C NMR (75 MHz, CDCl3): δ 137.4 (Ar-C), 133.8 (Ar-C), 
132.8 (Ar-C), 129.6 (Ar-C), 129.5 (Ar-C), 129.4 (Ar-C), 128.8 (Ar-C), 127.2 (Ar-C), 119.1 (Ar-C), 
48.1 (CH2). HRMS calculated for C10H10ClN2 [M+H]
+
 193.0527, found 193.0534. Rf= 0.13 (20/80 
ethyl acetate/petroleum ether). The NMR spectra are in agreement with the literature.[36] 
1-(2-Chlorobenzyl)-2-methyl-1H-imidazole (137) 
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Brown solid, 0.83 g (85 %). 
1
H NMR (300 MHz, CDCl3): δ 7.35 (1H, dd, J=7.3, 1.3 Hz, Ph-H), 
7.24-7.10 (2H, m, Ph-H), 6.92 (1H, d, J=1.3 Hz, NCHCHNCH2), 6.77 (1H, d, J=1.3 Hz, 
NCHCHNCH2), 6.60 (1H, d, J=6.5 Hz, Ph-H), 5.07 (2H, s, CH2), 2.28 (3H, s, CH3). 
13
C NMR (75 
MHz, CDCl3): δ 145.0 (Ar-C), 134.0 (Ar-C), 132.3 (Ar-C), 129.5 (Ar-C), 129.1 (Ar-C), 127.6 (Ar-
C), 127.5 (Ar-C), 127.3 (Ar-C), 119.8 (Ar-C), 47.2 (CH2), 12.8 (CH3). HRMS calculated for 
C11H12ClN2 [M+H]
+
 207.0684, found 207.0687. m.p=62.5-63.5 °C. 
(4-Chlorophenyl)methanol (175) 
 
Colorless solid, 2.80 g (98%). 
1
H NMR (300 MHz, CDCl3): δ 7.32-7.20 (4H, m, Ar-H), 4.61 (2H, s, 
CH2), 2.17 (1H, s). 
13
C NMR (75 MHz, CDCl3): δ 139.2 (Ar-C), 133.3 (Ar-C), 128.6 (Ar-C), 128.2 
(Ar-C), 64.3 (CH2). The NMR spectra are in agreement with the literature.[37] 
1-Chloro-4-(chloromethyl)benzene (163) 
 
Colorless oil, 2.01 g (80%). 
1
H NMR (300 MHz, CDCl3): δ 7.29 (4H, s, Ar-H), 4.52 (2H, s, CH2). 
13
C NMR (75 MHz, CDCl3): δ 135.9 (Ar-C), 134.3 (Ar-C), 129.9 (Ar-C), 128.9 (Ar-C), 45.3 (CH2). 
Rf= 0.88 (20/80 ethyl acetate/petroleum ether). The NMR spectra are in agreement with the 
literature.[38] 
1-(4-Chlorobenzyl)-1H-imidazole (138) 
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Pale yellow oil, 0.84 g (93 %). 
1
H NMR (300 MHz, CDCl3): δ 7.30 (1H, s, NCHN), 7.06 (2H, d, 
J=8.5 Hz, Ph-H), 6.88 (3H, m, Ph-H & NCHCHNCH2), 6.67 (1H, t, J=1.3 Hz, NCHCHNCH2), 
4.84 (2H, s, CH2). 
13
C NMR (75 MHz, CDCl3): δ 136.7 (Ar-C), 134.3 (Ar-C), 133.3 (Ar-C), 129.2 
(Ar-C), 128.4 (Ar-C), 128.1 (Ar-C), 118.6 (Ar-C), 49.3 (CH2). HRMS calculated for C10H10ClN2 
[M+H]
+
 193.0527, found 193.0533. The NMR spectra are in agreement with the literature.[33] 
1-(4-Chlorobenzyl)-2-methyl-1H-imidazole (139) 
 
Brown viscous oil, 0.85 g (88 %). 
1
H NMR (500 MHz, CDCl3): δ 7.29 (2H, t, J=13.6 Hz, Ph-H), 
6.98-6.92 (3H, m, Ph-H & NCHCHNCH2), 6.80 (1H, d, J=1.4 Hz, NCHCHNCH2), 5.00 (2H, s, 
CH2), 2.31 (3H, s, CH3).
 13
C NMR (125 MHz, CDCl3): δ 144.9 (Ar-C), 134.8 (Ar-C), 133.9 (Ar-C), 
129.2 (Ar-C), 128.0 (Ar-C), 127.4 (Ar-C), 119.8 (Ar-C), 49.1 (CH2), 13.0 (CH3). HRMS calculated 
for C11H12ClN2 [M+H]
+
 207.0684, found 207.0685. 
(4-Methoxyphenyl)methanol (177) 
 
Colorless oil, 2.71 g (98%). 
1
H NMR (300 MHz, CDCl3): δ 7.27 (2H, d, J=8.5 Hz, Ar-H), 6.87 (2H, 
d, J=8.5 Hz, Ar-H), 4.58 (2H, s, CH2), 3.79 (3H, s, CH3), 1.75 (1H, s, OH). 
13
C NMR (75 MHz, 
CDCl3): δ 159.2 (Ar-C), 133.1 (Ar-C), 128.6 (Ar-C), 114.0 (Ar-C), 65.0 (CH2), 55.3 (CH3). The 
NMR spectra are in agreement with the literature.[39] 
1-(Chloromethyl)-4-methoxybenzene (164) 
 
Pale yellow oil, 2.00 g (82%). 
1
H NMR (300 MHz, CDCl3): δ 7.30 (2H, d, J=8.5 Hz, Ar-H), 6.86 
(2H, d, J=8.5 Hz, Ar-H), 4.55 (2H, s, CH2), 3.79 (3H, s, CH3). 
13
C NMR (75 MHz, CDCl3): δ 159.7 
(Ar-C), 130.0 (Ar-C), 129.7 (Ar-C), 114.1 (Ar-C), 55.3 (CH3), 46.3 (CH2). The NMR spectra are in 
agreement with the literature.[40] 
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1-(4-Methoxybenzyl)-1H-imidazole (140) 
 
Pale yellow solid, 0.80 g (90%). 
1
H NMR (300 MHz, CDCl3): δ 7.42 (1H, s, NCHN), 7.03 (3H, t, 
J=8.5 Hz, Ph-H & NCHCHNCH2), 6.85-6.78 (3H, m, Ph-H & NCHCHNCH2), 4.97 (2H, s, CH2), 
3.73 (3H, s, CH3). 
13
C NMR (75 MHz, CDCl3): δ 159.3 (Ar-C), 137.1 (Ar-C), 129.5 (Ar-C), 128.7 
(Ar-C), 128.0 (Ar-C), 119.0 (Ar-C), 114.2 (Ar-C), 55.1 (CH3), 50.1 (CH2). HRMS calculated for 
C11H12N2NaO [M+Na]
+
 211.0842, found 211.0846. m.p. 57-59 °C (lit. [41] m.p. 57-58 °C). The 
NMR spectra are in agreement with the literature.[41] 
1-(4-Methoxybenzyl)-2-methyl-1H-imidazole (141) 
 
Brown viscous oil, 0.85 g (89%). 
1
H NMR (500 MHz, CDCl3): δ 6.93 (2H, d, J=11.0 Hz, Ph-H), 
6.84 (1H, d, J=1.3 Hz, NCHCHNCH2), 6.78 (2H, d, J=11.0 Hz, Ph-H), 6.72 (1H, d, J=1.3 Hz, 
NCHCHNCH2), 4.87 (2H, s, CH2), 3.69 (3H, s, CH3O), 3.25 (3H, s, CH3). 
13
C NMR (125 MHz, 
CDCl3): δ 159.0 (Ar-C), 144.5 (Ar-C), 128.1 (Ar-C), 127.9 (Ar-C), 126.9 (Ar-C), 119.5 (Ar-C), 
114.0 (Ar-C), 55.0 (CH3O), 49.0 (CH2), 12.9 (CH3). HRMS calculated for C12H15N2O [M+H]
+
 
203.1179, found 203.1179. 
1-(Chloromethyl)-3-nitrobenzene (165) 
 
Pale yellow solid, 2.62 g (98%). 
1
H NMR (400 MHz, CDCl3): δ 8.20 (1H, t, J=2.1 Hz, Ar-H), 8.11 
(1H, ddd, J=8.2, 2.34, 0.95 Hz, Ar-H), 7.71-7.67 (1H, m, Ar-H), 7.51 (1H, t, J=7.9 Hz, Ar-H), 4.62 
(2H, s, CH2). 
13
C NMR (100 MHz, CDCl3): δ 148.1 (Ar-C), 139.2 (Ar-C), 134.4 (Ar-C), 129.7 (Ar-
C), 123.2 (Ar-C), 123.1 (Ar-C), 44.5 (CH2). The NMR spectra are in agreement with the 
literature.[30] 
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1-(3-Nitrobenzyl)-1H-imidazole (142) 
 
Brown solid, 0.67 g (70 %). 
1
H NMR (300 MHz, DMSO-d6): δ 8.18-8.08 (2H, m, Ph-H), 7.82 (1H, 
s, NCHN), 7.73-7.60 (2H, m, Ph-H), 7.25 (1H, t, J=1.4 Hz, NCHCHNCH2), 6.93 (1H, t, J=1.0 Hz, 
NCHCHNCH2), 5.36 (2H, s, CH2). 
13
C NMR (75 MHz, DMSO-d6): δ 147.9 (Ar-C), 140.1 (Ar-C), 
137.6 (Ar-C), 134.1 (Ar-C), 130.3 (Ar-C), 129.0 (Ar-C), 122.7 (Ar-C), 122.1 (Ar-C), 119.6 (Ar-C), 
48.5 (CH2). HRMS calculated for C10H10N3O2 [M+H]
+
 204.0768, found 204.0767. m.p. 95-97 °C 
(lit. [42] m.p. 95-97 °C). The NMR spectra are in agreement with the literature.[43] 
2-Methyl-1-(3-nitrobenzyl)-1H-imidazole (143) 
 
Brown solid, 0.91 g (89 %). 
1
H NMR (500 MHz, CDCl3): δ 8.14 (1H, m, Ph-H), 7.95 (1H, s, Ph-H), 
7.51 (1H, t, J=8.0 Hz, Ph-H), 7.29 (1H, d, J=8.0 Hz, Ph-H), 6.97 (1H, s, NCHCHNCH2), 6.84 (1H, 
s, NCHCHNCH2), 5.14 (2H, s, CH2), 2.31 (3H, s, CH3).
 13
C NMR (125 MHz, CDCl3): δ 148.6 (Ar-
C), 144.8 (Ar-C), 138.6 (Ar-C), 132.3 (Ar-C), 130.1 (Ar-C), 128.1 (Ar-C), 123.0 (Ar-C), 121.5 (Ar-
C), 119.7 (Ar-C), 48.9 (CH2), 13.1 (CH3). HRMS calculated for C11H12N3O2 [M+H]
+
 218.0924, 
found 218.0929. m.p. 82-83 °C. 
(4-Nitrophenyl)methanol (180) 
 
Yellow solid, 2.57 g (84%). 
1
H NMR (300 MHz, CDCl3): δ 8.20 (2H, d, J=8.5 Hz, Ar-H), 7.51 
(2H, d, J=8.5 Hz, Ar-H), 4.81 (2H, s, CH2), 2.05 (1H, s, OH). 
13
C NMR (75 MHz, CDCl3): δ 148.2 
(Ar-C), 147.3 (Ar-C), 127.0 (Ar-C), 123.7 (Ar-C), 64.0 (CH2). Rf= 0.43 (30/70 ethyl 
acetate/petroleum ether). The NMR spectra are in agreement with the literature.[44] 
1-(Chloromethyl)-4-nitrobenzene (166) 
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Yellow solid, 2.25 g (85%). 
1
H NMR (300 MHz, CDCl3): δ 8.21 (2H, d, J=8.5 Hz, Ar-H), 7.55 
(2H, d, J=8.5 Hz, Ar-H), 4.63 (2H, s, CH2). 
13
C NMR (75 MHz, CDCl3): δ 147.8 (Ar-C), 144.3 
(Ar-C), 129.3 (Ar-C), 124.0 (Ar-C), 44.5 (CH2). The NMR spectra are in agreement with the 
literature.[30] 
1-(4-Nitrobenzyl)-1H-imidazole (144) 
 
Brown solid, 0.86 g (90 %). 
1
H NMR (300 MHz, DMSO-d6): δ 8.19 (2H, d, J=8.5 Hz, Ph-H), 7.55 
(1H, s, NCHN), 7.25 (2H, d, J=8.5 Hz, Ph-H), 7.11 (1H, t, J=1.2 Hz, NCHCHNCH2), 6.88 (1H, t, 
J=1.2 Hz, NCHCHNCH2), 5.23 (2H, s, CH2). 
13
C NMR (75 MHz, DMSO-d6): δ 147.8 (Ar-C), 
143.4 (Ar-C), 137.5 (Ar-C), 130.4 (Ar-C), 127.7 (Ar-C), 124.2 (Ar-C), 119.2 (Ar-C), 49.9 (CH2). 
HRMS calculated for C10H10N3O2 [M+H]
+
 204.0768, found 204.0770. m.p. 55-56 °C (lit. [44] m.p. 
55-56 °C). The NMR spectra are in agreement with the literature.[45] 
2-Methyl-1-(4-nitrobenzyl)-1H-imidazole (145) 
 
Black solid, 0.90 g (88%). 
1
H NMR (300 MHz, CDCl3): δ 8.19 (2H, d, J=8.8 Hz, Ph-H), 7.16 (2H, 
d, J=8.6 Hz, Ph-H), 7.00 (1H, s, NCHCHNCH2), 6.85 (1H, s, NCHCHNCH2), 5.16 (2H, s, CH2), 
2.32 (3H, s, CH3).
 13
C NMR (75 MHz, CDCl3): δ 147.7 (Ar-C), 143.4 (Ar-C), 127.7 (Ar-C), 127.2 
(Ar-C), 124.5 (Ar-C), 124.3 (Ar-C), 119.9 (Ar-C), 49.1 (CH2), 12.9 (CH3). HRMS calculated for 
C11H12N3O2 [M+H]
+
 218.0924, found 218.0927. m.p. 96-97 °C (lit. [45] m.p. 95-96 °C). The NMR 
spectra are in agreement with the literature.[46] 
1-Chloro-2-(chloromethyl)-4-nitrobenzene (167) 
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Brown solid, 3.01 g (95%). 
1
H NMR (500 MHz, CDCl3): δ 8.35 (1H, d, J=2.6 Hz, Ar-H), 8.11 (1H, 
dd, J=8.8, 2.8 Hz, Ar-H), 7.55 (1H, d, J=8.8 Hz, Ar-H), 4.71 (2H, s, CH2). 
13
C NMR (125 MHz, 
CDCl3): δ 146.6 (Ar-C), 140.6 (Ar-C), 136.7 (Ar-C), 130.7 (Ar-C), 125.5 (Ar-C), 124.4 (Ar-C), 
42.4 (CH2). The NMR spectra are in agreement with the literature.[47] 
1-(2-Chloro-5-nitrobenzyl)-1H-imidazole (146) 
 
Brown solid, 0.61 g (55 %). 
1
H NMR (500 MHz, CD3OD): δ 8.17 (1H, dd, J=8.8, 2.6 Hz, Ph-H), 
7.89 (1H, d, J=2.7 Hz, Ph-H), 7.83 (1H, s, NCHN), 7.70 (1H, d, J=8.8 Hz, Ph-H), 7.19 (1H, t, 
J=1.3 Hz, NCHCHNCH2), 7.05 (1H, t, J=1.2 Hz, NCHCHNCH2), 5.46 (2H, s, CH2). 
13
C NMR 
(125 MHz, CD3OD): δ 148.4 (Ar-C), 140.9 (Ar-C), 139.2 (Ar-C), 138.0 (Ar-C), 132.1 (Ar-C), 
129.8 (Ar-C), 125.5 (Ar-C), 125.0 (Ar-C), 121.1 (Ar-C), 48.8 (CH2). HRMS calculated for 
C10H9ClN3O2 [M+H]
+
 238.0378, found 238.0386. m.p. 107-109 °C. The NMR spectra are in 
agreement with the literature.[43] 
1-(2-Chloro-5-nitrobenzyl)-2-methyl-1H-imidazole (147) 
 
Dark brown solid, 0.65 g (55 %). 
1
H NMR (300 MHz, CD3OD): δ 8.16 (1H, dd, J=8.8, 2.7 Hz, Ph-
H), 7.72 (1H, d, J=8.7 Hz, Ph-H), 7.56 (1H, d, J=2.6 Hz, Ph-H), 7.06 (1H, d, J=1.3 Hz, 
NCHCHNCH2), 6.94 (1H, d, J=1.3 Hz, NCHCHNCH2), 5.37 (2H, s, CH2), 2.34 (3H, s, CH3). 
13
C 
NMR (75 MHz, CD3OD): δ 148.5 (Ar-C), 146.7 (Ar-C), 140.5 (Ar-C), 137.9 (Ar-C), 132.2 (Ar-C), 
127.8 (Ar-C), 125.3 (Ar-C), 123.9 (Ar-C), 121.5 (Ar-C), 48.0 (CH2), 12.5 (CH3). HRMS calculated 
for C11H11ClN3O2 [M+H]
+
 252.0534, found 252.0537. m.p. 88-90 °C. 
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Naphthalen-1-ylmethanol (183) 
 
Brown solid, 3.13 g (99%). 
1
H NMR (500 MHz, CDCl3): δ 8.11 (1H, d, J=3.1 Hz, Ar-H), 7.87 (1H, 
d, J=4.7 Hz, Ar-H), 7.80 (1H, d, J=8.20 Hz, Ar-H), 7.54-7.48 (3H, m, Ar-H), 7.43 (1H, dd, J=8.0, 
7.2 Hz, Ar-H), 5.13 (2H, s, CH2), 2.00 (1H, bs, OH). 
13
C NMR (125 MHz, CDCl3): δ 136.4 (Ar-C), 
133.9 (Ar-C), 131.4 (Ar-C), 128.8 (Ar-C), 128.7 (Ar-C), 126.5 (Ar-C), 126.00 (Ar-C), 125.5 (Ar-
C), 125.4 (Ar-C), 123.8 (Ar-C), 63.8 (CH2). The NMR spectra are in agreement with the 
literature.[48] 
1-(Chloromethyl)naphthalene (168) 
 
Brown oil, 2.39 g (88%). 
1
H NMR (500 MHz, CDCl3): δ 8.14 (1H, d, J=8.5 Hz, Ar-H), 7.88 (1H, d, 
J=8.5 Hz, Ar-H) 7.86 (1H, d, J=8.5 Hz, Ar-H), 7.60 (1H, t, J=6.0 Hz, Ar-H), 7.53 (2H, m, Ar-H), 
7.42 (1H, t, J=7.4 Hz, Ar-H), 5.05 (2H, s, CH2).
 13
C NMR (125 MHz, CDCl3): δ 133.9 (Ar-C), 
133.0 (Ar-C), 131.1 (Ar-C), 129.7 (Ar-C), 128.8 (Ar-C), 127.6 (Ar-C), 126.7 (Ar-C), 126.1 (Ar-C), 
125.2 (Ar-C), 123.6 (Ar-C), 44.5 (CH2). The NMR spectra are in agreement with the literature.[49] 
1-(Naphthalen-1-ylmethyl)-1H-imidazole (148) 
 
Dark brown viscous oil, 0.88 g (90 %). 
1
H NMR (400 MHz, CDCl3): δ 7.93-7.81 (3H, m, naphthyl), 
7.66 (1H, s, NCHN), 7.56-7.47 (2H, m, naphthyl), 7.43 (1H, dd, J=8.2, 7.0 Hz, naphthyl), 7.18 (1H, 
d, J=7.0 Hz, naphthyl), 7.09 (1H, s, NCHCHNCH2), 6.92 (1H, s, NCHCHNCH2), 5.59 (2H, s, 
CH2).
 13
C NMR (100 MHz, CDCl3): δ 137.3 (Ar-C), 133.8 (Ar-C), 131.0 (Ar-C), 130.8 (Ar-C), 
129.4 (Ar-C), 129.0 (Ar-C), 128.9 (Ar-C), 127.1 (Ar-C), 126.4 (Ar-C), 126.3 (Ar-C), 125.4 (Ar-C), 
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122.3 (Ar-C), 119.5 (Ar-C), 48.9 (CH2). HRMS calculated for C14H13N2 [M+H]
+
 209.1073, found 
209.1077. The NMR spectra are in agreement with the literature.[50] 
2-Methyl-1-(naphthalen-1-ylmethyl)-1H-imidazole (149) 
 
Dark brown solid, 0.84 g (80 %). 
1
H NMR (400 MHz, CDCl3): δ 7.90-7.71 (3H, m, naphthyl), 7.56-
7.46 (2H, m, naphthyl), 7.33 (1H, dd, J=8.2, 7.2 Hz, naphthyl), 6.94 (1H, d, J=1.3 Hz, 
NCHCHNCH2), 6.75 (1H, dd, J=7.1, 1.0 Hz, naphthyl), 6.72 (1H, d, J=1.4 Hz, NCHCHNCH2), 
5.39 (2H, s, CH2), 2.32 (3H, s, CH3). 
13
C NMR (100 MHz, CDCl3): δ 144.9 (Ar-C), 133.4 (Ar-C), 
131.5 (Ar-C), 130.2 (Ar-C), 128.8 (Ar-C), 128.4 (Ar-C), 127.2 (Ar-C), 126.6 (Ar-C), 126.0 (Ar-C), 
125.3 (Ar-C), 124.1 (Ar-C), 122.0 (Ar-C), 119.8 (Ar-C), 47.2 (CH2), 12.8 (CH3). HRMS calculated 
for C15H15N2 [M+H]
+
 223.1230, found 223.1234. m.p. 103.5-104.5 °C. 
4-((1H-imidazol-1-yl)methyl)phenol (150) 
 
Pale brown solid, 1.12 g (80%). 
1
H NMR (400 MHz, DMSO-d6): δ 9.47 (1H, bs, OH), 7.68 (1H, s, 
NCHN), 7.10-7.01 (3H, m, Ph-H & NCHCHNCH2), 6.86 (1H, t, J=1.0 Hz, NCHCHNCH2), 6.71 
(2H, d, J=8.5 Hz, Ph-H), 5.02 (2H, s, CH2). 
13
C NMR (100 MHz, DMSO-d6): δ 157.0 (Ar-C), 137.1 
(Ar-C), 129.1 (Ar-C), 128.5 (Ar-C), 127.9 (Ar-C), 119.3 (Ar-C), 115.3 (Ar-C), 49.1 (CH2). HRMS 
calculated for C10H10N2NaO [M+Na]
+
 197.0685, found 197.0689. m.p. 210-212 °C (lit. [50] m.p. 
210-211 °C). The NMR spectra are in agreement with the literature.[51] 
4-((2-Methyl-1H-imidazol-1-yl)methyl)phenol (151) 
 
Brown solid, 1.25 g (90%). 
1
H NMR (300 MHz, DMSO-d6): δ 9.46 (1H, bs, OH), 7.05 (1H, d, 
J=1.3 Hz, NCHCHNCH2), 6.99 (2H, d, J=8.6 Hz, Ph-H), 6.75-6.68 (3H, m, Ph-H & 
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NCHCHNCH2), 4.97 (2H, s, CH2), 2.22 (3H, s, CH3). 
13
C NMR (75 MHz, DMSO-d6): δ 156.8 (Ar-
C), 143.6 (Ar-C), 128.6 (Ar-C), 127.6 (Ar-C), 126.2 (Ar-C), 120.0 (Ar-C), 115.4 (Ar-C), 48.3 
(CH2), 12.8 (CH3). HRMS calculated for C11H13N2O [M+H]
+
 189.1022, found 189.1022. m.p. 209-
210 °C. The NMR spectra are in agreement with the literature.[26] 
1-(3-Aminobenzyl)-1H-imidazol-3-ium (152) 
 
Pale brown solid, 0.79 g (82 %). 
1
H NMR (400 MHz, DMSO-d6): δ 9.39 (1H, s, NHCHN), 7.79 
(1H, t, J=1.7 Hz, NHCHCHN), 7.72 (1H, t, J=1.7 Hz, NHCHCHN), 7.45 (1H, t, J=7.8 Hz, Ph-H), 
7.34-7.23 (3H, m, Ph-H), 5.50 (2H, s, CH2). 
13
C NMR (100 MHz, DMSO-d6): δ 136.8 (Ar-C), 
135.5 (Ar-C), 134.8 (Ar-C), 130.2 (Ar-C), 126.0 (Ar-C), 122.4 (Ar-C), 122.1 (Ar-C), 121.4 (Ar-C), 
120.3 (Ar-C), 51.0 (CH2). HRMS calculated for C10H12N3 [M+H]
+
 174.1031, found 174.1034. m.p. 
217-218 °C. 
1-(3-Aminobenzyl)-2-methyl-1H-imidazol-3-ium (153) 
 
Pale yellow solid, 0.82 g (80 %). 
1
H NMR (300 MHz, DMSO-d6): δ 8.28-8.18 (2H, m, Ph-H), 7.81-
7.66 (3H, m, Ph-H & NHCHCHN), 7.62 (1H, d J=2.1 Hz, NHCHCHN), 5.56 (2H, s, CH2), 2.63 
(3H, s, CH3). 
13
C NMR (75 MHz, DMSO-d6): δ 148.0 (Ar-C), 144.6 (Ar-C), 136.7 (Ar-C), 134.6 
(Ar-C), 130.6 (Ar-C), 123.4 (Ar-C), 122.9 (Ar-C), 122.2 (Ar-C), 118.3 (Ar-C), 48.9 (CH2), 10.5 
(CH3). HRMS calculated for C11H14N3 [M+H]
+
 188.1188, found 188.1191. m.p. 219-220 °C. 
1-(4-Aminobenzyl)-1H-imidazol-3-ium (154) 
 
Brown solid, 0.81 g (82 %). 
1
H NMR (300 MHz, DMSO-d6): δ 9.34 (1H, t, J=1.5 Hz, NHCHN), 
7.78 (1H, t, J=1.6 Hz, NHCHCHN), 7.68 (1H, t, J=1.6 Hz, NHCHCHN), 7.45 (2H, d, J=8.5 Hz, 
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Ph-H), 7.27 (2H, d, J=8.5 Hz, Ph-H), 5.43 (2H, s, CH2). 
13
C NMR (75 MHz, DMSO-d6): δ 135.3 
(Ar-C), 134.0 (Ar-C), 133.6 (Ar-C), 129.5 (Ar-C), 122.9 (Ar-C), 121.9 (Ar-C), 120.2 (Ar-C), 50.9 
(CH2). HRMS calculated for C10H12N3 [M+H]
+
 174.1031, found 174.1032. m.p. 209-210 °C. The 
1
H NMR spectrum of nuetral compound has been reported in the literature.[27] 
1-(4-Aminobenzyl)-2-methyl-1H-imidazol-3-ium (155) 
 
Brown solid, 0.84 g (80 %). 
1
H NMR (300 MHz, DMSO-d6): δ 8.23 (2H, d, J=8.5 Hz, Ph-H), 7.75 
(1H, d, J=2.0 Hz, NHCHCHN), 7.61 (1H, d, J=2.0 Hz, NHCHCHN), 7.56 (2H, d, J=8.7 Hz, Ph-
H), 5.60 (2H, s, CH2), 2.59 (3H, s, CH3).
 13
C NMR (75 MHz, DMSO-d6): δ 147.3 (Ar-C), 144.6 
(Ar-C), 142.2 (Ar-C), 128.9 (Ar-C), 124.0 (Ar-C), 122.3 (Ar-C), 118.5 (Ar-C), 49.0 (CH2), 10.4 
(CH3). HRMS calculated for C11H14N3 [M+H]
+
 188.1188, found 188.1193. m.p. 183-185 °C. 
1-(5-Amino-2-chlorobenzyl)-1H-imidazol-3-ium (156) 
 
Pale yellow solid, 1.06 g (92 %). 
1
H NMR (300 MHz, DMSO-d6): δ 9.35 (1H, t, J=1.3 Hz, 
NHCHN), 8.38 (1H, d, J=2.7 Hz, Ph-H), 8.28 (1H, dd, J=8.8, 2.8 Hz, Ph-H), 7.85 (1H, d, J=8.8 
Hz, Ph-H), 7.80 (1H, t, J=1.7 Hz, NHCHCHN), 7.74 (1H, t, J=1.7 Hz, NHCHCHN), 5.71 (2H, s, 
CH2). 
13
C NMR (75 MHz, DMSO-d6): δ 146.6 (Ar-C), 140.1 (Ar-C), 136.1 (Ar-C), 134.0 (Ar-C), 
131.3 (Ar-C), 126.2 (Ar-C), 125.6 (Ar-C), 122.3 (Ar-C), 120.2 (Ar-C), 49.2 (CH2). HRMS 
calculated for C10H11ClN3 [M+H]
+
 208.0642, found 208.0645. m.p. 233-234 °C. 
1-(5-Amino-2-chlorobenzyl)-2-methyl-1H-imidazol-3-ium (157) 
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Black solid, 1.12 g (92 %). 
1
H NMR (400 MHz, DMSO-d6): δ 8.26 (1H, dd, J=8.8, 2.8 Hz, Ph-H), 
8.11 (1H, d, J=2.7 Hz, Ph-H), 7.87 (1H, t, J=8.8 Hz, Ph-H), 7.64 (1H, d, J=2.0 Hz, NHCHCHN), 
7.58 (1H, d, J=2.0 Hz, NHCHCHN), 5.60 (2H, s, CH2), 2.66 (3H, s, CH3). 
13
C NMR (100 MHz, 
DMSO-d6): δ 146.7 (Ar-C), 145.2 (Ar-C), 139.7 (Ar-C), 133.7 (Ar-C), 131.4 (Ar-C), 125.3 (Ar-C), 
125.3 (Ar-C), 122.2 (Ar-C), 118.4 (Ar-C), 47.7 (CH2), 10.6 (CH3). HRMS calculated for 
C11H13ClN3 [M+H]
+
 222.0798, found 222.0799. m.p. 199-201 °C.  
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6.1 Conclusions 
β-Lactam antibiotics make up more than 50% of all commercially prescribed antibiotics for 
treatment of bacterial infections. The β-lactam ring is part of the structure of several antibiotic 
families; the principal β-lactam antibiotics are carbapenems,[1] cephalosporins,[2] penicillins,[2, 3] 
and monobactams.[4] The general mechanism of action of β-lactam antibiotics is inhibition of 
peptidoglycan synthesis which constitutes a major portion of bacterial cell wall synthesis.[5] The 
attachment of β-lactam antibiotics to penicillin-binding protein leads to the inhibition of 
transpeptidase (a bacterial enzyme that cross-links the peptidoglycan chains to form rigid cell walls) 
which eventually leads to the death of bacteria. Bacteria have several mechanisms to attain 
resistance against β-lactam antibiotics.[6] These include a) mutations to the active site of penicillin-
binding-protein to prevent drug binding, b) modification of the cell wall to prevent drug entry and 
assist active removal of antibiotic compounds, and c) producing the class of enzyme known as β-
lactamase, which includes serine-β-lactamases and metallo-β-lactamase (MBLs) which hydrolyze 
the β-lactam ring of the drug compounds, thereby inactivating them. One solution to inhibit these 
enzymes is co-administration of antibiotics with β-lactamase inhibitors. These inhibitors should 
prevent the metabolism of penicillins. For many years, β-lactam antibiotics have been used 
extensively by physicians throughout the world and hence many bacteria have developed resistance 
against several agents of this class of drugs. Due to this, many infections which were treated 
effectively in the past have become life threatening. This problem of resistance was overcome by 
including some new agents along with penicillin (sulbactam with ampicillin) which were able to 
inhibit the β-lactamase enzymes. Later, these agents were also found ineffective and there was a 
need to discover new classes of β-lactamase inhibitors.[5, 7, 8] The aim of the research reported in 
this thesis was to investigate, design, synthesize and screen new inhibitors against metallo-β-
lactamase (IMP-1) with the overall aim of identifying compounds that will have applications as 
drugs that can be administered with β-lactam antibiotics. 
In Chapter 2, a straightforward and efficient synthesis of novel thiol carboxylic acid compounds 
based on naturally occurring aromatic amino acids as IMP-1 inhibitors has been described. Firstly, a 
new series of thiol carboxylic acid inhibitors 72a-c, 73a-c, 74a-c and 75a-c has been designed 
(Figure ‎6-1). Secondly, the docking results were investigated and compared with the reference 
compound 68b which was reported by Liénard et al. as potent inhibitor with Kic value of 
0.086±0.024 µM. The demonstrated results Escore by MolDock software showed that most of these 
compounds have lower Escore than the reference compound 68b and so were expected to be more 
potent inhibitors of IMP-1. The survey of results on docking also described feasible coordination of 
thiolate group of inhibitors into the active site of IMP-1. Apart from the binuclear metal centre, 
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there was a possibility of π- π stack interaction of phenyl ring of inhibitors with both Trp64 and 
His263 or either of them. Therefore, these compounds were synthesized with the yield of ~60% and 
were examined against IMP-1. All of these compounds demonstrated good inhibitory activity 
against the metallo-β-lactamase IMP-1 ranging 0.086±0.024 µM to 9.39±4.60 µM (Table ‎1-1). 
Amongst those, compound 75a showed that the most potent inhibition, with a competitive Kic of 
0.086±0.024 µM. Although, the docking results were exhibited that the developed compounds have 
had lower docking energy (Escore) than the reference 68b, they showed higher Kic values except for 
75a. Nevertheless, another lead for the development of potent MBL inhibitors in this category 
might be based on changing the benzyl group or the central phenyl group with more polar aromatic 
ring such as imidazole and furan. 
 
Figure ‎6-1: Structures of thiol carboxylic acid inhibitors of IMP-1. 
Table ‎6-1: Inhibitory activities of the target compounds 72a-c, 73a-c, 74a-c and 75a-c against IMP-1. 
Compound Kic (µM)
a
 
72a 0.25 ± 0.20 
72b 1.45 ± 0.67 
72c 2.82 ± 1.98 
73a 0.47 ± 0.09 
73b 5.02 ± 1.64 
73c 8.62 ± 3.30 
74a 4.55 ± 1.96 
74b 5.18 ± 1.55 
74c 5.63 ± 4.50 
75a 0.086 ± 0.024 
75b 9.39 ± 4.60 
75c 5.85 ± 1.30 
a
 Kic: Inhibition constant for competitive inhibition mode. 
In Chapter 3, a new series of L-benzyl tyrosine thiol carboxylic acid inhibitors has been described. 
Firstly, the docking results were investigated and compared with the reference compound 75a 
which was potent inhibitor with Kic value of 0.086 µM. The results Escore by MolDock software 
showed that these compounds have lower Escore than the reference compound 75a so they were 
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expected to be more potent inhibitors of IMP-1. The docking results also showed feasible 
coordination of thiolate group of inhibitors into the active site of IMP-1. Although side groups of 
benzyl ring did not show a potent interaction with the amino acids of the active site, it caused the 
lower Escore of docking than the reference compound 75a. Therefore, these compounds were 
synthesized with the yield of ~80% and were examined against IMP-1. All of these compounds 
demonstrated good inhibitory activity against the metallo-β-lactamase IMP-1 ranging 1.04 to 4.77 
µM. Amongst those, compound 108a showed the most potent inhibition with a competitive Kic of 
1.04 µM. Although the docking results showed that the developed compounds 108a-k had lower 
docking energies (Escore) than the reference 75a, they showed higher Kic values.  
 
Figure ‎6-2: Structures of thiol L-tyrosine carboxylate inhibitors of IMP-1. 
Table ‎6-2: Inhibitory activities of the target compounds 108a-k against IMP-1. 
Compound MolDock Score (kcal/mol)  Compound MolDock Score (kcal/mol) 
75a* -190.88  108f -195.51 
108a -201.06  108g -201.91 
108b -202.92  108h -199.83 
108c -194.12  108i -207.01 
108d -197.28  108j -199.48 
108e -194.20  108k -194.08 
* Reference compound 
In Chapter 4, the ZINC Database Library (www.zinc.docking.org) was used for screening virtual 
compounds as inhibitors for IMP-1 based on their affinity towards the enzyme. Accordingly, 
compounds 109-112 were obtained with the highest ranked score (Figure ‎6-3). Compounds 109-112 
were manipulated for facilitation of synthesis as well as cheap commercially available materials in 
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market. Therefore, compounds 113-116 were designed (Figure ‎6-4). These compounds were 
docked, synthesized and assayed against IMP-1. Computer modeling showed that these compounds 
coordinated to both zinc atoms via the oxygen atoms of the ligands. It was also predicted that these 
ligands can also make some π-π stacking interaction with the indole ring of Trp64. However, none 
of these compounds showed inhibitory activity against IMP-1 (Table ‎6-3).  
 
Figure ‎6-3: Compounds with the highest ranking score obtained against IMP-1. 
 
Figure ‎6-4: The designed compounds against IMP-1. 
Table ‎6-3: Inhibitory activities of the target compounds 113-116 against IMP-1. 
Compound Inhibition% (100 µM) Inhibition% (10 µM) 
113 24
 
11 
114 6
 
2
 
115 0 0 
116 12
 
9 
In Chapter 5, two reference compounds 152 and 154 were used as leads for designing twenty-four 
imidazole derivatives (132-157). Their docking results were investigated with MolDock software 
and Escore Values were used for the prediction of inhibition activities. All compounds were 
synthesized with yields higher than 80%. Their inhibition activities were measured at two 
concentrations (1 mM and 100 µM). There was not observed an order between inhibition activities 
and Escore. The assay results showed that compounds 145 and 148 are the most potent inhibitors 
amongst compounds. Consequently, these two compounds can be used as leads for the future plan 
and development of new inhibitors. All designed imidazole derivatives as well as two reference 
compounds 152 and 154 are shown in Figure ‎6-5. As the compounds 152-157 were synthesized in 
acidic condition they were N3 protonated and the modeling predicted that they were coordinated to 
zinc atoms via their amine groups.  
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Figure ‎6-5: Designed imidazole derivatives as inhibitors against IMP-1.  
Although computational modeling is a good method for the prediction of the strength of inhibitory 
activities of molecules, but the predicted results are not always accurate. Because the prediction of 
docking is only limited to the active site and the rest part of the protein is ignored during the 
docking. Therefore, the results of computational modeling are not always accurate. Sometimes the 
designed molecule is able to bind to another part of the protein which causes inactivity of the 
molecule as inhibitor. The other thing is the solubility of the inhibitors; when a molecule is docked 
into the active site, its solubility is not considered by docking software. The software can only 
predict the orientation of binding of the molecule into the active site as well as its interactions with 
amino acids of protein. Therefore, maybe the computational modeling predicts that the designed 
compound can be excellent compound to be synthesized as inhibitor but it might be insoluble 
during the assay. 
The results of computational modeling for Chapters 2 and 3 showed that Escore values were around 
200 kcal/mol. When their inhibitory activities were measured, it was observed that they are potent 
inhibitors; therefore, maybe the Escore values of -200 kcal/mol or higher values are expected to be 
potent. On the other hand the results of Chapter 4 showed lower Escore values than compounds of 
Chapters 2 and 3 but higher than the results of Chapter 5. But their activities were almost zero. The 
Escore values of compounds of Chapter 5 were lower than Escore values of Chapter 4 but most of them 
showed 30 to 70% inhibitory activities at 100 µM. As the prediction of computational modeling is 
an important role for designing of inhibitors, it is better to use few docking software to have a better 
prediction. The results of software are different and even their coordination and interaction is also 
different. 
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6.2 Future Plans 
Plan 1: As discussed in Chapter 1, Lienard et al. reported the most potent thiol-carboxylic acid 
inhibitors against different subclasses B1, B2 and B3.[9] The structures and their kinetic data are 
shown in Table ‎6-4. Entry 27 (2-(3-mercaptopropanamido)-2-phenylacetic acid) shows the lowest 
Ki value as 0.019 µM against IMP-1. These compounds could bind to the zinc atoms of the active 
site of IMP-1 via their thiolate. They are also polar enough to be soluble in the body. The other 
positive aspect of this class of inhibitor is that they are not restricted to only one subclass and could 
be active in different subclasses as well. The aromatic rings of these compounds might make π-π 
stacking interaction which cause they be better fitted in the active site of IMP-1. 
Table ‎6-4: Competitive inhibition constants Ki (µM) of potent thiol-carboxylic acid inhibitors against MBLs.[9] 
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Accordingly, L- and D- derivatives of compound 27 could be synthesized individually as well as 
decreasing and increasing of the side chain of thiol group. As already discussed, the other 
modification of this lead compound could be carried out with replacing phenyl ring with indole, 
imidazole and furan. Some recommended compounds for synthesis as IMP-1 inhibitors are shown 
in Figure ‎6-6. 
 
Figure ‎6-6: A few recommended compounds for synthesis of IMP-1 inhibitors. 
Plan 2: As already discussed in Chapter 2, the obtained results Escore for D-derivatives of thiol 
carboxylic acid compounds (68a-c, 69a-c, 70a-c and 71a-c) were better than L-derivatives (72a-c, 
73a-c, 74a-c and 75a-c). Therefore, synthesis of D-derivatives is so promising and it is expected to 
show more potent inhibitors of IMP-1 than L-derivatives. It is also predicted that these compounds 
could coordinate via their thiolate into the active site of IMP-1. The other prediction is making π-π 
stacking interaction with the aromatic rings of Trp64 which cause better fitting in the active site of 
IMP-1. The polar carboxylate groups of these compounds may form hydrogen bonds with the 
amino acids of the active site of IMP-1. The other possible prediction which is not discussed before 
is the coordination of carboxylate groups with zinc atoms of IMP-1. Consequently, synthesis and 
assay of these compounds against IMP-1 is promising. 
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Appendix A 
Expression and Purification of Metallo-β-lactamase Enzyme 
(IMP-1)
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Protein Expression 
Purification of IMP-1 was mainly done by Peter Vella (former PhD student). The following 
precudure is prepared by cooperation of McGeary‟s group members for facilliation of study of 
purification of IMP-1. 
Materials: 
1. Luria bertani (LB) Broth (Schott Bottles Flask) 
2. LB Agar 
3. Petri dish 
4. Kanamycin Stock (50 mg/ml) 
5. IPTG Stock (100 mM) 
6. Autoclave flask 
7. Shaker 
8. Water Bath (42 oC) 
9. BL21(DE3) competent cells 
Recipes: 
Day 0 
LB Agar (1L) 
10 grams tryptone 
5 grams of yeast extract 
10 grams of NaCl 
Adjust pH to 7.0 with NaOH (Adjust to pH 7.0 is not necessary according to some people) 
Add 15 g agar 
Melt in microwave. Top up to 1L 
Autoclave 
LB Broth (2L) 
20 grams tryptone 
10 grams of yeast extract 
20 grams of NaCl 
Adjust to pH 7.0 (Adjust to pH 7.0 is not necessary). Then, autoclave. 
Tryptone (20 g), yeast extract (10 g) and NaCl (20 g) dissolved in milliQ water (2 L) then 
the soulution transferred to four big flask (2L). each one 500 ml. 
Kanamycin (50 mg/ml) Stock Solution 
0.5 g Kanamycin (10 ml MilliQ water) 
Filter sterilized with 0.22 micron Aliquot 
Store at -20 - -70 °C 
Addition (50 µg/ml, dilution factor 1000) 
Total volume of LB Broth/flask is 550 ml 
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550/1000 = 0.55 ml 
So 0.55 ml of 50 mg/ml Kanamycin need to be added to 550 ml LB Broth big flask. 
IPTG (Isoproyl-β-D-thiogalacto-pyranoside) (100 mM, 25 ml) Stock Solution 
Mw: 238.3 g/mole         the mass = C x V x Mw = 0.1 M x 0.025L x 238.3 = 0.595 g 
So 0.595 g in 25 ml MilliQ water. 
Filter sterilized with 0.22 micron 
Short term: store at 4°C or -20°C for long term. 
Addition (1 mM, dilution factor 100) 
Total volume of LB Broth/flask is 550 ml 
550/100 = 5.5 ml 
So 5.5 ml of 100 mM IPTG need to be added to 550 ml LB Broth big flask. 
ZnCl2 (500 mM, 10 ml) Stock Solution 
Mw: 136.3 g/mole         the mass = C x V x Mw = 0.5 M x 0.01L x 136.3 = 0.6815 g 
So 0.6815 g in 10 ml MilliQ water. 
Filter sterilized with 0.22 micron 
Store at 4 °C. 
Addition (25µ M, dilution factor 20000) 
Total volume of LB Broth/flask is 550 ml 
550/20000 = 0.0275 ml = 28 µL. 
So 28 µL of 500 mM ZnCl2 need to be added to 550 ml LB Broth big flask. 
Autoclave 
1 ml tip box 
200 µL tip box 
flask 
Caps for flask 
Day 1 
Transformation 
Make sure that water bath is set to 42
o
C prior to transformation 
1. In the biological hood, 2 µL Plasmid + 50-100 µL BL21 (DE3) comptent cell 
2. Leave on ice for 25-30 mins 
3. Heat shock at 42 oC 40-45sec 
4. Immediately, place on ice for 2 mins 
5. Add 750 µL fresh LB broth (no Kanamycin to transformed cells) 
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6. Incubate for 1-1.5 hour at 37 oC shaker with agitation (leave everything clean and turn off 
the biological hood) 
7. Slow spin (remove some supernatant). This step carried out through centrifuge 60 sec and 
another water eppendorf tube the same weight needs to be used for balancing, then suck 
about 500 µL from the supernatant to concentrate the cells 
8. Resuspend cells by mixing (this concentrates cells) 
9. Spread 50-100 µL on LB/Kan plate and spread by using the blue spreader 
10. Incubate at 37 oC overnight (16-18 hours), the plate needs to be turned upside down before 
incubation to keep the agar on the top, then wrap the plate with parafilm. 
11. Turn off the biological hood 
Day 2 
Inoculation 
1. Pick single colonies using tips and inoculate in 4 (50 ml volume) falcon tubes each of them 
filled with 20 ml of fresh LB broth + 20 µL Kanamycin (50 mg/ml) by throwing the tip inside 
the falcon tube, each colony can be used for two falcon tubes by picking it with two tips. 
NB. The final concentration of Kanamycin is 50 mg/ml / dilution factor (1000) = 50 µg/ml.  
2. Grow at 30 oC and 200 RPM shaker for 12-16 hours (overgrow will create mutations) 
      NB. The 4 falcon tubes should be fixed very well in the shaker using elastic rubbers. 
Day 3 
Enzyme Expression 
1. 500 µL of Kanamycin (50 mg/ml) stock needs to be added to 0.5L LB broth (sterilized in the 
autoclave).  
NB. We need 4 big flasks to be used for the 4 falcon tubes.  
2. Then add the 20 ml falcon tube contents including the tip (starter culture) to the big flask 
containing 0.5L LB broth and 500 µL of Kanamycin. 
3. Shake the 4 big flasks in the incubator at 37oC and 200 RPM for 1 hour. The 4 flasks need to be 
fixed very well in the incubator using elastic rubbers and 4 elastic chains. 
4. Then add 28 µL of 500 mM ZnCl2 stock to each 550 ml big flask. 
NB. Before adding the 5.5 ml IPTG, we need to measure the optical density (OD) for the 4 big 
flasks and should be in the range 0.5 – 0.8. 
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To measure the OD, we need to use the spectrophotometer 
Steps: 
a.   Switch on the instrument from the left button 
a. Click the icon UV. Probe 2.31 
b. Choose connect then OK 
c. Put the blank (only LB broth) then hit atuozero 
d. Put the 4 samples (about 1 ml using a certain sterilized pipette into plastic cuvette) from 
the 4 big flasks (only one for each measurement). 
e. The absorbance should be 0.5 – 0.8 to indicate optimum growth before adding the IPTG 
to induce the bacteria to produce the IMP-1 enzyme. 
5. Add 5.5 ml of 100 mM IPTG stock to each 550 ml big flask to induce the enzyme. 
6. Collect 1.5 ml from only one big flask every one hour (1, 2, 3, 4, 5, 6, 7, 8 and 24). 
NB. The temperature needs to be 30 
o
C if we need to incubate the culture overnight in LB 
broth. 
Steps of collecting the samples and harvesting the cells 
a. Take a sample every one hour up to 9 samples in eppendorf tubes 
b. To harvest the sample (cells), centrifuge the sample at a maximum speed for 2 min, 
discard the supernatant. Centrifuge again for 30 sec to discard the remaining supernatant. 
c. Stored cells at -20oC.  
7. Transfer the 4 flask contents to 6 centrifuge bottles (bleached and cleaned). The weight of the 6 
flasks including their contents and their leads should be the same. 
NB. DO not forget to turn off the incubator. 
8. Centrifuge the 6 bottles in the big centrifuge (the purple one) at 5000 RPM for 20 min. 
NB. Do not forget to put the lead, close the big coarse first then the smaller one. 
9. Transfer the cells using a certain spatula (like a ruler) from the 4 centrifuge bottles into one new 
50 ml falcon tube.  
10. Freeze the cells at -20 oC. 
11. In the second day, in the biological hood, to the frozen bacterial cells add little amount of buffer 
(about 3 plastic pipettes) to be 18 ml total volume approximately. 
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12. Wait till be defrosted, we can use a normal water bath. 
13. Add solid lysozyme 0.2 mg/ml (18 ml x 0.2 mg = 3.6 mg need to be added) to break the cell 
wall and leave for 30 min with bacteria. 
14. Add a tablet of protease inhibitor (without EDTA) to the falcon tube to stop the lyses effect of 
the protease enzyme on the proteins including IMP-1 enzyme. 
15. Shake very well and leave for 30 min. 
NB. After 30 min it looks like gum. 
16. Put the sonicator inside the biological hood, clean the tip with ethanol.  
17. Immerse the sonicator tip inside the falcon tube and sonicate for 4 times each time about 2-3 sec 
till the contents looks like a liquid. Use the ice to cool the cells after each sonication. 
NB. Do not forget to use an ear block and ear lead. 
18. Add 1 µg DNAse/ml x 25 ml (the new total volume) = 25 µg to lyses the DNA.  
19. Add 0.25 ml MgCl2 (1 M) to the 25 ml falcon tube contents to be 10 mM concentrations. 
NB. MgCl2 helps the effect of DNAse. 
20. Leave 20 min in ice, the contents become thinner. 
21. Divide the contents into 2 centrifuge tubes (the same mass including the leads) 
22. Centrifuge using the black one 12500 RPM for 32 min. 
23. Collect the supernatant (the most important part including the IMP-1 enzyme) in a labeled 
falcon tube (IMP-1 culture). 
24. Filter the supernatant through 0.22 micron. 
NB. If the filtration is too slow we can add another amounts of both DNAse and MgCl2 
and leave overnight then centrifuge again. 
25. Concentrate the sample using Millipore (Amicon ultra) centrifugal filter devices, for 25 min at 
5000 speed (balancing tubes i.e. the same mass including the leads of the tubes) because we 
need less than 5 ml total volume of the sample to be injected to FPLC to get good resolution. 
NB. The Millipore tubes need to be washed firstly with water to get red off polyethylene 
glycol and azides by centrifuging for 5 min using water. Also, after we finish using the 
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tubes, we need to rinse the tubes with water, centrifuge, add ethanol and keep in the fridge 
for the next use. 
26. Transfer the sample using a plastic pipette to another 15 ml flacon tube to be ready to be 
injected into the FPLC.  
27. Keep a few drops in an eppendorf tube. 
Buffers for the purification of IMP-1 
Purification Table 
HEPES A HEPES B HEPES X (ASSAY Buffer) 
50 mM HEPES 
NO SALT 
500 µM ZnCl2 
pH 7, Degas 
50 mM HEPES 
1.0 M NaCl 
500 µM ZnCl2 
pH 7, Degas 
50 mM HEPES 
0.1 M NaCl 
100 µM ZnCl2 
pH 7, Degas 
HEPES 11.91 g 
NO SALT 
In one liter of milliQ water 
HEPES 11.91 g 
58.44 g NaCl 
In one liter of milliQ water 
HEPES 11.91 g 
5.844 g NaCl 
In one liter of milliQ water 
Used in SP Sepharose 16/10 
(Amersham Biosciences) along with 
HEPES B to create an eluting 
gradient. 
Used to dialyse out DNAse etc. 
Used in Gel filtration (superpose 12) 
Used in SP Sepharose 16/10 
(Amersham Biosciences) along with 
HEPES A to create an eluting 
gradient. 
 
Used for assay purposes 
Zinc Chloride for Buffers:  
ZnCl2 (500 mM, 10 ml) Stock Solution 
Mw: 136.3 g/mole         the mass = C x V x Mw = 0.5 M x 0.01 L x 136.3 = 0.6815 g 
So 0.6815 g in 10 ml MilliQ water. 
Filter sterilized with 0.22 micron 
Store at 4 
o
C. 
Addition to HEPES A buffer (500 µM, dilution factor 1000) 
Total volume of HEPES A buffer is 1000 ml 
1000 ml/1000 (DF) = 1.0 ml. 
So 1.0 ml of 500 mM ZnCl2 needs to be added to 1.0L HEPES A buffer. 
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Addition to HEPES X (Assay Buffer) (100 µM, dilution factor 5000) 
Total volume of HEPES X (Assay buffer) is 1000 ml 
1000 ml/5000 (DF) = 0.2 ml. 
So 0.2 ml of 500 mM ZnCl2 needs to be added to 1.0L HEPES X (Assay buffer). 
Mw Table 
Substance Mwt  
HEPES 238.31 g/mol In a big container 
ZnCl2 136.30 g/mol  
NaCl 58.44 g/mol  
SDS Page Gel 
SDS page gel is usd to find out the enzyme is pure. 
Running Buffer 
Methods (5x) 
1. About 15 g Tris Base weighed, followed by 72 g Glycine 
2. Add 5 g SDS 
3. Place above chemicals in a beaker. 
4. Add milliQ water to 1L, (pH will be 8.6) 
5. Adjusted to pH 8.3 using 32% HCl 
Dilution to 1X: Take 200 ml of running buffer and add 800 ml MilliQ water. 
Amount of protein to use: 1250 µg/ml (i.e. 1.2 mg/ml) 
Stacking Gel (Top) 
Water (MilliQ): 5.6 ml 
0.5 M TRIS-HCl, pH 6.8 2.5 ml 
Bis-acrylamide 0.75 ml 
10% SDS 100 µL 
10% APS 100 µL 
TEMED 10 µL 
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Separating Gel (bottom) 
Water (MilliQ): 4.79 ml 
1.5 M TRIS-HCl, pH 8.8 2.5 ml 
Bis-acrylamide 2.5 ml 
10% SDS 100 µL 
10% APS 100 µL 
TEMED 10 µL 
 20 µL of sample + 5 µL of denaturing sample buffer. Aim for 10 µg of protein per lane. 
Example 
A protein at a concentration of 10 mg/ml = 1 µg/µL 
So 10 µL contain 10 µg protein. 
Proteins that more concentrated than this (e.g. 4.39 mg/ml) need to be diluted. 
Here's how: 
4.39 mg/ml protein divided by 1 mg/ml is 4.39 (dilution factor). 
So 100 µL (total volume) divided by 4.39df is 22 µL of the concentrated sample needs to be diluted 
to 100 µL as a total volume.  
i.e. so we need to add 22 µL of the concentrated sample, and then add enough water/buffer to make 
it up to 100 µL. 
APS 
10% SDS is 0.5 g in 5 ml MilliQ water. 
10% APS is 0.1 g in 1 ml or 0.05 g (i.e. 50 mg) in 500 µL 
Run at 200 Volts. Running at slower speed takes longer time but gives better resolution. 
Coomassie Blue Staining Solution 
Destaining Solution 
Materials (scale down for 1L solution) 
7.5% acetic acid 
10% ethanol 
Add 300 ml acetic acid and 420 ml 95% ethanol to 3280 ml water. 
Transfer to 4L solvent storage bottle. 
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Fast Performance Liquid Chromatography (FPLC) 
Important notices: 
1. Keep your eye most of the time on the pressure to avoid to be too high. 
2. Every solution must be filtered through 0.22 µM to avoid any particles can be stuck 
onto the column which can increase the pressure. 
3. All used buffers must be degassed to avoid any air bubbles which can increase the 
pressure. 
General Instructions for FPLC 
1. Before starting anything, we need to disconnect the super loop (the yellow one) and rinse it 
very well with water, detergent and water. Try to avoid the air bubbles while reassembling the 
super loop again. We need to rinse it again also, after using it. Be careful it is very expensive. 
NB. The importance of the super loop, it is the area where the sample be loaded in the bottom 
between the two black lines after the sample injection.  
2. All of the column should be stored in ethanol after using them. 
3. To use any new solution, we need to do pump wash at a pressure 5.000 MPa to get red off any 
air bubbles and fill the pump with the new solution. 
4. After mounting a new column we need to flush it with water firstly to get red off the ethanol in a 
rate (according to the column instructions).  
Procedure 
1. Click on Unicorn, System control, Manual, Pump, Pump wash (it takes about 15 min), 
On, On then hit insert 
2. Choose Alarm&Monitoring, Alarm Pressure, 5 MPa then hit insert and execute but 
after checking the two tubes immersed correctly in the correct solution vessel.  
3. Dismounting and mounting the column procedures 
a. Pump, flow, 0.2 ml/min then insert (according to the column instructions) 
b. Alarm&monitoring, Alarm pressure, 0.3 MPa then insert and hit execute 
c. Disconnect the lower connection of the column 
d. Put a water syringe to the lower tube (you can leave the syringe for few seconds to fill it 
with water if required). 
e. Put the spring and the lead of the syringe, you need to be very careful in this step. 
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f. Hit pause till you be ready to mount the new column 
g. Disconnect the upper connection of the column 
h. Take the column away and clamp it safely. 
i. Connect the new column  
j. Hit continue 
k. Connect the upper connection of the new column drop to drop 
l. Disconnect the syringe from the lower part of the column and keep it in a plastic beaker 
m. Connect the lower connection of the column (usually you need a certain connector).  
n. Flush with water to remove all the ethanol (according to the column instructions). 
4. Pump wash with buffer then flush the column (according to the column instructions). 
5. Inject the 4 ml sample with a 5 ml syringe covered with a small piece of parafilm then get 
red off any air bubbles. 
6. Flow rate (according to the column instructions) 
7. Gradient zero flow_path must be inject 
8. Alarm&mon (according to the column instructions) 
9. Volume, other, acc volume 2.5 ml to be less than the total volume of the sample to avoid 
any air bubbles that can be kept in the super loop. 
NB. a. We need to wait all of the samples moved to the top of the column (high load) then inject 
1 ml water with the same flow rate but volume 0.9 ml. 
 b. if we need to use another buffer (HEPES B), we need to transfer the line B to the HEPES 
B vessel after rinsing it with dist water, then as usual flush the pump B with HEBES B. 
10. Then now after loading the sample on the top of the column, we need to run the FPLC 
automatically: 
a. Click on RUN 
b. Choose the correct column method 
c. Tick everything in the bottom   
d. Change the pressure (according to the column instructions) 
e. Sample injection EMPTY THE LOOP must be zero 
d. hit next 
f. wavelength 280 (very important) 
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g. e.g. Crude IMP-1, Hiload 16/10 sp sepharose, HEPES A, HEPES B, Remarks: type the date 
then hit next 
h. Integrate full report must be ticked, then next, next then type the name as a date then hit Start 
NB. We need to put the test tubes before starting and after the run, collect the whole test 
tubes and fridge them. 
IMP-1 requires a simple two-step FPLC method 
Step 1: SP-Sepharose 16/10 (Amersham Biosciences); 
Step 2: gel filtration, Hiprep 16/60 Sephacryl (superpose 12). 
After every purification step, we need to perform two types of assay on the fractions containing the 
crude protein or enzyme. 
Assay A. Protein assay: to quantify how much protein at A280nm absorbance e.g. 400 units 
activity 
B. Kinetic: A235nm absorbance, specific for substrate i.e. penicillin G 
 Measure the activity of enzyme (rate of change). 
A. Protein assay:  
1. Turn on the spectrophotometer and the water pump 
2. Choose simple reads; wait till the noises stop and the temperature constant 
3. Choose set up then adjust it to be 280nm 
4. Use a clean and air dried quartz cuvette (the plastic one can not be used because the plastic 
material absorbs light at 280nm i.e. interfere with our samples) 
5. Add 990 µL HEPES X (Assay Buffer) to the cuvette then hit autozero (Blanck) 
6. Then add 10 µL of the samples, put the lead, mix 4 times and hit read then record the reading 
of absorbance in nm (measure the odd or even number of fractions only to save time then 
double the amount in the final calculations). 
7. Collect the contents of the cell in a labeled eppendorf tube after each reading. 
8. Clean the cell with water and then ethanol and dry with air after every reading 
9. Save report as e.g. type the date of assay 
B. Kinetic 
1. Choose kinetics, then set up 235nm 
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2. Analyze from the top toolbar, tick both Autocalculate and Display fit 
3. Autostore from the top toolbar, choose the storage on (prompt at end) then hit OK 
4. 980 µL HEPES X + 10 µL substrate (filtered penicillin G 50 mM) then add 10 µL sample 
mix 4 times quickly and read by hitting start then record the slope. 
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Appendix B 
Measuring Kic and Kiuc From Chapter 2 
 
 
Wincurve Software Data 
a Vmax 
b Kiuc 
c Km 
d Kic 
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Kic  = 0.25 ± 0.19 µM 
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Kic  = 1.46 ± 0.67 µM 
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Kic  = 2.81 ± 1.98 µM 
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Kic  = 0.47 ± 0.09 µM 
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Kic  = 5.02 ± 1.64 µM 
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Kic  = 8.62 ± 3.30 µM 
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Kic  = 4.55 ± 1.96 µM 
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Kic  = 5.17 ± 1.55 µM 
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Kic  = 5.57 ± 4.69 µM 
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Kic  = 0.086 ± 0.024 µM 
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Kic  = 9.4 ±  4.6 µM 
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Kic  = 5.85 ± 1.29 µM 
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Appendix C 
Molegro Virtual Docker predicted binding orientations of 
compounds 72a-c, 73a-c, 74a-c and 75a-c (from Chapter 2) in 
IMP-1 (PBD code: 1JJT) 
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Compound 72a 
 
Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 72a (electrostatic surface view). Atom colors on inhibitor 
are as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. The yellow spheres are zinc atoms. 
 
 
Interaction of docked ligand 72a at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–
sulfur (on inhibitor). 
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Compound 72b 
 
Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 72b (electrostatic surface view). Atom colors on inhibitor 
are as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. The yellow spheres are zinc atoms. 
 
 
Interaction of docked ligand 72b at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–
sulfur (on inhibitor). 
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Compound 72c 
 
Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 72c (electrostatic surface view). Atom colors on inhibitor 
are as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. The yellow spheres are zinc atoms. 
 
 
Interaction of docked ligand 72c at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–
sulfur (on inhibitor). 
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Compound 73a 
 
Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 73a (electrostatic surface view). Atom colors on inhibitor 
are as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. The yellow spheres are zinc atoms. 
 
 
Interaction of docked ligand 73a at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–
sulfur (on inhibitor). 
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Compound 73b 
 
Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 73b (electrostatic surface view). Atom colors on inhibitor 
are as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. The yellow spheres are zinc atoms. 
 
 
Interaction of docked ligand 73b at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–
sulfur (on inhibitor). 
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Compound 73c 
 
Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 73c (electrostatic surface view). Atom colors on inhibitor 
are as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. The yellow spheres are zinc atoms. 
 
 
Interaction of docked ligand 73c at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–
sulfur (on inhibitor). 
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Compound 74a 
 
Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 74a (electrostatic surface view). Atom colors on inhibitor 
are as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. The yellow spheres are zinc atoms. 
 
 
Interaction of docked ligand 74a at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–
sulfur (on inhibitor). 
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Compound 74b 
 
Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 74b (electrostatic surface view). Atom colors on inhibitor 
are as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. The yellow spheres are zinc atoms. 
 
 
Interaction of docked ligand 74b at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–
sulfur (on inhibitor). 
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Compound 74c 
 
Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 74c (electrostatic surface view). Atom colors on inhibitor 
are as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. The yellow spheres are zinc atoms. 
 
 
Interaction of docked ligand 74c at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–
sulfur (on inhibitor). 
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Compound 75a 
 
Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 75a (electrostatic surface view). Atom colors on inhibitor 
are as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. The yellow spheres are zinc atoms. 
 
 
Interaction of docked ligand 74a at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–
sulfur (on inhibitor). 
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Compound 75b 
 
Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 75b (electrostatic surface view). Atom colors on inhibitor 
are as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. The yellow spheres are zinc atoms. 
 
 
Interaction of docked ligand 75b at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–
sulfur (on inhibitor). 
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Compound 75c 
 
Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 75c (electrostatic surface view). Atom colors on inhibitor 
are as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. The yellow spheres are zinc atoms. 
 
 
 
Interaction of docked ligand 75c at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–
sulfur (on inhibitor).  
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Appendix D 
Measuring Kic and Kiuc From Chapter 3 
 
 
Wincurve Software Data 
a Vmax 
b Kiuc 
c Km 
d Kic 
  
 216 
 
 
Kic  = 1.04 ± 0.28 µM 
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Kic  = 1.15 ± 0.49 µM 
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Kic  = 1.07 ± 0.21 µM 
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Kic  = 1.81 ± 0.90 µM 
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Kic  = 4.77 ± 2.81 µM 
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Kic  = 3.2 ± 0.59 µM 
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Kic  = 1.65 ± 0.34 µM 
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Kic  = 2.86 ± 1.23 µM 
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Kic  = 3.20 ± 0.62 µM 
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Kic  = 3.14 ± 0.71 µM 
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Kic  = 3.30 ± 0.90 µM 
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Appendix E 
Molegro Virtual Docker predicted binding orientations of 
compounds 108a-k (from Chapter 3) in IMP-1 (PBD code: 1JJT) 
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Compound 108a 
 
Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 108a (electrostatic surface view). Atom colors on inhibitor 
are as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. The yellow spheres are zinc atoms. 
 
 
Interaction of docked ligand 108a at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–
sulfur (on inhibitor). 
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Compound 108b 
 
Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 108b (electrostatic surface view). Atom colors on inhibitor 
are as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. The yellow spheres are zinc atoms. 
 
 
Interaction of docked ligand 108b at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–
sulfur (on inhibitor). 
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Compound 108c 
 
Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 108c (electrostatic surface view). Atom colors on inhibitor 
are as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. The yellow spheres are zinc atoms. 
 
 
Interaction of docked ligand 108c at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–
sulfur (on inhibitor). 
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Compound 108d 
 
Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 108d (electrostatic surface view). Atom colors on inhibitor 
are as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. The yellow spheres are zinc atoms. 
 
 
Interaction of docked ligand 108d at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–
sulfur (on inhibitor). 
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Compound 108e 
 
Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 108e (electrostatic surface view). Atom colors on inhibitor 
are as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. The yellow spheres are zinc atoms. 
 
 
Interaction of docked ligand 108e at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–
sulfur (on inhibitor). 
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Compound 108f 
 
Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 108f (electrostatic surface view). Atom colors on inhibitor 
are as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. The yellow spheres are zinc atoms. 
 
 
Interaction of docked ligand 108f at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–
sulfur (on inhibitor). 
 
 234 
 
 
Compound 108g 
 
Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 108g (electrostatic surface view). Atom colors on inhibitor 
are as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. The yellow spheres are zinc atoms. 
 
 
Interaction of docked ligand 108g at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–
sulfur (on inhibitor). 
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Compound 108h 
 
Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 108h (electrostatic surface view). Atom colors on inhibitor 
are as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. The yellow spheres are zinc atoms. 
 
 
Interaction of docked ligand 108h at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–
sulfur (on inhibitor). 
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Compound 108i 
 
Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 108i (electrostatic surface view). Atom colors on inhibitor 
are as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. The yellow spheres are zinc atoms. 
 
 
Interaction of docked ligand 108i at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–
sulfur (on inhibitor). 
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Compound 108j 
 
Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 108j (electrostatic surface view). Atom colors on inhibitor 
are as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. The yellow spheres are zinc atoms. 
 
 
Interaction of docked ligand 108j at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–
sulfur (on inhibitor). 
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Compound 108k 
 
Binding site of IMP-1 (PDB: 1JJT) showing docked ligand 108k (electrostatic surface view). Atom colors on inhibitor 
are as follows: blue–nitrogen, red–oxygen, green–carbon, and yellow–sulfur. The yellow spheres are zinc atoms. 
 
 
Interaction of docked ligand 108k at the active site of IMP-1 (PDB: 1JJT). Atom colors are as follows: blue–nitrogen, 
red–oxygen, grey–carbon and yellow-zinc atom (of IMP-1), and red–oxygen, blue–nitrogen, green–carbon, and yellow–
sulfur (on inhibitor). 
 
  
 
 
 
 
 
 
 
Appendix F 
1H and 13C NMR Spectra of Compounds From Chapter 2 
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Appendix G 
1H and 13C NMR Spectra of Compounds From Chapter 3 
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Appendix H 
1H and 13C NMR Spectra of Compounds From Chapter 4 
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Appendix I 
1H and 13C NMR Spectra of Compounds From Chapter 5 
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
